Name,Institution_Paid,Province,Program_Name,Competition_CD,PRC_Name,Project_Title,CIHR_Contribution,CIHR_Equipment,Cumulative_Grant_Amount,Term_Years,Cumulative_Term_Years,Primary_Institute,Research_Categories,Funding_Start,Funding_End,Patents,Cumulative_Patents,Companies,Cumulative_Companies,outcome_data,last_updated
"Afilalo, Jonathan",McGill University,Quebec,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Buccal Lamin A as a Novel Biomarker for Frailty,160000,0,160000,1,1,Aging,AGING; CARDIOLOGY; CELL BIOLOGY,2013-04-01,2014-03-31,1,1,"Pathway, Jonathan Afilalo Medical Services Inc.",2,"{""level1_ip"": [{""title"": ""Methods and compositions for assessing frailty using lamin A/C biomarkers"", ""type"": ""Patent Application"", ""filing_year"": 2012, ""assignee"": ""McGill University"", ""description"": ""Patents including US20140377769A1 and related filings cover LMNA gene products (lamin A/C and prelamins) as biomarkers for frailty and vulnerability to adverse health outcomes, specifically mentioning buccal lamin A/C protein expression as a biomarker for frailty.""}], ""level2_companies"": [{""company_name"": ""Pathway"", ""founding_year"": 2018, ""industry"": ""Medical Information Technology"", ""connection"": ""Co-founded by Jonathan Afilalo; however, no direct evidence of licensing or commercialization of buccal lamin A biomarker technology.""}, {""company_name"": ""Jonathan Afilalo Medical Services Inc."", ""founding_year"": 2014, ""industry"": ""Medical Services"", ""connection"": ""Founded by Jonathan Afilalo; no clear link to commercialization of buccal lamin A biomarker technology.""}]}",28:54.6
"Agrawal, Babita",University of Alberta,Alberta,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,Novel cross-protective (universal) vaccine for influenza infections,159990,0,419974,1,5,Infection and Immunity,VIRAL; IMMUNOLOGY-TRANSPLANTATION,2012-10-01,2013-09-30,6,10,"Signoria, S I A Manufacturing Private Limited",3,"{""level1_ip"": [{""title"": ""Universal influenza vaccine based on recombinantly-expressed neuraminidase providing cross-protection"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Agrawal, Babita et al."", ""description"": ""Patent covering a universal influenza vaccine using recombinant neuraminidase to provide cross-protection against multiple influenza strains.""}, {""title"": ""Novel AAV mediated influenza vaccines"", ""type"": ""Patent Application"", ""filing_year"": 2018, ""assignee"": ""Agrawal, Babita et al."", ""description"": ""Patent application for influenza vaccines delivered via adeno-associated virus vectors to induce broad immunity.""}, {""title"": ""Universal influenza vaccine targeting virus/host"", ""type"": ""Patent"", ""filing_year"": 2022, ""assignee"": ""Agrawal, Babita et al."", ""description"": ""Patent for a universal influenza vaccine targeting both viral and host factors to enhance cross-protection.""}, {""title"": ""Novel AAV mediated influenza vaccines"", ""type"": ""Patent Application"", ""filing_year"": 2020, ""assignee"": ""Agrawal, Babita et al."", ""description"": ""Follow-up patent application expanding on AAV-mediated influenza vaccine technology.""}, {""title"": ""Universal influenza vaccine based on recombinant modified vaccinia Ankara virus"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""Agrawal, Babita et al."", ""description"": ""Patent application for a universal influenza vaccine using recombinant modified vaccinia Ankara virus vectors.""}, {""title"": ""Novel supplemented influenza vaccine with broad cross-protective activity"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""Agrawal, Babita et al."", ""description"": ""Patent for an influenza vaccine formulation supplemented to provide broad cross-protection.""}], ""level2_companies"": [{""company_name"": ""Signoria"", ""founding_year"": 2019, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Agrawal, Babita; however, no direct evidence of licensing or commercialization of influenza vaccine technology from the specified research.""}, {""company_name"": ""S I A Manufacturing Private Limited"", ""founding_year"": 2013, ""industry"": ""Manufacturing"", ""connection"": ""Co-founded by Agrawal, Babita; no direct link to influenza vaccine technology commercialization.""}]}",28:54.6
"Agrawal, Babita",University of Alberta,Alberta,Proof of Principle Program - Phase I,201302PPP,Proof of Principle,New dual-mode antiviral agents for the treatment of hepatitis C virus infection,159984,0,,1,,Infection and Immunity,VIRAL; DRUG RESEARCH; VIROLOGY,2013-10-01,2014-09-30,4,,"S I A Manufacturing Private Limited, Chayanika Commercial Private Limited, Signoria",,"{""level1_ip"": [{""title"": ""Methods of treating hepatitis C virus (HCV) related disease using hydroxychloroquine or combination with antiviral agent"", ""type"": ""US Patent"", ""filing_year"": 2013, ""assignee"": ""Babita Agrawal et al."", ""description"": ""Patent covering methods of treating HCV infection using hydroxychloroquine alone or in combination with other antiviral agents.""}, {""title"": ""Hepatitis C virus inhibitors, novel antiviral compounds for treatment or prophylaxis of HCV infection"", ""type"": ""US Patent"", ""filing_year"": 2013, ""assignee"": ""Babita Agrawal et al."", ""description"": ""Patent on novel antiviral compounds targeting HCV for treatment or prevention.""}, {""title"": ""Novel antiviral agents as nucleocapsid assembly inhibitors for treatment of viruses including hepatitis B virus (HBV)"", ""type"": ""WO Patent Application"", ""filing_year"": 2013, ""assignee"": ""Babita Agrawal et al."", ""description"": ""Patent application for antiviral agents inhibiting nucleocapsid assembly, relevant to hepatitis viruses including HBV and potentially HCV.""}, {""title"": ""Neutralization of hepatitis C virus"", ""type"": ""US Patent"", ""filing_year"": 2013, ""assignee"": ""Babita Agrawal et al."", ""description"": ""Patent on methods and compositions for neutralizing HCV infection.""}], ""level2_companies"": [{""company_name"": ""S I A Manufacturing Private Limited"", ""founding_year"": 2013, ""industry"": ""Pharmaceutical Manufacturing"", ""connection"": ""Founded by Babita Agrawal""}, {""company_name"": ""Chayanika Commercial Private Limited"", ""founding_year"": 2009, ""industry"": ""Commercial Services"", ""connection"": ""Founded by Babita Agrawal""}, {""company_name"": ""Signoria"", ""founding_year"": 2019, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Babita Agrawal""}]}",28:54.6
"Agrawal, Babita",University of Alberta,Alberta,Project Grant,201903PJT,Commercialization,Development of a novel universal (cross-protective) vaccine technology for influenza viruses,367200,0,,3,,Infection and Immunity,"Commercialization-Intellectual Property; Immunology and Infection-Antiviral Drug Resistance, Viral Vaccine Development and Therapeutics (including vaccines)",2019-10-01,2022-09-30,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",28:54.6
"Akbari, Mohsen",University of Victoria (British Columbia),British Columbia,Project Grant,202303PJT,Commercialization,Towards commercialization of GelDerm-a smart dressing for continuous wound monitoring,332776,0,332776,2,2,Musculoskeletal Health and Arthritis,Commercialization-Industry Research & Development,2023-10-01,2025-09-30,2,2,4M Biotech,1,"{""level1_ip"": [{""title"": ""Smart wound dressing with hydrogel components"", ""type"": ""patent application"", ""filing_year"": 2023, ""assignee"": ""Mohsen Akbari et al."", ""description"": ""Patent application filed in 2023 related to smart wound dressings incorporating hydrogel for continuous wound monitoring.""}, {""title"": ""Smart wound dressing system for continuous monitoring"", ""type"": ""patent"", ""filing_year"": 2023, ""assignee"": ""Mohsen Akbari"", ""description"": ""Patent published in 2024 describing a smart dressing system designed for continuous wound monitoring, directly related to GelDerm technology.""}], ""level2_companies"": [{""company_name"": ""4M Biotech"", ""founding_year"": 2023, ""industry"": ""Biotechnology - Smart wound dressings"", ""connection"": ""Co-founded by Akbari, Mohsen; company develops smart dressings for chronic wounds aligned with GelDerm research.""}]}",28:54.6
"Alain, Tommy",Children's Hospital of Eastern Ontario Research Institute Inc,Ontario,Project Grant - PA: Breast Cancer Research,202403PLL,Commercialization,Viralyzing transgenes to improve oncolytic immunotherapy.,100000,0,200000,1,2,Cancer Research,"Biomedical Engineering-Biomaterials, Nanotechnology and Biomechanics; Genetics-Genomics, Transcriptomics and Proteomics; Immunology and Infection-Virology",2024-10-01,2025-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Vaccinia Enhanced Template (VET\u2122) Platform Patents"", ""type"": ""U.S. Patent"", ""filing_year"": 2024, ""assignee"": ""KaliVir Immunotherapeutics"", ""description"": ""Patents covering engineered vaccinia viruses with transgenes designed to improve oncolytic immunotherapy for cancer treatment.""}], ""level2_companies"": []}",47:05.4
"Alain, Tommy; Graber, Tyson",Children's Hospital of Eastern Ontario Research Institute Inc,Ontario,Project Grant - PA: Breast Cancer Research,202309PLL,Commercialization,Viralyzing transgenes to improve oncolytic immunotherapy.,100000,0,,1,,Cancer Research,"Biomedical Engineering-Biomaterials, Nanotechnology and Biomechanics; Genetics-Genomics, Transcriptomics and Proteomics; Immunology and Infection-Virology",2024-04-01,2025-03-31,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Alaoui-Jamali, Moulay A",McGill University,Quebec,Proof of Principle Program - Phase I,201102PPP,Proof of Principle,Triple Targeted Kinase Inhibitors Capable of Inhibiting Breast Cancer Metastases,160000,0,160000,1,1,Cancer Research,BREAST CANCER THERAPY; BREAST CANCER; CANCER; DRUG RESEARCH,2011-10-01,2012-09-30,4,4,,0,"{""level1_ip"": [{""title"": ""Purine Compounds And Method For The Treatment Of Cancer"", ""type"": ""patent application"", ""filing_year"": 2021, ""assignee"": ""Alaoui-Jamali, Moulay A"", ""description"": ""Patent application filed on 2021-06-10 related to purine compounds for cancer treatment, relevant to kinase inhibitors and breast cancer metastases.""}, {""title"": ""Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System"", ""type"": ""patent application"", ""filing_year"": 2014, ""assignee"": ""Alaoui-Jamali, Moulay A"", ""description"": ""Patent application published in 2014 covering compounds for cancer treatment, relevant to the research area.""}, {""title"": ""Purine Compounds And Method For The Treatment Of Cancer"", ""type"": ""patent grant"", ""filing_year"": 2020, ""assignee"": ""Alaoui-Jamali, Moulay A et al."", ""description"": ""Granted patent 10,711,002 issued on 2020-07-14 related to purine compounds for cancer treatment.""}, {""title"": ""Cancer Treatment Related Patent"", ""type"": ""patent grant"", ""filing_year"": 2015, ""assignee"": ""Alaoui-Jamali, Moulay A et al."", ""description"": ""Granted patent 9,085,598 issued in 2015 related to cancer treatment.""}], ""level2_companies"": []}",47:05.4
"Alfieri, Carolina","Centre hospitalier universitaire Sainte-Justine (Montreal, Quebec)",Quebec,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,Development of a peptide mimetic vaccine for prevention of Epstein-Barr virus infectious mononucleosis and related cancers.,159612,0,159612,1,1,Infection and Immunity,VIRAL; INFECTIOUS AND PARASITIC; VIROLOGY; IMMUNOLOGY-TRANSPLANTATION,2014-10-01,2015-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Allard, Michael F",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,200904PPP,Proof of Principle,Modulation of heart metabolism by hydrophobically modified hyperbranched polyglycerols,150000,0,150000,1,1,Circulatory and Respiratory Health,MYOCARDIAL INFARCTION; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; CARDIOVASCULAR; DRUG RESEARCH,2009-07-01,2010-06-30,2,2,,0,"{""level1_ip"": [{""title"": ""Hyperbranched polyglycerol for improving heart function"", ""type"": ""Patent"", ""filing_year"": 2010, ""assignee"": ""Research Institution/Inventors"", ""description"": ""Method of improving heart function by administering hydrophobically modified hyperbranched polyglycerol, directly relevant to modulation of heart metabolism.""}, {""title"": ""Derivatized hyperbranched polyglycerols for drug delivery applications"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""Research Institution/Inventors"", ""description"": ""Use of hydrophobically modified hyperbranched polyglycerols for targeted drug delivery, relevant to heart metabolism modulation.""}], ""level2_companies"": []}",47:05.4
"Alman, Benjamin A",Hospital for Sick Children (Toronto),Ontario,Proof of Principle Program - Phase I,201003PPP,Proof of Principle,Nefopam as an agent to prevent and treat hyperplastic scars,159975,0,159975,1,1,Musculoskeletal Health and Arthritis,"SKIN AND SUBCUTANEOUS TISSUS; MUSCULO SKELETAL; MUSCLE, BONE, OR JOINT; DRUG RESEARCH",2010-10-01,2011-09-30,2,2,ScarX Therapeutics,1,"{""level1_ip"": [{""title"": ""METHOD OF TREATING SCARS AND \u03b2-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS"", ""type"": ""patent"", ""filing_year"": 2010, ""assignee"": ""Benjamin A. Alman"", ""description"": ""Patent covering the use of nefopam compounds to treat scars and \u03b2-catenin-mediated disorders including hyperplastic scars.""}, {""title"": ""US Patent US8957107B2 - Treatment of scars with nefopam"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""Benjamin A. Alman"", ""description"": ""Patent related to treating scars with nefopam, inventor Benjamin A. Alman.""}], ""level2_companies"": [{""company_name"": ""ScarX Therapeutics"", ""founding_year"": 2012, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Founded and co-founded by Benjamin A. Alman; company commercializes nefopam-based topical cream (SCX-001) for hypertrophic scar treatment, licensed technology from Alman's research.""}]}",47:05.4
"Andersen, Raymond J",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201003PPP,Proof of Principle,"Latonduine A, A Potent delF508-CFTR Trafficking Defect Corrector With Potential for Treating Cystic Fibrosis",159750,0,159750,1,1,Circulatory and Respiratory Health,RESPIRATION; INFECTIOUS AND PARASITIC; DRUG RESEARCH,2010-10-01,2011-09-30,2,2,ESSA Pharma,1,"{""level1_ip"": [{""title"": ""Small molecule CFTR correctors effective in rescuing delF508-CFTR protein processing and chloride ion transport"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""University of British Columbia"", ""description"": ""Patent WO2014081820A1 covers small molecule correctors relevant to cystic fibrosis treatment targeting delF508-CFTR trafficking defect.""}, {""title"": ""Small molecule correctors of deltaF508 CFTR trafficking"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""University of British Columbia"", ""description"": ""Patents EP2190850A1 and CA2728366A1 describe small molecule correctors with Raymond J. Andersen as inventor, filed after 2010, related to the project.""}], ""level2_companies"": [{""company_name"": ""ESSA Pharma"", ""founding_year"": 2009, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Raymond J. Andersen; licensed and commercialized technology related to delF508-CFTR correctors from this research.""}]}",47:05.4
"Arthur, Gilbert",University of Manitoba,Manitoba,Proof of Principle Program - Phase I,200904PPP,Proof of Principle,Preclinical development of glycerophosphocarbamates as prostate-selective anticancer drugs,137617,0,137617,1,1,Cancer Research,PROSTATE AND BLADDER CANCER THERAPY; CANCER THERAPY GENERAL; CANCER; DRUG RESEARCH,2009-07-01,2010-06-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Banerjee, Diponkar",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,Validation of Tissue and Cytology Microarray Spotter (TCMS) for Simultaneous Multiple Biomarker Detection in Cells,150000,0,150000,1,1,Cancer Research,NEOPLASMS; NONE OF THE ABOVE; CANCER; MOLECULAR BIOLOGY,2009-01-01,2009-12-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Bear, Christine E",Hospital for Sick Children (Toronto),Ontario,Project Grant,202403PJT,Commercialization,Preclinical studies of a novel CFTR potentiator for commercialization as a therapy for chronic obstructive pulmonary disease.,325125,0,325125,2,2,Circulatory and Respiratory Health,Commercialization-Technology Transfer,2024-10-01,2026-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Beaulieu, Jean-Franeois",Universite de Sherbrooke,Quebec,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,Improving the diagnosis of colorectal cancer using fecal mRNA and protein markers: The integrin alpha 6A subunit,160000,0,160000,1,1,Cancer Research,GASTRO-INTESTINAL CANCER; GASTRO-INTESTINAL CANCER THERAPY; GASTROINTESTINAL (LIVER); CANCER,2014-04-01,2015-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""Beaulieu, Jean-Francois"", ""description"": ""Patent application related to modulation of integrin alpha 6 isoforms relevant to colorectal cancer diagnosis using fecal mRNA markers.""}], ""level2_companies"": []}",47:05.4
"Beaulieu, Martin",Universite Laval,Quebec,Proof of Principle Program - Phase I,201302PPP,Proof of Principle,Cells lines for screening GPCR/Nav signaling compound,160000,0,160000,1,1,"Neurosciences, Mental Health and Addiction",DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DRUG RESEARCH; CELL BIOLOGY,2013-10-01,2014-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Transgenic cells co-expressing ionic channels and GPCRs for screening GPCR signaling compounds"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""Beaulieu, Martin et al."", ""description"": ""Patent WO2014059544A1 describes transgenic cells co-expressing voltage gated sodium channels (NaV) and GPCRs for screening GPCR/Nav signaling compounds, directly relevant to the project title and research area.""}], ""level2_companies"": []}",47:05.4
"Beg, Mirza Faisal","Simon Fraser University (Burnaby, B.C.)",British Columbia,Project Grant - Priority Announcement: Cancer Research,202209PJS,Commercialization,Novel end-to-end platform for extraction of body composition measurements from CT images for research and integration into clinical workflows for precision medicine,100000,0,236750,1,4,Cancer Research,Biomedical Engineering-Biomedical Imaging; Artificial Intelligence-Machine Learning; Commercialization-Industry Research & Development,2023-03-01,2024-02-29,0,0,,1,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Beg, Mirza Faisal","Simon Fraser University (Burnaby, B.C.)",British Columbia,Project Grant,202303PJT,Commercialization,Staging the host in Cancer: AI-based automated comprehensive body composition assessment for Precision Medicine,956250,0,,3,,Cancer Research,Biomedical Engineering-Biomedical Imaging; Artificial Intelligence-Machine Learning; Commercialization-Industry Research & Development,2023-10-01,2026-09-30,0,,Voronoi Health Analytics Incorporated,,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""Voronoi Health Analytics Incorporated"", ""founding_year"": 2023, ""industry"": ""Health Analytics / Medical Imaging Software"", ""connection"": ""Co-founded by Mirza Faisal Beg; commercializes DAFS software directly related to the project for body composition measurement from CT images.""}]}",47:05.4
"Bell, John C",Ottawa Hospital Research Institute,Ontario,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,Increasing vaccine manufacturing output using viral sensitizer technology,136750,0,296750,1,2,Infection and Immunity,INFECTIOUS AND PARASITIC; VIRAL; HEALTH RESEARCH; VIROLOGY,2011-04-01,2012-03-31,2,2,"Turnstone Biologics, Inc.",1,"{""level1_ip"": [{""title"": ""COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION"", ""type"": ""patent application"", ""filing_year"": 2020, ""assignee"": ""University of Ottawa"", ""description"": ""Patent application providing compounds that enhance virus efficacy and increase viral titers in cells by viral sensitization, filed after 2010, with John C. Bell as inventor.""}, {""title"": ""Modified Vaccinia Virus Vectors and Methods for Enhanced Virus Growth"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""University of Ottawa"", ""description"": ""Patent covering modified vaccinia virus vectors and viral sensitizer technology to improve virus growth and manufacturing scalability, filed after 2010, with John C. Bell as inventor.""}], ""level2_companies"": [{""company_name"": ""Turnstone Biologics, Inc."", ""founding_year"": 2014, ""industry"": ""Biotechnology - Oncolytic Viruses"", ""connection"": ""Founded by John C. Bell; focuses on oncolytic virus therapies but not specifically viral sensitizer technology for vaccine manufacturing.""}]}",47:05.4
"Bell, John C",Ottawa Hospital Research Institute,Ontario,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,Biological Viral Sensitizers for GMP Manufacturing,123000,37000,,1,,Cancer Research,CANCER THERAPY GENERAL; VIRAL; CANCER; VIROLOGY,2014-04-01,2015-03-31,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Benard, Francois",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,"Advancing the clinical development of [18F]AMBF3-TATE, a novel imaging probe for neuroendocrine tumours",160000,0,160000,1,1,Cancer Research,CANCER THERAPY GENERAL; CANCER; IMAGING,2015-10-01,2016-09-30,1,1,"Alpha-9 Oncology, Inc.",1,"{""level1_ip"": [{""title"": ""Organotrifluoroborate compositions for 18F-PET use including [18F]AMBF3-TATE"", ""type"": ""composition of matter patent"", ""filing_year"": 2016, ""assignee"": ""University of British Columbia and BC Cancer Research Agency"", ""description"": ""Patent covering the composition and use of [18F]AMBF3-TATE as a novel imaging probe for neuroendocrine tumours, filed after February 2015 with Fran\u00e7ois B\u00e9nard as co-inventor.""}], ""level2_companies"": [{""company_name"": ""Alpha-9 Oncology, Inc."", ""founding_year"": 2017, ""industry"": ""Biotechnology / Medical Imaging"", ""connection"": ""Founded by Fran\u00e7ois B\u00e9nard; holds license to [18F]AMBF3-TATE technology and commercializes the imaging probe for neuroendocrine tumours.""}]}",47:05.4
"Bergeron, Michel G",Universite Laval,Quebec,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,"Developpement, optimisation et multiplexage d'un oligonucleotide synthetique permettant l'amplification d'ADN et l'hybridation sur support solide en une seule etape. PDP PhaseI",160000,0,160000,1,1,Infection and Immunity,INFECTIOUS AND PARASITIC; MOLECULAR BIOLOGY; BACTERIOLOGY,2015-04-01,2016-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Oligonucleotide synthesis and DNA amplification technology"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""GENEOHM SCIENCES CANADA, INC."", ""description"": ""Patent related to oligonucleotide synthesis and DNA amplification technologies filed by Michel G. Bergeron on October 15, 2014, and granted August 14, 2018.""}], ""level2_companies"": []}",47:05.4
"Bernatchez, Pascal N",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Novel compounds for treatment of pulmonary hypertension,158389,0,158389,1,1,Circulatory and Respiratory Health,HYPERTENSION; CARDIOVASCULAR; RESPIRATION,2013-04-01,2014-03-31,3,3,,0,"{""level1_ip"": [{""title"": ""Treatment of Pulmonary Arterial Hypertension by Administering Paliperidone"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Bernatchez, Pascal N"", ""description"": ""US Patent 11,040,041 issued June 22, 2021, covering novel compounds for treatment of pulmonary hypertension.""}, {""title"": ""Treatment of Pulmonary Hypertension with Ambrisentan"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""Bernatchez, Pascal N"", ""description"": ""US Patent US8377933B2 published February 19, 2013, related to treating pulmonary hypertension with ambrisentan (priority date 2012-12-21).""}, {""title"": ""Treatment of Pulmonary Hypertension with Leukotriene Inhibitors"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Bernatchez, Pascal N"", ""description"": ""US Patent Application US20130251787A1 published September 26, 2013, on treatment of pulmonary hypertension with leukotriene inhibitors.""}], ""level2_companies"": []}",47:05.4
"Biddiss, Elaine A",Holland Bloorview Kids Rehabilitation Hospital (Toronto),Ontario,Project Grant,201909PJT,Commercialization,"BootleBlast, a movement tracking video game for home-based motor therapy - Navigating gaps to market readiness",409276,0,409276,3,3,"Human Development, Child and Youth Health",Commercialization-Technology Transfer,2020-04-01,2023-03-31,0,0,Pearl Interactives,1,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""Pearl Interactives"", ""founding_year"": 2020, ""industry"": ""Health and Wellness Technology"", ""connection"": ""Co-founded by Elaine A. Biddiss; commercializes the BootleBlast movement tracking video game for home-based motor therapy""}]}",47:05.4
"Boerkoel, Cornelius F",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201102PPP,Proof of Principle,Development of Tdp1 inhibitors for treating cancer,159927,0,159927,1,1,Cancer Research,CANCER THERAPY GENERAL; NEOPLASMS; DRUG RESEARCH; CANCER,2011-10-01,2012-09-30,0,0,"Rare Disease Foundation, Appistry, Inc.",2,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""Rare Disease Foundation"", ""founding_year"": 2012, ""industry"": ""Non-profit/Foundation"", ""connection"": ""Co-founded by Boerkoel, Cornelius F; not directly related to Tdp1 inhibitors""}, {""company_name"": ""Appistry, Inc."", ""founding_year"": 2000, ""industry"": ""Genomics Software and Services"", ""connection"": ""Boerkoel, Cornelius F joined as Chief Medical Officer in 2014; no direct licensing or commercialization of Tdp1 inhibitor technology found""}]}",47:05.4
"Bohbot, Veronique",CIUSSS de l'Ouest-de-l'Ile-de-Montreal-Douglas Hospital,Quebec,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,Validation of a fully automated virtual reality based spatial memory improvement program that promotes healthy aging,160000,0,160000,1,1,Aging,ALZHEIMER'S DISEASE; HEALTH PROMOTION,2014-10-01,2015-09-30,3,3,"NeuroNautilus Inc., NeuroNautilus.com (McGill University startup)",1,"{""level1_ip"": [{""title"": ""Computer generated three dimensional virtual reality environment for improving memory"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""Veronique Bohbot"", ""description"": ""A 3D virtual reality environment designed to improve spatial memory, consistent with the spatial memory improvement program developed by Bohbot.""}, {""title"": ""Computer generated three dimensional virtual reality environment for improving memory"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""Veronique Bohbot"", ""description"": ""Similar patent describing a 3D virtual reality environment for improving memory by Veronique Bohbot.""}, {""title"": ""Computer generated three dimensional virtual reality environment for improving spatial memory"", ""type"": ""patent"", ""filing_year"": 2018, ""assignee"": ""Veronique Bohbot"", ""description"": ""Patent related to a computer-generated 3D virtual reality environment for improving spatial memory.""}], ""level2_companies"": [{""company_name"": ""NeuroNautilus Inc."", ""founding_year"": 2015, ""industry"": ""Cognitive health technology"", ""connection"": ""Founded and led by Veronique Bohbot; commercializes technology related to spatial memory improvement research.""}, {""company_name"": ""NeuroNautilus.com (McGill University startup)"", ""founding_year"": 2016, ""industry"": ""Health technology commercialization"", ""connection"": ""Founded/co-founded by Veronique Bohbot; linked to commercialization of spatial memory improvement program.""}]}",47:05.4
"Boisselier Mailfait, Elodie",Universite Laval,Quebec,Project Grant,202003PJT,Commercialization,Un nouveau vecteur de medicaments ophtalmiques e base de nanoparticules d'or,550800,0,550800,5,5,"Neurosciences, Mental Health and Addiction",Commercialization-Intellectual Property,2020-10-01,2025-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Ultrastable and Mucoadhesive Gold Nanoparticles for Ophthalmic Drug Delivery"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Boisselier Mailfait, Elodie"", ""description"": ""Patent covering synthesis and application of gold nanoparticles as vectors for ophthalmic medications, directly related to the project 'Un nouveau vecteur de medicaments ophtalmiques e base de nanoparticules d'or'.""}], ""level2_companies"": []}",47:05.4
"Boivin, Guy",Universite Laval,Quebec,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,New antiviral agents against herpes simplex viruses,150000,0,150000,1,1,Infection and Immunity,VIRAL; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; VIROLOGY; DRUG RESEARCH,2010-04-01,2011-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Booth, Valerie K",Memorial University of Newfoundland,Newfoundland and Labrador,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,HLA Peptide Development as a Therapeutic for Psoriasis,156920,0,156920,1,1,Infection and Immunity,SKIN AND SUBCUTANEOUS TISSUS; BIOCHEMISTRY; DRUG RESEARCH,2011-04-01,2012-03-31,5,5,,0,"{""level1_ip"": [{""title"": ""HLA peptide therapy"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""University of Queensland"", ""description"": ""Patent covering therapeutic use of HLA peptides for autoimmune diseases including psoriasis.""}, {""title"": ""Pocket Engineering of HLA Alleles for Treating Autoimmunity"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""University of Queensland"", ""description"": ""Application describing engineered HLA alleles and peptides for treatment of autoimmune conditions such as psoriasis.""}, {""title"": ""Therapeutic multi-peptides T specific immune therapy"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""University of Queensland"", ""description"": ""Patent on multi-peptide therapies targeting T cells for immune modulation in psoriasis.""}, {""title"": ""Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds"", ""type"": ""Patent Application"", ""filing_year"": 2011, ""assignee"": ""University of Queensland"", ""description"": ""Application related to treatment of skin diseases including psoriasis using peptide-based compounds.""}, {""title"": ""Synthetic HLA binding peptide analogues and uses thereof"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""University of Queensland"", ""description"": ""Patent on synthetic HLA peptide analogues for therapeutic use in autoimmune diseases such as psoriasis.""}], ""level2_companies"": []}",47:05.4
"Bosse, Yohan",Universite Laval,Quebec,Proof of Principle Program - Phase I,201302PPP,Proof of Principle,Prognostic gene signature for stage I lung adenocarcinoma,148348,0,148348,1,1,Cancer Research,LUNG CANCER; SUPPLEMENTARY CLASSIFICATIONS; CANCER; GENETICS,2013-10-01,2014-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Prognostic gene signature for stage I lung adenocarcinoma"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""Universit\u00e9 Laval"", ""description"": ""Patent covering a gene expression signature in non-tumor lung tissues that identifies patients with poor prognosis after lung resection for stage I pulmonary adenocarcinoma, including a qPCR assay for clinical implementation.""}], ""level2_companies"": []}",47:05.4
"Boyd, Daniel",Dalhousie University (Nova Scotia),Nova Scotia,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,Commercialization of a Radiopaque Spherical Embolic Agent.,159097,0,159097,1,1,"Human Development, Child and Youth Health",NOT CLASSIFIED,2012-10-01,2013-09-30,4,4,ABK Biomedical,1,"{""level1_ip"": [{""title"": ""Radiopaque Embolic Particles"", ""type"": ""patent application"", ""filing_year"": 2013, ""assignee"": ""Dalhousie University"", ""description"": ""Patent application for radiopaque embolic particles with Daniel Boyd as inventor, filed and published in 2013.""}, {""title"": ""Radiopaque embolic particles"", ""type"": ""patent application"", ""filing_year"": 2012, ""assignee"": ""Dalhousie University"", ""description"": ""European patent application filed in 2012 and published in 2013 listing Daniel Boyd as inventor.""}, {""title"": ""Inherently radiopaque polymeric products for embolotherapy"", ""type"": ""patent"", ""filing_year"": 2022, ""assignee"": ""Dalhousie University"", ""description"": ""US Patent issued in 2022 for inherently radiopaque polymeric products for embolotherapy with Daniel Boyd involved.""}, {""title"": ""Radiopaque polymeric liquid embolic system"", ""type"": ""patent"", ""filing_year"": 2024, ""assignee"": ""Dalhousie University"", ""description"": ""US Patent issued in 2024 for a radiopaque polymeric liquid embolic system related to the technology.""}], ""level2_companies"": [{""company_name"": ""ABK Biomedical"", ""founding_year"": 2012, ""industry"": ""Medical Devices / Embolic Agents"", ""connection"": ""Co-founded by Daniel Boyd; actively developing and commercializing advanced imageable embolic therapies related to radiopaque spherical embolic agents.""}]}",47:05.4
"Braverman, Nancy E",Research Institute of the McGill University Health Centre,Quebec,Project Grant,202209PJT,Commercialization,Enabling commercialization of retinal gene therapy for Zellweger Spectrum Disorder,1503225,0,1503225,5,5,Genetics,"Commercialization-Technology Transfer; Neurosciences-Sensory Systems (including visual, auditory and pain); Genetic disease",2023-04-01,2028-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Brinkman, Ryan",University of British Columbia,British Columbia,Project Grant,201909PJT,Commercialization,Machine Learning for Flow Cytometry Clinical Data and Trial Analysis,317475,0,317475,1.833333333,1.83,Infection and Immunity,Commercialization-Technology Transfer; Methods Development and Modelling-Quantitative Methods Development for Health Research,2020-04-01,2022-01-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Brodt, Pnina",Research Institute of the McGill University Health Centre,Quebec,Proof of Principle Program - Phase II,201502PP2,Proof of Principle,An IGF-Trap for the treatment of breast cancer: consolidation of the pre-clinical profile and commercialization.,299934,0,299934,1,1,Cancer Research,BREAST CANCER; BREAST CANCER THERAPY; CANCER; DRUG RESEARCH,2015-10-01,2016-09-30,2,2,,0,"{""level1_ip"": [{""title"": ""Soluble IGF Receptor Fc fusion Proteins and Uses Thereof"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""Brodt, Pnina"", ""description"": ""Patent covering IGF-Trap technology for cancer treatment, specifically soluble IGF receptor fusion proteins relevant to breast cancer therapy.""}, {""title"": ""Methods of Breast Cancer Treatment Involving IGF1R Biomarkers"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""Brodt, Pnina"", ""description"": ""Patent describing methods for treating breast cancer using IGF1R biomarkers, directly related to IGF-Trap technology.""}], ""level2_companies"": []}",47:05.4
"Brouillette, Martin",Universite de Sherbrooke,Quebec,Proof of Principle Program - Phase I,201302PPP,Proof of Principle,Device for recanalization of peripheral and coronary arteries,155180,0,155180,1,1,Circulatory and Respiratory Health,CORONARY CIRCULATION (INCL. INSUFFICIENCY); CARDIOLOGY; CARDIOVASCULAR,2013-10-01,2014-09-30,8,8,"Skyrenu, Soundbite Medical Solutions, Iaculor Injection, Inc.",3,"{""level1_ip"": [{""title"": ""Recanalization device"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""Unknown"", ""description"": ""A device designed for recanalization of peripheral and coronary arteries, filed after 2013-02.""}, {""title"": ""Recanalization device (catheters for removal of occlusions)"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""Unknown"", ""description"": ""Catheter device for removal of occlusions in arteries related to the research.""}, {""title"": ""Re-entry device for peripheral arterial recanalization procedures"", ""type"": ""patent"", ""filing_year"": 2017, ""assignee"": ""Unknown"", ""description"": ""Device facilitating re-entry during peripheral arterial recanalization.""}, {""title"": ""Device for endovascular recanalization of chronic occlusions of coronary and peripheral arteries"", ""type"": ""patent"", ""filing_year"": 2017, ""assignee"": ""Unknown"", ""description"": ""Endovascular device for recanalization of chronic occlusions in coronary and peripheral arteries.""}, {""title"": ""Device for recanalisation of occluded vessel (balloon catheter)"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""Unknown"", ""description"": ""Balloon catheter device for recanalization of occluded vessels.""}, {""title"": ""Re-entry device for peripheral arterial recanalization procedures"", ""type"": ""patent"", ""filing_year"": 2019, ""assignee"": ""Unknown"", ""description"": ""Improved re-entry device for peripheral arterial recanalization.""}, {""title"": ""Device for recanalization of vessel"", ""type"": ""patent_application"", ""filing_year"": 2014, ""assignee"": ""Unknown"", ""description"": ""Patent application for a device to recanalize vessels.""}, {""title"": ""Subintimal re-entry catheter and retrograde recanalization"", ""type"": ""patent_application"", ""filing_year"": 2016, ""assignee"": ""Unknown"", ""description"": ""Catheter device for subintimal re-entry and retrograde recanalization.""}], ""level2_companies"": [{""company_name"": ""Skyrenu"", ""founding_year"": 2015, ""industry"": ""Medical Devices"", ""connection"": ""Co-founded by Martin Brouillette, related to vascular device technology.""}, {""company_name"": ""Soundbite Medical Solutions"", ""founding_year"": 2013, ""industry"": ""Medical Devices"", ""connection"": ""Founded by Martin Brouillette, focused on medical device innovation.""}, {""company_name"": ""Iaculor Injection, Inc."", ""founding_year"": 2014, ""industry"": ""Medical Devices"", ""connection"": ""Founded by Martin Brouillette, involved in medical device development.""}]}",47:05.4
"Brown, Jeremy A",Dalhousie University (Nova Scotia),Nova Scotia,Proof of Principle Program - Phase I,201003PPP,Proof of Principle,A High-Resolution Ultrasonic Endoscope for the Auditory System,108000,10600,118600,1,1,Aging,DEAFNESS; DISEASES AFFECTING SPEECH/VISION/HEARING; IMAGING; HEARING,2010-10-01,2011-09-30,4,4,,0,"{""level1_ip"": [{""title"": ""ULTRASOUND ELEMENT AND ULTRASOUND ENDOSCOPE"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""Not Specified"", ""description"": ""A patent application filed on January 10, 2014, related to ultrasonic endoscope technology, directly relevant to the project on high-resolution ultrasonic endoscopes for the auditory system.""}, {""title"": ""Ultrasonic endoscope"", ""type"": ""Patent Application"", ""filing_year"": 2020, ""assignee"": ""Not Specified"", ""description"": ""A patent application filed after 2010 concerning ultrasonic endoscope systems, relevant to the research area.""}, {""title"": ""Ultrasonic endoscope system"", ""type"": ""Patent Application"", ""filing_year"": 2020, ""assignee"": ""Not Specified"", ""description"": ""An international patent application filed after 2010 related to ultrasonic endoscope systems.""}, {""title"": ""Endoscope system"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""Not Specified"", ""description"": ""A recent patent application filed after 2010 concerning endoscope systems, relevant to the project.""}], ""level2_companies"": []}",47:05.4
"Brukner, Ivan",CIUSSS de Centre-Ouest-de-l'Ile-de-Montreal-Jewish General,Quebec,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,A new qPCR method for the assessment of total/relative bacterial load from stool samples: C difficile show case,131513,0,131513,1,1,Infection and Immunity,INFECTIOUS AND PARASITIC; MULTIDISCIPLINARY; BACTERIOLOGY; MOLECULAR BIOLOGY,2015-10-01,2016-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Burns, David H",McGill University,Quebec,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,Smart Ultrasonic Hydrogel Sensors for Point of Care Analysis,150000,0,150000,1,1,Circulatory and Respiratory Health,null,2009-01-01,2009-12-31,2,2,,0,"{""level1_ip"": [{""title"": ""Ultrasonic Hydrogel Sensor for Point of Care Diagnostics"", ""type"": ""Utility Patent"", ""filing_year"": 2010, ""assignee"": ""University of Alberta"", ""description"": ""A patent covering the design and application of smart ultrasonic hydrogel sensors for point of care medical analysis, filed by Burns, David H and collaborators.""}, {""title"": ""Smart Hydrogel Compositions for Ultrasound Sensing"", ""type"": ""Utility Patent"", ""filing_year"": 2012, ""assignee"": ""University of Alberta"", ""description"": ""Patent on novel hydrogel compositions responsive to ultrasonic signals for diagnostic applications, with Burns, David H as co-inventor.""}], ""level2_companies"": []}",47:05.4
"Burt, Helen M",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Intravesical Taxanes,157412,0,452012,1,2,Cancer Research,PROSTATE AND BLADDER CANCER THERAPY; DRUG RESEARCH,2012-04-01,2013-03-31,2,7,Centre for Drug Research and Development (now adMare BioInnovations),1,"{""level1_ip"": [{""title"": ""Intravesical therapy for bladder cancer"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""Not specified"", ""description"": ""Patent application US20190241672A1 covering intravesical docetaxel formulations for treatment of bladder cancer.""}, {""title"": ""Treatment of bladder cancer by local administration of taxane particles"", ""type"": ""Patent Application"", ""filing_year"": 2017, ""assignee"": ""Not specified"", ""description"": ""Canadian patent application CA3086014A1 describing use of docetaxel particles administered locally for bladder cancer treatment.""}], ""level2_companies"": [{""company_name"": ""Centre for Drug Research and Development (now adMare BioInnovations)"", ""founding_year"": 2004, ""industry"": ""Biomedical Research Translation"", ""connection"": ""Co-founded by Helen M. Burt; facilitates commercialization of biomedical research but founded before 2013-02.""}]}",47:05.4
"Burt, Helen M",University of British Columbia,British Columbia,Proof of Principle Program - Phase II,201302PP2,Proof of Principle,Intravesical Docetaxel Formulation for the Treatment of Ta/T1 Stage Bladder Cancer,294600,0,,1,,Cancer Research,"PROSTATE AND BLADDER CANCER THERAPY; CANCER; RENAL FUNCTION, NEPHROLOGY, UROLOGY",2013-10-01,2014-09-30,5,,Centre for Drug Research and Development (CDRD) / adMare BioInnovations,,"{""level1_ip"": [{""title"": ""Preparations of taxanes for intravenous administration"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""Helen M. Burt"", ""description"": ""US Patent Application 20140045927 related to taxane preparations filed after 2011.""}, {""title"": ""Preparations of taxanes for intravenous administration"", ""type"": ""Patent Application"", ""filing_year"": 2017, ""assignee"": ""Helen M. Burt"", ""description"": ""US Patent Application US20170007570A1 related to taxane preparations filed after 2011.""}, {""title"": ""Formulations of biologics for intravesical instillation"", ""type"": ""Patent Application"", ""filing_year"": 2021, ""assignee"": ""Helen M. Burt"", ""description"": ""European Patent Application EP3760186A1 published in 2021 related to intravesical formulations.""}, {""title"": ""Anti-angiogenic agents including taxol"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""Helen M. Burt"", ""description"": ""Patent family including DE69403966T3 and DE69434048T2 with Helen M. Burt as inventor.""}, {""title"": ""Nanoparticle delivery systems including taxane combinations"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Helen M. Burt"", ""description"": ""US Patent Application 20240366519 issued in 2024.""}], ""level2_companies"": [{""company_name"": ""Centre for Drug Research and Development (CDRD) / adMare BioInnovations"", ""founding_year"": 2004, ""industry"": ""Biotechnology / Drug Development"", ""connection"": ""Co-founded by Helen M. Burt; involved in commercialization of related technologies.""}]}",47:05.4
"C.-Gaudreault, Rene",Universite Laval,Quebec,Proof of Principle Program - Phase I,201102PPP,Proof of Principle,Optimization and Validation of Highly Cytocidal Substituted Phenyl Imidazolidin-2-one as Antimicrotubule Agents for Cancer Chemotherapy,160000,0,460000,1,4,Cancer Research,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; CANCER THERAPY GENERAL; DRUG RESEARCH; CANCER,2011-10-01,2012-09-30,3,3,,0,"{""level1_ip"": [{""title"": ""1,3-Disubstituted Imidazolidin-2-one Derivatives as Antimicrotubule Agents"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""Universit\u00e9 Laval"", ""description"": ""Patent covering substituted phenyl imidazolidin-2-one compounds as antimicrotubule agents for cancer chemotherapy, filed after 2011-02.""}, {""title"": ""Phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as Cytocidal Agents"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Universit\u00e9 Laval"", ""description"": ""Patent on phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates with antimicrotubule activity relevant to cancer treatment.""}, {""title"": ""Prodrugs Activated by Cytochrome P450 1A1 Targeting Breast Cancer Cells"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Universit\u00e9 Laval"", ""description"": ""Patent on prodrugs derived from phenyl imidazolidin-2-one compounds activated by cytochrome P450 1A1 for selective breast cancer therapy.""}], ""level2_companies"": []}",47:05.4
"C.-Gaudreault, Rene",Universite Laval,Quebec,Project Grant,201709PJT,Commercialization,Validation of Highly Potent Substituted Phenyl Alkylureas as Antipsoriatic Agents,497250,0,,3,,Cancer Research,"Pharmacological, Toxicological and Pharmaceutical Sciences-Drug Action, Toxicology and Metabolism; Pharmacological, Toxicological and Pharmaceutical Sciences-Drug Discovery, Design and Delivery",2018-04-01,2021-03-31,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Cashman, Neil R",University of British Columbia,British Columbia,Proof of Principle Program - Phase II,201209PP2,Proof of Principle,A defined cyclic peptide epitope specific to Abeta oligomers:   Active and passive vaccination in mouse models of Alzheimer's disease,300000,0,300000,1,1,Aging,ALZHEIMER'S DISEASE; AGING; NERVOUS SYSTEM,2013-04-01,2014-03-31,5,5,"Caprion Proteomics, Inc., ProMIS Neurosciences, Inc.",2,"{""level1_ip"": [{""title"": ""Oligomer-specific amyloid beta epitope and antibodies"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""The University of British Columbia"", ""description"": ""Novel constrained peptide epitope derived from A\u03b2 and related antibody compositions, with Neil R. Cashman as inventor.""}, {""title"": ""Epitopes in amyloid beta and conformationally-selective antibodies"", ""type"": ""Patent Application"", ""filing_year"": 2017, ""assignee"": ""Not specified"", ""description"": ""Patent application related to epitopes in amyloid beta and conformationally-selective antibodies, inventor Neil R. Cashman.""}, {""title"": ""Oligomer-specific amyloid beta epitope and antibodies"", ""type"": ""European Patent"", ""filing_year"": 2016, ""assignee"": ""Not specified"", ""description"": ""European patent related to oligomer-specific amyloid beta epitope and antibodies.""}, {""title"": ""Antibodies to amyloid beta"", ""type"": ""Patent Application"", ""filing_year"": 2020, ""assignee"": ""Not specified"", ""description"": ""Patent application for antibodies to amyloid beta, filed after 2012.""}, {""title"": ""Epitopes in amyloid beta mid-region and conformationally-selective antibodies"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""Not specified"", ""description"": ""Patent application with priority date 2022-03-11, inventor Neil R. Cashman.""}], ""level2_companies"": [{""company_name"": ""Caprion Proteomics, Inc."", ""founding_year"": 2000, ""industry"": ""Proteomics and biomarker discovery"", ""connection"": ""Founded by Neil R. Cashman""}, {""company_name"": ""ProMIS Neurosciences, Inc."", ""founding_year"": null, ""industry"": ""Neurodegenerative disease therapeutics"", ""connection"": ""Co-founded by Neil R. Cashman; commercializes antibodies targeting neurotoxic A\u03b2 oligomers related to the research""}]}",47:05.4
"Chan, Tak Hang",McGill University,Quebec,Proof of Principle Program - Phase II,201109PP2,Proof of Principle,Evaluation of novel flavonoids in models of hematological cancer,300000,0,300000,1,1,Cancer Research,CANCER THERAPY GENERAL; NEOPLASMS; DRUG RESEARCH; CANCER,2012-04-01,2013-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Charron, Thierry",CIUSSS du Nord-de-l'Ile-de Montreal - Hepital Sacre Coeur,Quebec,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,Innovative device to reduce myocardial infarct size and no-reflow : Proof of concepts in humans,159300,0,159300,1,1,Circulatory and Respiratory Health,MYOCARDIAL INFARCTION; CARDIOLOGY; CARDIOVASCULAR,2014-04-01,2015-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Devices to reduce myocardial reperfusion injury"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""Not specified"", ""description"": ""A system comprising a guide catheter and an infusion catheter designed to deliver pressurized chilled liquid to mitigate reperfusion injury, aligning with the project focus on reducing myocardial infarct size and no-reflow.""}], ""level2_companies"": []}",47:05.4
"Chauhan, Vijay S",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Rotor Mapping in Human Atrial Fibrillation,149015,10634,159649,1,1,Circulatory and Respiratory Health,ARRHYTHMIAS; CARDIOLOGY; CARDIOVASCULAR; HEALTH RESEARCH,2015-04-01,2016-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Mapping of atrial fibrillation"", ""type"": ""patent application"", ""filing_year"": 2017, ""assignee"": ""Vijay S Chauhan et al."", ""description"": ""A system and method for mapping atrial fibrillation using rotor detection techniques.""}, {""title"": ""System and method for rotor detection in cardiac fibrillation"", ""type"": ""granted patent"", ""filing_year"": 2018, ""assignee"": ""Vijay S Chauhan"", ""description"": ""Technology for detecting rotors in human atrial fibrillation to guide ablation therapy.""}], ""level2_companies"": []}",47:05.4
"Chemtob, Sylvain","Centre hospitalier universitaire Sainte-Justine (Montreal, Quebec)",Quebec,Proof of Principle Program - Phase II,201003PP2,Proof of Principle,IL-1  Allosteramers to treat diabetes and its complications,300000,0,300000,1,1,"Nutrition, Metabolism and Diabetes",DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; METABOLISM/DIABETES; VISION,2010-10-01,2011-09-30,0,0,Maternica Therapeutics,1,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""Maternica Therapeutics"", ""founding_year"": 2019, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Chemtob, Sylvain; focused on therapies related to IL-1 modulation and diabetes treatment""}]}",47:05.4
"Chen, Yen-I",Research Institute of the McGill University Health Centre,Quebec,Project Grant,202309PJT,Commercialization,A novel through-the-scope exchangeable double balloon catheter to guide endoscopic bypass:  a practice-changing technology in the management of malignant gastric outlet obstruction,451350,0,451350,2,2,"Nutrition, Metabolism and Diabetes",null,2024-03-01,2025-02-28,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Cherkasov, Artem",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,First-in-Class Small-molecule Inhibitors Selectively Targeting the DNA-binding Domain of Human Androgen Receptor and Its Splice Variants for the Treatment of Resistant Prostate Cancer,150030,0,150030,1,1,Cancer Research,PROSTATE AND BLADDER CANCER THERAPY; CANCER THERAPY GENERAL; CANCER; DRUG RESEARCH,2014-10-01,2015-09-30,2,2,"Arctoris Inc., InhibRx Therapeutics",2,"{""level1_ip"": [{""title"": ""Small-molecule inhibitors targeting the DNA-binding domain of human androgen receptor for prostate cancer treatment"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""University of British Columbia"", ""description"": ""Patent covering novel small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor and its splice variants, aimed at treating resistant prostate cancer.""}, {""title"": ""Selective androgen receptor modulators for cancer therapy"", ""type"": ""patent"", ""filing_year"": 2017, ""assignee"": ""University of British Columbia"", ""description"": ""Patent on selective modulators of androgen receptor activity, including small molecules designed to inhibit receptor splice variants implicated in prostate cancer resistance.""}], ""level2_companies"": [{""company_name"": ""Arctoris Inc."", ""founding_year"": 2016, ""industry"": ""Biotechnology / Drug Discovery"", ""connection"": ""Co-founded by Artem Cherkasov; focuses on AI-driven drug discovery including cancer therapeutics relevant to androgen receptor targeting.""}, {""company_name"": ""InhibRx Therapeutics"", ""founding_year"": 2015, ""industry"": ""Biopharmaceuticals"", ""connection"": ""Founded by Artem Cherkasov; commercializes small-molecule inhibitors targeting androgen receptor splice variants for resistant prostate cancer treatment.""}]}",47:05.4
"Chopra, Rajiv","Sunnybrook Health Sciences Centre (Toronto, Ontario)",Ontario,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,Development of endorectal MR elastography for prostate cancer detection,153344,0,300844,1,2,Cancer Research,PROSTATE AND BLADDER CANCER; IMAGING; CANCER,2011-04-01,2012-03-31,3,5,"Profound Medical Inc., FUS Instruments, Solenic Medical, Texas Prostate Center, Perigon Imaging",5,"{""level1_ip"": [{""title"": ""Histotripsy therapy systems and methods for the treatment of brain tissue"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Rajiv Chopra et al."", ""description"": ""Ultrasound therapy systems designed for treatment of brain tissue using histotripsy methods.""}, {""title"": ""Histotripsy Therapy Systems And Methods For The Treatment Of Brain Tissue"", ""type"": ""Patent"", ""filing_year"": 2025, ""assignee"": ""Rajiv Chopra et al."", ""description"": ""Advanced histotripsy therapy systems for brain tissue treatment.""}, {""title"": ""MRI-controlled interstitial ultrasound therapy delivery system"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""Profound Medical Inc. / Rajiv Chopra"", ""description"": ""Systems and methods for delivering and controlling thermal therapy using MRI-controlled interstitial ultrasound applicators.""}], ""level2_companies"": [{""company_name"": ""Profound Medical Inc."", ""founding_year"": 2010, ""industry"": ""Medical Devices - Therapeutic Ultrasound"", ""connection"": ""Co-founded by Rajiv Chopra; commercializes MRI-controlled transurethral ultrasound therapy technology licensed from Sunnybrook Health Sciences Centre, clinically used since 2012.""}, {""company_name"": ""FUS Instruments"", ""founding_year"": 2009, ""industry"": ""Research Ultrasound Platforms"", ""connection"": ""Founded by Rajiv Chopra; provides research platforms related to therapeutic ultrasound.""}, {""company_name"": ""Solenic Medical"", ""founding_year"": 2015, ""industry"": ""Therapeutic Ultrasound"", ""connection"": ""Co-founded by Rajiv Chopra; develops therapeutic ultrasound technologies.""}, {""company_name"": ""Texas Prostate Center"", ""founding_year"": 2013, ""industry"": ""Medical Services - MRI-guided Ultrasound Therapy"", ""connection"": ""Co-founded by Rajiv Chopra; commercializes the TULSA Procedure, an MRI-guided ultrasound therapy for prostate disease derived from his research.""}, {""company_name"": ""Perigon Imaging"", ""founding_year"": 2018, ""industry"": ""Diagnostic and Image-Guided Therapy Centers"", ""connection"": ""Founded by Rajiv Chopra; offers MRI-guided focused ultrasound for prostate cancer treatment.""}]}",47:05.4
"Chopra, Rajiv","Sunnybrook Health Sciences Centre (Toronto, Ontario)",Ontario,Proof of Principle Program - Phase II,201102PP2,Proof of Principle,Evaluation of MRI-controlled interstitial ultrasound therapy for the treatment of cerebral neoplasms,147500,0,,1,,Cancer Research,BRAIN TUMORS THERAPY; IMAGING; CANCER,2011-10-01,2012-09-30,2,,"Profound Medical Inc., Texas Prostate Center",,"{""level1_ip"": [{""title"": ""Systems and methods for intracorporeal elastography using vibratory members to generate shear waves for MR elastography"", ""type"": ""patent"", ""filing_year"": 2011, ""assignee"": ""Rajiv Chopra"", ""description"": ""Patent related to intracorporeal elastography technology applicable to endorectal MR elastography for prostate cancer detection.""}, {""title"": ""Transurethral ultrasound system for prostate treatment"", ""type"": ""patent"", ""filing_year"": 2012, ""assignee"": ""Rajiv Chopra"", ""description"": ""Patent covering transurethral ultrasound devices and methods for prostate cancer treatment, relevant to the research area.""}], ""level2_companies"": [{""company_name"": ""Profound Medical Inc."", ""founding_year"": 2008, ""industry"": ""Medical Devices - Prostate Cancer Treatment"", ""connection"": ""Co-founded by Rajiv Chopra; commercializes transurethral ultrasound technology related to MR elastography research.""}, {""company_name"": ""Texas Prostate Center"", ""founding_year"": 2011, ""industry"": ""Healthcare - Prostate Cancer Treatment"", ""connection"": ""Co-founded by Rajiv Chopra; utilizes technology developed from MR elastography research for prostate cancer treatment.""}]}",47:05.4
"Coderre, Terence J",McGill University,Quebec,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,Synergistic topical combinations for chronic pain aimed at treating microvascular dysfunction.,160000,0,160000,1,1,"Neurosciences, Mental Health and Addiction",MULTIPLE DISEASE RELEVANCE; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DRUG RESEARCH; NERVOUS SYSTEM,2012-10-01,2013-09-30,1,1,SynergesX Pharma,1,"{""level1_ip"": [{""title"": ""Synergistic Topical Compositions for Treating Chronic Pain and Microvascular Dysfunction"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""University of Toronto"", ""description"": ""Patent covering synergistic topical combinations aimed at treating chronic pain by addressing microvascular dysfunction, with inventors including Terence J. Coderre.""}], ""level2_companies"": [{""company_name"": ""SynergesX Pharma"", ""founding_year"": 2015, ""industry"": ""Pharmaceuticals / Pain Management"", ""connection"": ""Co-founded by Terence J. Coderre to commercialize synergistic topical combinations for complex regional pain syndrome and neuropathic pain, directly related to the research project.""}]}",47:05.4
"Coles, John G",Hospital for Sick Children (Toronto),Ontario,Project Grant,201709PJT,Commercialization,Integrin Linked Kinase as a Novel Therapeutic Target for Heart Failure,512550,0,512550,3,3,Circulatory and Respiratory Health,"Cardiovascular, Respiratory and Circulatory Systems-Cardiovascular and Circulatory Sciences",2018-04-01,2021-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Compounds Modulating Integrin Linked Kinase (ILK) for Treatment of ILK-Mediated Diseases"", ""type"": ""Patent"", ""filing_year"": 2023, ""assignee"": ""Research Institution/Inventors including John G. Coles"", ""description"": ""Patent covering novel compounds that modulate ILK activity for therapeutic use in diseases such as heart failure, cancer, and inflammatory conditions.""}], ""level2_companies"": []}",47:05.4
"Conway, Edward M",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,Novel therapeutic approach for 'wet' and 'dry' age-related macular degeneration,160000,0,160000,1,1,Aging,DISEASES AFFECTING SPEECH/VISION/HEARING; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DRUG RESEARCH; AGING,2014-10-01,2015-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",47:05.4
"Cripton, Peter A",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,200904PPP,Proof of Principle,Pro-Neck-Tor: A helmet to prevent spinal cord injuries occuring during sports and transportation,149752,0,149752,1,1,Musculoskeletal Health and Arthritis,"INJURY, REGENERATION; MUSCULO SKELETAL; MUSCLE, BONE, OR JOINT; NERVOUS SYSTEM",2009-07-01,2010-06-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",35:50.8
"Crystal, Eugene","Sunnybrook Health Sciences Centre (Toronto, Ontario)",Ontario,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Three-dimensional Catheter Tracking using a Single Two-dimensional Image,130077,12873,142950,1,1,Circulatory and Respiratory Health,CARDIOLOGY; ARRHYTHMIAS; IMAGING; CARDIOVASCULAR,2010-04-01,2011-03-31,3,3,,0,"{""level1_ip"": [{""title"": ""Method and system for three-dimensional localization of an interventional medical device using a single two-dimensional image"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Sunnybrook Health Sciences Centre"", ""description"": ""A method for determining the 3D location of an object such as a catheter in real-time from a single 2D medical image, relevant to three-dimensional catheter tracking using a single two-dimensional image.""}, {""title"": ""Three-dimensional display of multi-electrode catheters and signals acquired over time"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""Biosense Webster Israel Ltd"", ""description"": ""Technology related to 3D visualization and tracking of multi-electrode catheters, relevant to the project on 3D catheter tracking from 2D images.""}, {""title"": ""Catheter tracking based on a model of an impedance tracking field"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Biosense Webster Israel Ltd"", ""description"": ""Patent related to tracking catheters using impedance models, relevant to 3D catheter tracking using 2D imaging.""}], ""level2_companies"": []}",35:50.8
"Cummins, Carolyn L",University of Toronto,Ontario,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,Developing a Novel Therapeutic for Cushing's Syndrome,160000,0,160000,1,1,"Nutrition, Metabolism and Diabetes",ENDOCRINOLOGY; MUSCULO SKELETAL; DRUG RESEARCH,2014-04-01,2015-03-31,4,4,,0,"{""level1_ip"": [{""title"": ""Methods of Treating Cushing's Syndrome with Improved Liver Safety"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""Therapeutics, Inc."", ""description"": ""A patent application describing novel therapeutic methods for treating Cushing's syndrome with a focus on liver safety.""}, {""title"": ""Treatment of Hypercoagulopathy in Cushing's Syndrome Patients"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Therapeutics, Inc."", ""description"": ""Patent covering methods to treat hypercoagulopathy associated with Cushing's syndrome.""}, {""title"": ""Compositions and Methods for Treating Cushing's Disease"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""Therapeutics, Inc."", ""description"": ""Patent application for novel compositions and treatment methods targeting Cushing's disease.""}, {""title"": ""Identification and Treatment of Hypokalemia in Cushing's Syndrome"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Therapeutics, Inc."", ""description"": ""Patent related to identifying and treating hypokalemia in patients with Cushing's syndrome.""}], ""level2_companies"": []}",35:50.8
"Cunningham, Charles H","Sunnybrook Health Sciences Centre (Toronto, Ontario)",Ontario,Proof of Principle Program - Phase I,201003PPP,Proof of Principle,Wire for MRI-Guided Interventions,139840,8395,148235,1,1,Circulatory and Respiratory Health,CORONARY CIRCULATION (INCL. INSUFFICIENCY); IMAGING; CARDIOVASCULAR,2010-10-01,2011-09-30,2,2,,0,"{""level1_ip"": [{""title"": ""MRI guidewire"", ""type"": ""patent"", ""filing_year"": 2010, ""assignee"": ""Charles H. Cunningham et al."", ""description"": ""Patent for an MRI-compatible guidewire technology filed after March 2010.""}, {""title"": ""MRI-guided catheters"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""MRI Interventions, Inc."", ""description"": ""Patent related to MRI-guided catheters filed in 2013, relevant to MRI-guided interventions.""}], ""level2_companies"": []}",35:50.8
"Cynader, Max S",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Novel peptide as potential therapeutic for treatment of ischemic stroke,160000,0,160000,1,1,"Neurosciences, Mental Health and Addiction","STROKE, HEART FAILURE",2012-04-01,2013-03-31,2,2,Primary Peptides Inc.,1,"{""level1_ip"": [{""title"": ""Neuroprotective peptides for treatment of ischemic stroke"", ""type"": ""Patent Application"", ""filing_year"": 2018, ""assignee"": ""Max S. Cynader"", ""description"": ""Patent application related to novel peptides inhibiting palmitoyl acyl transferase zinc-finger DHHC interaction, relevant to ischemic stroke therapy.""}, {""title"": ""Microglial Healing Peptides (MHPs) for ischemic stroke treatment"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""Max S. Cynader"", ""description"": ""Patent application covering novel peptides designed to promote microglial healing in ischemic stroke.""}], ""level2_companies"": [{""company_name"": ""Primary Peptides Inc."", ""founding_year"": 2015, ""industry"": ""Biotechnology - Peptide Therapeutics"", ""connection"": ""Founded and co-founded by Max S. Cynader; developing peptide therapeutics for ischemic stroke treatment; active commercialization and clinical trials ongoing post-2011.""}]}",35:50.8
"Dacosta, Ralph S",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase I,201102PPP,Proof of Principle,"Development of PRODIGI, a Handheld Optical Imaging Technology for Real-time Intraoperative-guidance of Breast Tumour Resection",121250,24000,145250,1,1,Cancer Research,BREAST CANCER; BREAST CANCER THERAPY; IMAGING; CANCER,2011-10-01,2012-09-30,2,2,MolecuLight Inc.,1,"{""level1_ip"": [{""title"": ""Handheld endoscopic imaging device"", ""type"": ""Design Patent"", ""filing_year"": 2021, ""assignee"": ""Ralph S DaCosta"", ""description"": ""Design patent for a handheld endoscopic imaging device related to intraoperative guidance.""}, {""title"": ""Handheld fluorescence imaging device"", ""type"": ""Utility Patent"", ""filing_year"": 2013, ""assignee"": ""Ralph S DaCosta"", ""description"": ""Patent covering a handheld fluorescence imaging system for real-time intraoperative tumor detection.""}], ""level2_companies"": [{""company_name"": ""MolecuLight Inc."", ""founding_year"": 2012, ""industry"": ""Medical Imaging Technology"", ""connection"": ""Founded by Ralph S DaCosta; commercializes handheld optical imaging devices based on the PRODIGI technology.""}]}",35:50.8
"Daugaard, Mads",University of British Columbia,British Columbia,Project Grant,202403PJT,Commercialization,An integrated AI-powered platform for cell analytics,730576,0,730576,4,4,Cancer Research,Commercialization-Technology Transfer; Artificial Intelligence-Machine Learning; Methods Development and Modelling-Qualitative Methods Development for Health Research,2024-10-01,2028-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",35:50.8
"de Rezende, Joao B",Unity Health Toronto,Ontario,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,A Non-Traumatic Binder for Temporary Abdominal Wall Closure,115768,0,115768,1,1,Infection and Immunity,NONE OF THE ABOVE; NOT CLASSIFIED,2015-10-01,2016-09-30,0,0,InventoRR MD Inc.,1,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""InventoRR MD Inc."", ""founding_year"": 2017, ""industry"": ""Medical Devices"", ""connection"": ""Co-founded by de Rezende, Joao B; commercializes technology from the research on non-traumatic binder for temporary abdominal wall closure (AbClo device)""}]}",04:25.6
"DeWitte-Orr, Stephanie","Wilfrid Laurier University (Waterloo, Ontario)",Ontario,Project Grant - PA: Pandemic Preparedness and Health Emergencies Research,202209PPE,Commercialization,Developing intranasal dsRNA molecules as broadly effective therapeutics against highly pathogenic coronaviruses,100000,0,100000,1,1,Infection and Immunity,"Immunology and Infection-Virology; Commercialization-Intellectual Property; Biomedical Engineering-Biomaterials, Nanotechnology and Biomechanics",2023-03-01,2024-02-29,0,0,HELIX FOUNDRY INC.,1,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""HELIX FOUNDRY INC."", ""founding_year"": null, ""industry"": ""Biotechnology"", ""connection"": ""Founded or co-founded by DeWitte-Orr, Stephanie""}]}",35:50.8
"Diallo, Jean-Simon",Ottawa Hospital Research Institute,Ontario,Proof of Principle Program - Phase II,201402PP2,Proof of Principle,Evaluation of viral sensitizer technology in improving egg-based influenza vaccine manufacturing processes,222143,77857,300000,1,1,Infection and Immunity,VIRAL; NONE OF THE ABOVE; VIROLOGY; BIOCHEMISTRY,2014-10-01,2015-09-30,0,0,Virica Biotech,1,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""Virica Biotech"", ""founding_year"": 2018, ""industry"": ""Biotechnology - Viral Sensitizer Technology for Vaccine Manufacturing"", ""connection"": ""Founded by Jean-Simon Diallo; commercializes viral sensitizer technology relevant to improving egg-based influenza vaccine manufacturing processes""}]}",35:50.8
"Diamandis, Eleftherios P",Sinai Health System (Toronto),Ontario,Project Grant,202203PJT,Commercialization,"KaliDerm Therapeutics: A research/commercialization plan to validate, better define and add value to our proprietary dual KLK5/7 inhibitor as a novel topical therapeutic for Netherton Syndrome.",336600,0,336600,2,2,Infection and Immunity,"Pharmacological, Toxicological and Pharmaceutical Sciences-Drug Discovery, Design and Delivery",2022-10-01,2024-09-30,2,2,,0,"{""level1_ip"": [{""title"": ""Dual inhibitor kallikrein antibodies and uses thereof"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""KaliDerm Therapeutics"", ""description"": ""Patent covering dual KLK5/7 inhibitor antibodies for treatment of Netherton Syndrome.""}, {""title"": ""KLK5/7 + IL-13 targeting antibodies and uses thereof"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""KaliDerm Therapeutics"", ""description"": ""Patent application for antibodies targeting KLK5/7 and IL-13 for therapeutic use in Netherton Syndrome.""}], ""level2_companies"": []}",35:50.8
"Dmitrienko, Gary I",University of Waterloo (Ontario),Ontario,Proof of Principle Program Phase I - Drug Development,200904PDD,Proof of Principle,Novel beta lactamase inhibitors to combat antibiotic resistance,150000,0,283277,1,2,Infection and Immunity,INFECTIOUS AND PARASITIC; DRUG RESEARCH; BACTERIOLOGY,2009-07-01,2010-06-30,2,6,Waterloo Pharmaceuticals Inc.,1,"{""level1_ip"": [{""title"": ""Inhibitors of Carbapenemase Enzymes for Treating Antibiotic Resistant Bacterial Infections"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""University of Waterloo"", ""description"": ""Patent covering novel compounds that inhibit carbapenemase enzymes, restoring efficacy of carbapenem antibiotics against resistant bacteria.""}, {""title"": ""Novel Antibacterial Agents Targeting Gram-negative Resistant Pathogens"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""University of Waterloo"", ""description"": ""Patent for new drug candidates effective against multidrug-resistant Gram-negative bacterial infections.""}], ""level2_companies"": [{""company_name"": ""Waterloo Pharmaceuticals Inc."", ""founding_year"": 2011, ""industry"": ""Biopharmaceuticals"", ""connection"": ""Founded by Dmitrienko, Gary I to commercialize new drugs for antibiotic resistant bacterial infections based on his research.""}]}",35:50.8
"Dmitrienko, Gary I",University of Waterloo (Ontario),Ontario,Proof of Principle Program - Phase II,201009PP2,Proof of Principle,New drugs for antibiotic resistant bacterial infections,133277,0,,1,,Infection and Immunity,INFECTIOUS AND PARASITIC; DRUG RESEARCH; BIOCHEMISTRY,2011-04-01,2012-03-31,4,,,,"{""level1_ip"": [{""title"": ""\u03b1-Aminoboronic acids as beta-lactamase inhibitors"", ""type"": ""patent"", ""filing_year"": 2010, ""assignee"": ""Dmitrienko, Gary I et al."", ""description"": ""Patent covering \u03b1-aminoboronic acid compounds as inhibitors of beta-lactamase enzymes to combat antibiotic resistance.""}, {""title"": ""\u03b1-Aminoboronic acids and derivatives as beta-lactamase inhibitors"", ""type"": ""patent"", ""filing_year"": 2010, ""assignee"": ""Dmitrienko, Gary I et al."", ""description"": ""Continuation patent on derivatives of \u03b1-aminoboronic acids targeting beta-lactamase inhibition.""}, {""title"": ""Novel beta-lactamase inhibitors for overcoming bacterial antibiotic resistance"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""Dmitrienko, Gary I et al."", ""description"": ""Patent describing new classes of beta-lactamase inhibitors to restore antibiotic efficacy.""}, {""title"": ""Peptide inhibitors of beta-lactamase against antibiotic resistance"", ""type"": ""patent"", ""filing_year"": 2023, ""assignee"": ""Dmitrienko, Gary I et al."", ""description"": ""Recent patent on novel peptide-based beta-lactamase inhibitors.""}], ""level2_companies"": []}",35:50.8
"Doschak, Michael R",University of Alberta,Alberta,Proof of Principle Program Phase I - Drug Development,201003PDD,Proof of Principle,Bisphosphonate-conjugated Calcitonin,117929,0,277929,1,2,Musculoskeletal Health and Arthritis,"DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; MUSCULO SKELETAL; DRUG RESEARCH; MUSCLE, BONE, OR JOINT",2010-10-01,2011-09-30,3,4,Osteometabolix,1,"{""level1_ip"": [{""title"": ""Bone-targeting PEGylated salmon calcitonin analogs"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""Osteometabolix"", ""description"": ""Patents covering synthesis and evaluation of bone-targeting PEGylated salmon calcitonin analogs filed after March 2010.""}, {""title"": ""Bisphosphonate conjugated calcitonin formulations"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""Osteometabolix"", ""description"": ""Patent-protected bisphosphonate conjugated calcitonin formulations with improved efficacy for bone diseases.""}, {""title"": ""Bisphosphonate conjugates for diagnosis and therapy of bone diseases"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""Osteometabolix"", ""description"": ""Patents on conjugated bisphosphonates for diagnosis and therapy of bone diseases filed after 2010.""}], ""level2_companies"": [{""company_name"": ""Osteometabolix"", ""founding_year"": 2011, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Founded by Michael R. Doschak to commercialize bisphosphonate-conjugated calcitonin technology; holds patent-protected BP-CT products with demonstrated superior preclinical efficacy.""}]}",35:50.8
"Doschak, Michael R",University of Alberta,Alberta,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,Bone-Seeking Iron Oxide Nanoparticles for Imaging Bone Metabolism,160000,0,,1,,Musculoskeletal Health and Arthritis,"DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; MUSCULO SKELETAL; DRUG RESEARCH; MUSCLE, BONE, OR JOINT",2016-04-01,2017-03-31,1,,Osteo Metabolics,,"{""level1_ip"": [{""title"": ""Preparation of bone-seeking superparamagnetic iron nanoparticles as contrast agents and methods for using the same"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""University of Alberta"", ""description"": ""Patent covering bone-seeking iron oxide nanoparticles for imaging bone metabolism; patent granted in 2018, filed before 2015-09 but granted after.""}], ""level2_companies"": [{""company_name"": ""Osteo Metabolics"", ""founding_year"": 2017, ""industry"": ""Biomedical Imaging / Nanotechnology"", ""connection"": ""Founded/co-founded by Michael R. Doschak; spin-off company related to bone-seeking iron oxide nanoparticle technology from University of Alberta.""}]}",35:50.8
"Drangova, Maria",Western University (Ontario),Ontario,Project Grant,202010PJT,Commercialization,Contact-force controller to eliminate the effects of motion during cardiac radiofrequency ablation,367200,0,367200,2,2,Circulatory and Respiratory Health,"Biomedical Engineering-Biophysics, Medical Technologies and Instrumentation",2021-04-01,2023-03-31,1,1,Aufero Medical,1,"{""level1_ip"": [{""title"": ""Contact-force controller for cardiac radiofrequency ablation"", ""type"": ""patent application"", ""filing_year"": 2021, ""assignee"": ""Daniel Gelman, Allan C. Skanes, Maria Drangova"", ""description"": ""Patent application related to a contact-force controller technology designed to eliminate the effects of motion during cardiac radiofrequency ablation, directly relevant to the project title and filed after October 2020.""}], ""level2_companies"": [{""company_name"": ""Aufero Medical"", ""founding_year"": 2021, ""industry"": ""Medical Devices/Cardiac Ablation Technology"", ""connection"": ""Co-founded by Drangova, Maria; licensed and commercialized the contact-force controller technology from this research.""}]}",35:50.8
"Du, Caigan",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Preclinical Development of a Novel Organ Transplant Solution,160000,0,160000,1,1,"Nutrition, Metabolism and Diabetes","GENITO/URINARY SYSTEM; MULTIPLE DISEASE RELEVANCE; RENAL FUNCTION, NEPHROLOGY, UROLOGY; DRUG RESEARCH",2015-04-01,2016-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Polymer Based Transplant Preservation Solution"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Caigan Du"", ""description"": ""Patent covering polymer-based solutions for organ transplant preservation, filed after September 2014.""}, {""title"": ""Solution for preserving and/or rinsing an organ to be transplanted"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Caigan Du"", ""description"": ""Patent for a novel solution designed to preserve or rinse organs prior to transplantation.""}], ""level2_companies"": []}",35:50.8
"Dumont, Guy A",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,Certifiably safe closed-loop control of anesthesia,158740,0,158740,1,1,Circulatory and Respiratory Health,HEALTH RESEARCH,2015-10-01,2016-09-30,2,2,,0,"{""level1_ip"": [{""title"": ""Closed-loop control system for anesthesia"", ""type"": ""Patent Application"", ""filing_year"": 2018, ""assignee"": ""University of Toronto"", ""description"": ""A system for controlled delivery of analgesic and hypnotic agents in clinical anesthesia using closed-loop control methods ensuring safety and efficacy.""}, {""title"": ""Safety-preserving control methods for anesthesia delivery"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""University of Toronto"", ""description"": ""Methods and apparatus for certifiably safe closed-loop control of anesthesia to maintain patient safety during automated drug delivery.""}], ""level2_companies"": []}",35:50.8
"Dutta, Tilak",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,Pressure ulcer prevention: a novel prompting system for patient repositioning,137401,0,137401,1,1,Aging,SKIN AND SUBCUTANEOUS TISSUS; MULTIPLE DISEASE RELEVANCE; AGING; GERIATRICS,2016-04-01,2017-03-31,4,4,,0,"{""level1_ip"": [{""title"": ""System and method for patient location determination and pressure ulcer monitoring"", ""type"": ""patent application"", ""filing_year"": 2016, ""assignee"": ""Tilak Dutta"", ""description"": ""A system using wireless communicators and cameras to monitor patient position and encourage repositioning to prevent pressure ulcers.""}, {""title"": ""Pressure ulcer prevention system with fabric-based sensing components"", ""type"": ""patent application"", ""filing_year"": 2019, ""assignee"": ""Tilak Dutta"", ""description"": ""A system integrating fabric sensors to monitor pressure and moisture for pressure ulcer prevention.""}, {""title"": ""Device for detection and prevention of pressure ulcers using sensors and fluid systems"", ""type"": ""patent"", ""filing_year"": 2018, ""assignee"": ""Tilak Dutta"", ""description"": ""A device employing sensors and fluid systems to detect and prevent pressure ulcers.""}, {""title"": ""System for monitoring medical conditions including pressure ulcers with sensors detecting patient characteristics"", ""type"": ""patent"", ""filing_year"": 2017, ""assignee"": ""Tilak Dutta"", ""description"": ""A system monitoring patient position, moisture, and other characteristics to prevent pressure ulcers.""}], ""level2_companies"": []}",35:50.8
"Dyck, Jason R",University of Alberta,Alberta,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Preclinical Development and Optimization of Small Molecules for the Treatment of Atrial Fibrillation,160000,0,160000,1,1,Circulatory and Respiratory Health,ARRHYTHMIAS; CARDIOLOGY; CARDIOVASCULAR; DRUG RESEARCH,2015-04-01,2016-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""INHIBITION OF OXIDATIVE STRESS IN ATRIAL FIBRILLATION"", ""type"": ""patent application"", ""filing_year"": 2015, ""assignee"": ""University of Alberta"", ""description"": ""Patent application involving shRNA molecules targeting NOX2 to reduce oxidative stress in atrial tissues to treat atrial fibrillation.""}, {""title"": ""Atrial fibrillation therapy"", ""type"": ""patent WO2015140571A1"", ""filing_year"": 2015, ""assignee"": ""University of Alberta"", ""description"": ""Methods for determining treatment of atrial fibrillation based on pitx2c expression levels.""}], ""level2_companies"": []}",35:50.8
"Fenster, Aaron",Western University (Ontario),Ontario,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,3D Ultrasound Scanner System For Management Of Intraventricular Hemorrhage In Preterm Neonates,148062,0,301485,1,2,"Human Development, Child and Youth Health",MULTIDISCIPLINARY; NONE OF THE ABOVE; IMAGING; BIOPHYSICS,2014-04-01,2015-03-31,1,3,NeoVision,3,"{""level1_ip"": [{""title"": ""3D Ultrasound Imaging System for Neonatal Brain Assessment"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""Western University"", ""description"": ""A patent covering a 3D ultrasound scanner system designed specifically for the management and assessment of intraventricular hemorrhage in preterm neonates, filed by Aaron Fenster and collaborators.""}], ""level2_companies"": [{""company_name"": ""NeoVision"", ""founding_year"": 2016, ""industry"": ""Medical Imaging Technology"", ""connection"": ""Co-founded by Aaron Fenster to commercialize neonatal brain imaging technology derived from his research on 3D ultrasound systems for intraventricular hemorrhage management.""}]}",35:50.8
"Fenster, Aaron",Western University (Ontario),Ontario,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,MR-Guided Focal Ablation of Prostate Cancer,143110,10313,,1,,Cancer Research,PROSTATE AND BLADDER CANCER THERAPY; IMAGING; CANCER,2016-04-01,2017-03-31,2,,"Centre for Imaging Technology Commercialization (CIMTEC), Focal Healthcare",,"{""level1_ip"": [{""title"": ""MRI-Guided Focal Laser Ablation System for Prostate Cancer"", ""type"": ""patent"", ""filing_year"": 2016, ""assignee"": ""Aaron Fenster et al."", ""description"": ""Patent covering MRI-guided focal laser ablation technology for targeted prostate cancer treatment.""}, {""title"": ""Mechatronic Needle Guidance System for Prostate Interventions"", ""type"": ""patent"", ""filing_year"": 2017, ""assignee"": ""Aaron Fenster et al."", ""description"": ""Patent for a robotic needle guidance system enhancing precision in prostate cancer focal ablation.""}], ""level2_companies"": [{""company_name"": ""Centre for Imaging Technology Commercialization (CIMTEC)"", ""founding_year"": 2016, ""industry"": ""Medical Imaging Technology Commercialization"", ""connection"": ""Founded and led by Aaron Fenster; licenses and commercializes imaging technologies including those for prostate cancer focal ablation.""}, {""company_name"": ""Focal Healthcare"", ""founding_year"": 2018, ""industry"": ""Medical Devices - Prostate Cancer Imaging and Therapy"", ""connection"": ""Co-founded by Aaron Fenster; licensed patents from CIMTEC related to MRI-guided focal ablation and AI-based 3D ultrasound imaging for prostate cancer.""}]}",35:50.8
"Fernie, Geoffrey R",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase II,201202PP2,Proof of Principle,A novel point-of-care method of handling human waste in healthcare institutions: technical improvements and evaluation.,51544,0,51544,1,1,Infection and Immunity,INFECTIOUS AND PARASITIC; NONE OF THE ABOVE; NOT CLASSIFIED,2012-10-01,2013-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",35:50.8
"Finlay, Barton B",University of British Columbia,British Columbia,Proof of Principle Program - Phase II,201009PP2,Proof of Principle,A sub-unit based vaccine for Salmonella,149685,0,149685,1,1,Infection and Immunity,GASTRO-INTESTINAL DISEASE; INFECTIOUS AND PARASITIC; BACTERIOLOGY; GASTROINTESTINAL (LIVER),2011-04-01,2012-03-31,5,5,"Vedanta Biosciences, Inc.",1,"{""level1_ip"": [{""title"": ""Salmonella ribonucleic acid vaccines inducing immune response"", ""type"": ""Patent Application"", ""filing_year"": 2017, ""assignee"": ""Finlay, Barton B et al."", ""description"": ""Patent application for RNA-based vaccines targeting Salmonella antigens to induce immune response.""}, {""title"": ""Nanoparticle compositions for vaccines against Salmonella"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Finlay, Barton B et al."", ""description"": ""Patent covering nanoparticle vaccine formulations designed to protect against Salmonella infection.""}, {""title"": ""Salmonella vaccines with RNA encoding Salmonella antigens"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""Finlay, Barton B et al."", ""description"": ""Application describing RNA vaccines encoding Salmonella antigens for immunization.""}, {""title"": ""Novel Salmonella mutants and vaccines eliciting humoral response"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""Finlay, Barton B et al."", ""description"": ""Patent on genetically modified Salmonella strains used as vaccines to elicit humoral immunity.""}, {""title"": ""Salmonella conjugate vaccines"", ""type"": ""Patent Application"", ""filing_year"": 2016, ""assignee"": ""Finlay, Barton B et al."", ""description"": ""Application for conjugate vaccine compositions targeting Salmonella species.""}], ""level2_companies"": [{""company_name"": ""Vedanta Biosciences, Inc."", ""founding_year"": 2010, ""industry"": ""Biotechnology"", ""connection"": ""Founded by Barton B Finlay; however, no direct evidence found that this company has licensed or commercialized technology specifically from the 'A sub-unit based vaccine for Salmonella' research.""}]}",35:50.8
"Flynn, Lauren E",Western University (Ontario),Ontario,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Development of novel porous extracellular matrix-derived bioscaffolds for cutaneous wound healing,160000,0,160000,1,1,Musculoskeletal Health and Arthritis,"SKIN AND SUBCUTANEOUS TISSUS; INJURY, REGENERATION; HEALTH RESEARCH; CELL BIOLOGY",2015-04-01,2016-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Porous foams derived from extracellular matrix for wound healing"", ""type"": ""patent"", ""filing_year"": 2016, ""assignee"": ""University of Toronto"", ""description"": ""Porous wound healing foam compositions derived from extracellular matrix materials relevant to novel porous extracellular matrix-derived bioscaffolds for cutaneous wound healing.""}, {""title"": ""Porous wound healing foam composition made from extracellular matrix"", ""type"": ""patent"", ""filing_year"": 2021, ""assignee"": ""University of Toronto"", ""description"": ""Porous wound healing foam compositions made from extracellular matrix, directly relevant to the project on novel porous extracellular matrix-derived bioscaffolds for cutaneous wound healing.""}], ""level2_companies"": []}",35:50.8
"Fon, Edward A",McGill University,Quebec,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,Targeting Alpha-Synuclein Propagation in the Treatment of Parkinson's Disease and Other Synucleinopathies,159946,0,159946,1,1,"Neurosciences, Mental Health and Addiction",PARKINSON'S DISEASE; AGING; NERVOUS SYSTEM; DRUG RESEARCH,2014-10-01,2015-09-30,5,5,,0,"{""level1_ip"": [{""title"": ""Methods and compositions for preventing and treating conditions related to alpha-synuclein, including Parkinson's Disease and other synucleinopathies"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Edward A. Fon et al."", ""description"": ""Patent covering methods and compositions targeting alpha-synuclein propagation for treatment of Parkinson's Disease and related synucleinopathies.""}, {""title"": ""Methods, antibodies, and vaccines utilizing epitopes of alpha-synuclein for treatment of Parkinson's Disease"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""Edward A. Fon et al."", ""description"": ""Patent describing antibodies and vaccines targeting alpha-synuclein epitopes for Parkinson's Disease treatment.""}, {""title"": ""Antisense oligonucleotides targeting alpha-synuclein transcript for treatment of synucleinopathies"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""Edward A. Fon et al."", ""description"": ""Patent application for antisense oligonucleotides designed to reduce alpha-synuclein expression in synucleinopathies.""}, {""title"": ""Antisense oligonucleotides targeting alpha-synuclein for treatment of synucleinopathies"", ""type"": ""Patent"", ""filing_year"": 2023, ""assignee"": ""Edward A. Fon et al."", ""description"": ""Patent for antisense oligonucleotides targeting alpha-synuclein to treat synucleinopathies.""}, {""title"": ""Antisense oligonucleotides targeting SNCA mRNA to reduce alpha-synuclein expression for treatment of neurological disorders including synucleinopathies"", ""type"": ""Patent Application"", ""filing_year"": 2021, ""assignee"": ""Edward A. Fon et al."", ""description"": ""Patent application covering antisense oligonucleotides targeting SNCA mRNA to reduce alpha-synuclein in neurological disorders.""}], ""level2_companies"": []}",35:50.8
"Foster, Leonard J",University of British Columbia,British Columbia,Project Grant - PA: Pandemic Preparedness and Health Emergencies Research,202403PPE,Commercialization,Development and Commercialization of a Safe and Effective Mpox Subunit Vaccine witheGlobaleImpact,100000,0,200000,1,2,Population and Public Health,"Population and Health-Health Promotion and Disease Prevention; Immunology and Infection-Antiviral Drug Resistance, Viral Vaccine Development and Therapeutics (including vaccines); Commercialization-Industry Research & Development",2009-01-01,2009-12-31,4,5,,0,"{""level1_ip"": [{""title"": ""Subunit vaccine delivery platform for robust humoral and cellular immune responses"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Leonard J Foster et al"", ""description"": ""A patent application filed after March 2024 covering a delivery platform for subunit vaccines enhancing immune responses, directly related to the Mpox subunit vaccine project.""}, {""title"": ""Molecular vaccines for infectious disease"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Leonard J Foster et al"", ""description"": ""A patent application filed after March 2024 for molecular vaccine technologies applicable to infectious diseases including Mpox.""}, {""title"": ""Mpox vaccine compositions and methods"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Leonard J Foster et al"", ""description"": ""A patent application filed after March 2024 describing compositions and methods for Mpox vaccine development.""}, {""title"": ""Human metapneumovirus combination vaccine"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Leonard J Foster et al"", ""description"": ""A patent application filed after March 2024 related to subunit vaccine technology, relevant to the vaccine platform used in the Mpox vaccine project.""}], ""level2_companies"": []}",35:50.8
"Foster, Leonard J",University of British Columbia,British Columbia,Project Grant - PA: Pandemic Preparedness and Health Emergencies Research,202309PPE,Commercialization,Development and Commercialization of a Safe and Effective Mpox Subunit Vaccine witheGlobaleImpact,100000,0,,1,,Population and Public Health,"Population and Health-Health Promotion and Disease Prevention; Immunology and Infection-Antiviral Drug Resistance, Viral Vaccine Development and Therapeutics (including vaccines)",2024-03-01,2025-02-28,1,,,,"{""level1_ip"": [{""title"": ""Mpox vaccine compositions and methods"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""University of British Columbia"", ""description"": ""Discloses vaccine compositions including polyvalent icosahedral compositions for presentation of an mpox antigen, directly relevant to the development of a safe and effective Mpox subunit vaccine.""}], ""level2_companies"": []}",35:50.8
"Fraser, Paul E",University of Toronto,Ontario,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,Amyloid-Based Therapies for Type 2 Diabetes,150000,0,150000,1,1,"Nutrition, Metabolism and Diabetes",DIABETES MELLITUS; METABOLISM AND NUTRITION; METABOLISM/DIABETES; BIOCHEMISTRY,2009-01-01,2009-12-31,3,3,,0,"{""level1_ip"": [{""title"": ""Inhibitors of Amyloid Fibril Formation and Uses Thereof"", ""type"": ""Patent Application Publication"", ""filing_year"": 2010, ""assignee"": ""Paul E. Fraser"", ""description"": ""Methods for treating type 1 or type 2 diabetes by administering antifibrillogenic agents to inhibit amyloid deposit formation.""}, {""title"": ""Inhibitors of Amyloid Fibril Formation Targeting Islet Amyloid Polypeptide Deposits"", ""type"": ""Patent Application"", ""filing_year"": 2008, ""assignee"": ""Paul E. Fraser"", ""description"": ""Compounds and methods to inhibit amyloid fibril formation related to islet amyloid polypeptide in type 2 diabetes.""}, {""title"": ""Diabetes Treatment Related to Islet Amyloid Polypeptide"", ""type"": ""European Patent"", ""filing_year"": 2012, ""assignee"": ""Paul E. Fraser"", ""description"": ""Therapeutic approaches targeting islet amyloid polypeptide for diabetes treatment.""}], ""level2_companies"": []}",35:50.8
"Frost, Eric H",Universite de Sherbrooke,Quebec,Proof of Principle Program - Phase I,201102PPP,Proof of Principle,"Simultaneous Influenza A detection, subtyping, and oseltamivir resistance determination",95000,65000,160000,1,1,Infection and Immunity,INFECTIOUS AND PARASITIC; MULTIPLE DISEASE RELEVANCE; VIROLOGY; HEALTH RESEARCH,2011-10-01,2012-09-30,4,4,,0,"{""level1_ip"": [{""title"": ""Methods for detecting influenza virus nucleic acid including subtyping and oseltamivir resistance (H275Y mutation)"", ""type"": ""Patent"", ""filing_year"": 2022, ""assignee"": ""Eric H Frost et al."", ""description"": ""Patent covering methods for simultaneous detection of Influenza A virus, subtyping, and determination of oseltamivir resistance mutation H275Y.""}, {""title"": ""Optimized probes and primers for binding, detecting, differentiating influenza A, B, and H1N1 RNA sequence mutation associated with oseltamivir resistance"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""Eric H Frost et al."", ""description"": ""Patent application for probes and primers designed to detect and differentiate influenza strains and oseltamivir resistance mutations.""}, {""title"": ""Antibodies and methods for influenza virus treatment and prophylaxis, including resistance considerations"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""Eric H Frost et al."", ""description"": ""Patent application describing antibodies and methods relevant to influenza virus treatment, including resistance detection.""}, {""title"": ""Methods for rapid detection of SARS-CoV-2, influenza A and B, including subtyping and oseltamivir resistance"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Eric H Frost et al."", ""description"": ""Patent for rapid detection methods covering influenza A subtyping and oseltamivir resistance determination.""}], ""level2_companies"": []}",35:50.8
"Garnis, Cathie",University of British Columbia,British Columbia,Project Grant,201809PJT,Commercialization,Blood based biomarker for the early detection of recurrent head and neck cancer,539324,0,1013624,4,8,Cancer Research,Cancer-Clinical Oncology,2019-04-01,2023-03-31,4,4,,0,"{""level1_ip"": [{""title"": ""Blood-based protein biomarker panel for early and accurate detection of cancer"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Garnis, Cathie et al."", ""description"": ""A patent application filed and issued in 2024 covering a blood-based protein biomarker panel for early detection of cancers including head and neck cancer using ultrasensitive immunoassays.""}, {""title"": ""Biomarkers for determining response to cancer therapy"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""Garnis, Cathie et al."", ""description"": ""A 2019 patent application for biomarkers useful in determining response to cancer therapy, including methods and kits for detection in biological fluids such as blood, relevant to head and neck cancer.""}, {""title"": ""Multiple biomarkers for early cancer detection"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""Garnis, Cathie et al."", ""description"": ""A 2022 patent application covering multiple biomarkers for early detection of cancer, including head and neck cancer.""}, {""title"": ""Methods evaluating head and neck cancers"", ""type"": ""Patent"", ""filing_year"": 2022, ""assignee"": ""Garnis, Cathie and Guillaud, M."", ""description"": ""Patent number 11377699 issued in 2022 for methods evaluating head and neck cancers using biomarker profiling.""}], ""level2_companies"": []}",35:50.8
"Garnis, Cathie",University of British Columbia,British Columbia,Project Grant,202309PJT,Commercialization,Blood based biomarker for the early detection of recurrent oropharyngeal cancer,474300,0,,4,,Cancer Research,Cancer-Cancer Progression and Metastasis; Cancer-Clinical Oncology,2024-04-01,2028-03-31,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",35:50.8
"Gatignol, Anne",CIUSSS de Centre-Ouest-de-l'Ile-de-Montreal-Jewish General,Quebec,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,Development of antisense-based small RNA agents targeting the GAG open reading frame of HIV-1 RNA for use in gene and drug therapy against HIV-1 infection.,159550,0,159550,1,1,Infection and Immunity,AIDS; VIRAL; VIROLOGY; MOLECULAR BIOLOGY,2014-04-01,2015-03-31,3,3,,0,"{""level1_ip"": [{""title"": ""Antisense nucleic acid molecules targeting the Gag region of HIV-1 RNA for inhibiting HIV-1 replication"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Universit\u00e9 de Montr\u00e9al"", ""description"": ""Patent application WO2015027334A1 discloses antisense nucleic acid molecules such as ribozymes, shRNA, and siRNA targeting the Gag open reading frame of HIV-1 RNA to inhibit HIV-1 replication and infection.""}, {""title"": ""Antisense nucleic acid molecules targeting the Gag region of HIV-1 RNA"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""Universit\u00e9 de Montr\u00e9al"", ""description"": ""Patent CA2958402A1 covers antisense nucleic acid molecules targeting the Gag region of HIV-1 RNA for therapeutic use against HIV-1 infection.""}, {""title"": ""Antisense nucleic acid molecules targeting the Gag region of HIV-1 RNA for inhibiting HIV-1 replication"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""Universit\u00e9 de Montr\u00e9al"", ""description"": ""Patent US-9932364-B2 filed after 2013 covers antisense nucleic acid molecules such as ribozymes, shRNA, and siRNA targeting the Gag region of HIV-1 open reading frame for inhibiting HIV-1 replication and infection.""}], ""level2_companies"": []}",35:50.8
"Ghahary, Aziz",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Discovery of a Novel Anti-fibrogenic factor and its Therapeutic evaluation,150932,0,298021,1,2,Musculoskeletal Health and Arthritis,"SKIN AND SUBCUTANEOUS TISSUS; INJURY, REGENERATION",2012-04-01,2013-03-31,2,2,"Si-Fi, Blue Room, TAO Clean",2,"{""level1_ip"": [{""title"": ""Anti-fibrogenic compounds, methods and uses thereof"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""The University of British Columbia"", ""description"": ""Patent related to novel anti-fibrogenic compounds and their therapeutic applications, inventors include Aziz Ghahary.""}, {""title"": ""Anti-fibrogenic compounds, methods and uses thereof"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""University of British Columbia"", ""description"": ""Similar patent covering anti-fibrogenic compounds and methods, inventors include Aziz Ghahary.""}], ""level2_companies"": [{""company_name"": ""Si-Fi"", ""founding_year"": null, ""industry"": ""Consumer Products/Personal Care"", ""connection"": ""Co-founded by Ghahary, Aziz; no direct evidence linking to anti-fibrogenic research but is his venture.""}, {""company_name"": ""Blue Room"", ""founding_year"": null, ""industry"": ""Consumer Products/Personal Care"", ""connection"": ""Co-founded by Ghahary, Aziz; no direct evidence linking to anti-fibrogenic research but is his venture.""}, {""company_name"": ""TAO Clean"", ""founding_year"": null, ""industry"": ""Consumer Products/Personal Care"", ""connection"": ""Co-founded by Ghahary, Aziz; no direct evidence linking to anti-fibrogenic research but is his venture.""}]}",35:50.8
"Ghahary, Aziz",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,Re -constitutable skin substitute powder kit,147089,0,,1,,Musculoskeletal Health and Arthritis,"SKIN AND SUBCUTANEOUS TISSUS; INJURY, REGENERATION",2014-04-01,2015-03-31,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",35:50.8
"Gibbings, Derrick J",University of Ottawa,Ontario,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,Technology to build a drug delivery platform for silencing RNAs using exosomes,159941,0,159941,1,1,Aging,MULTIPLE DISEASE RELEVANCE; MULTIDISCIPLINARY; HEALTH RESEARCH; DRUG RESEARCH,2015-10-01,2016-09-30,4,4,Hitchhike Therapeutics Inc.,1,"{""level1_ip"": [{""title"": ""Pharmaceutical compositions comprising exosomes containing RNAi agents"", ""type"": ""patent"", ""filing_year"": 2019, ""assignee"": ""Evox Therapeutics"", ""description"": ""Patents covering exosome-mediated RNA therapeutics and targeted drug delivery.""}, {""title"": ""Exosome engineering platform for loading therapeutic cargo proteins"", ""type"": ""patent"", ""filing_year"": 2020, ""assignee"": ""ILIAS Biologics"", ""description"": ""Patent covering EXPLOR platform technology for therapeutic cargo loading into exosomes.""}, {""title"": ""Methods of delivering and encapsulating exosomes for therapeutic purposes"", ""type"": ""patent application"", ""filing_year"": 2015, ""assignee"": ""Research team led by Derrick Gibbings"", ""description"": ""Patent application describing exosome delivery and encapsulation methods.""}, {""title"": ""Engineering endogenous vesicles as drug delivery platform for silencing RNAs"", ""type"": ""patent"", ""filing_year"": 2016, ""assignee"": ""Research team led by Derrick Gibbings"", ""description"": ""Patents related to engineering exosomes for RNA silencing drug delivery.""}], ""level2_companies"": [{""company_name"": ""Hitchhike Therapeutics Inc."", ""founding_year"": 2021, ""industry"": ""Biotechnology / Drug Delivery"", ""connection"": ""Founded by Derrick J. Gibbings to commercialize exosome drug delivery technology for silencing RNAs.""}]}",35:50.8
"Gleave, Martin E",University of British Columbia,British Columbia,Project Grant,201709PJT,Commercialization,Preclinical development of a novel androgen receptor antagonist to treat castration-resistant prostate cancer,351900,0,351900,2,2,Cancer Research,Cancer-Cancer Drug Development and Therapeutics,2018-04-01,2020-03-31,2,2,"TRiADD Therapeutics, Sustained Therapeutics, Sitka Biopharma",3,"{""level1_ip"": [{""title"": ""Androgen receptor inhibitors for treatment of non-metastatic castration-resistant prostate cancer"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Janssen Pharmaceutica NV"", ""description"": ""Patent WO2021089649A1 filed on 2019-11-04 discloses androgen receptor inhibitors relevant to castration-resistant prostate cancer.""}, {""title"": ""Compositions and methods for treating castration-resistant prostate cancer using androgen receptor inhibitors"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""Not specified"", ""description"": ""Patent US20230302021A1 published in 2023 describes novel compositions and methods targeting castration-resistant prostate cancer with androgen receptor antagonists.""}], ""level2_companies"": [{""company_name"": ""TRiADD Therapeutics"", ""founding_year"": 2018, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Martin E. Gleave, focused on therapeutics for prostate cancer.""}, {""company_name"": ""Sustained Therapeutics"", ""founding_year"": 2019, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Martin E. Gleave, developing treatments related to prostate cancer.""}, {""company_name"": ""Sitka Biopharma"", ""founding_year"": 2020, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Martin E. Gleave, involved in oncology drug development.""}]}",35:50.8
"Glogauer, Michael",University of Toronto,Ontario,Proof of Principle Program - Phase II,200904PP2,Proof of Principle,Clinical Evaluation of a Chair-side In Vitro Rinse Test for Predicting Onset and Recurrent Adult Periodontitis,88399,0,88399,1,1,Musculoskeletal Health and Arthritis,DENTAL DISEASE (INCL. ORAL BIOLOGY); DENTAL SCIENCE - Oral Biology; IMMUNOLOGY-TRANSPLANTATION,2009-07-01,2010-06-30,2,2,"Ostia Sciences Inc., OMG Perio",2,"{""level1_ip"": [{""title"": ""Diagnostic methods for periodontitis using chair-side saliva biomarker testing"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Michael L. Glogauer et al."", ""description"": ""Patent covering chair-side in vitro rinse test methods for predicting onset and recurrence of adult periodontitis, filed after 2009-04.""}, {""title"": ""Oral rinse compositions for treatment of periodontal disease"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Michael L. Glogauer et al."", ""description"": ""Patents covering oral rinse formulations aimed at treating periodontal disease, relevant to the project and filed after 2009-04.""}], ""level2_companies"": [{""company_name"": ""Ostia Sciences Inc."", ""founding_year"": 2019, ""industry"": ""Biotechnology - Oral Health"", ""connection"": ""Co-founded by Michael Glogauer; commercializes probiotics and diagnostic technologies related to oral health and periodontitis.""}, {""company_name"": ""OMG Perio"", ""founding_year"": null, ""industry"": ""Dental Clinic"", ""connection"": ""Founded by Michael Glogauer; focused on periodontal care consistent with research area.""}]}",35:50.8
"Gobbi, Gabriella",McGill University,Quebec,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,Novel first-in-class MT2 melatonin receptor partial agonists for neuropathic pain,160000,0,160000,1,1,"Neurosciences, Mental Health and Addiction",DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; MENTAL AND BEHAVIOURAL DISEASES; DRUG RESEARCH; NERVOUS SYSTEM,2016-04-01,2017-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Novel melatonin ligands modulating MT2 receptors for neuropathic pain"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""Gabriella Gobbi et al."", ""description"": ""Patent application WO2022259219A1 filed in 2022 covering novel first-in-class MT2 melatonin receptor partial agonists for neuropathic pain.""}], ""level2_companies"": []}",35:50.8
"Gobeil, Fernand J",Universite de Sherbrooke,Quebec,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Agonistes synthetiques de kinines : Optimiser la livraison et l'efficacite des chimiotherapies des tumeurs cerebrales,149418,0,149418,1,1,Cancer Research,BRAIN TUMORS THERAPY; BRAIN TUMORS (INCL. RETINAL TUMORS); CANCER; HEALTH RESEARCH,2012-04-01,2013-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Kinin B1 receptor peptide agonists and uses thereof"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""Fernand J. Gobeil et al."", ""description"": ""Patent covering synthetic kinin B1 receptor agonists designed to optimize delivery and efficacy of chemotherapies for brain tumors.""}, {""title"": ""Kinin-based theranostic probes for solid cancers and uses thereof"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Fernand J. Gobeil et al."", ""description"": ""Patent on kinin-based probes for diagnosis and treatment of solid tumors, enhancing chemotherapy delivery.""}], ""level2_companies"": []}",35:50.8
"Gong, Siew-Ging",University of Toronto,Ontario,Project Grant,202203PJT,Commercialization,Streptococcus salivarius Probiotics Against Dental Caries Pathogens,535501,0,535501,4,4,Musculoskeletal Health and Arthritis,"Commercialization-Intellectual Property; Health Determinants-Etiology of Disease and Conditions; Immunology and Infection-Antimicrobial Drug Resistance, Drug Discovery and Therapeutics (including vaccines)",2022-10-01,2026-09-30,0,0,SaliBiotics,1,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""SaliBiotics"", ""founding_year"": 2022, ""industry"": ""Biotechnology/Probiotics"", ""connection"": ""Founded by Gong, Siew-Ging; engaged in commercialization of probiotic bacteria targeting dental caries pathogens with research funding in 2022""}]}",35:50.8
"Graham, Simon J","Sunnybrook Health Sciences Centre (Toronto, Ontario)",Ontario,Proof of Principle Program - Phase I,201102PPP,Proof of Principle,Tablet Technology for Assessing Dementia,116402,0,116402,1,1,"Neurosciences, Mental Health and Addiction",ALZHEIMER'S DISEASE; IMAGING; NERVOUS SYSTEM,2011-10-01,2012-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Method and System for Computerized Drawing and Writing during Functional Magnetic Resonance Imaging"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""Simon J. Graham et al."", ""description"": ""Patent related to tablet technology used in neuropsychological assessments including dementia, filed after 2011-02.""}], ""level2_companies"": []}",35:50.8
"Granville, David J",University of British Columbia,British Columbia,Proof of Principle Program - Phase II,200910PP2,Proof of Principle,Therapeutic antibody development towards granzyme B,101240,0,101240,1,1,Circulatory and Respiratory Health,NONE OF THE ABOVE; AGING; CARDIOVASCULAR,2010-04-01,2011-03-31,2,2,"viDA Therapeutics, Inc.",1,"{""level1_ip"": [{""title"": ""Granzyme B inhibitor compositions and methods for promoting wound healing"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""University of British Columbia"", ""description"": ""Patent covering compositions and methods using granzyme B inhibitors for therapeutic antibody development and wound healing.""}, {""title"": ""Therapeutic antibodies targeting granzyme B"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""University of British Columbia"", ""description"": ""Patent describing therapeutic antibodies developed against granzyme B for disease treatment.""}], ""level2_companies"": [{""company_name"": ""viDA Therapeutics, Inc."", ""founding_year"": 2008, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by David J. Granville; commercializes granzyme B inhibitor technology derived from this research.""}]}",35:50.8
"Gratzer, Paul F",Dalhousie University (Nova Scotia),Nova Scotia,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,Decellularization of Human Skin,149034,10900,159934,1,1,Musculoskeletal Health and Arthritis,SKIN AND SUBCUTANEOUS TISSUS; IMMUNOLOGY-TRANSPLANTATION; NOT CLASSIFIED,2011-04-01,2012-03-31,3,3,DeCell Technologies Inc.,1,"{""level1_ip"": [{""title"": ""Methods for tissue decellularization"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""DeCell Technologies Inc."", ""description"": ""US Patent Application 13/580367 filed on 2013-01-31 for methods for tissue decellularization, credited to Paul F. Gratzer.""}, {""title"": ""Methods for tissue decellularization"", ""type"": ""patent"", ""filing_year"": 2011, ""assignee"": ""DeCell Technologies Inc."", ""description"": ""US Patent US9566369B2 granted for methods for tissue decellularization, filed around 2011, inventor Paul F. Gratzer.""}, {""title"": ""Tissue decellularization technology"", ""type"": ""patent"", ""filing_year"": 2016, ""assignee"": ""DeCell Technologies Inc."", ""description"": ""US Patent US11027048B2 related to tissue decellularization, with priority date 2016-09-01, inventor Paul F. Gratzer.""}], ""level2_companies"": [{""company_name"": ""DeCell Technologies Inc."", ""founding_year"": 2012, ""industry"": ""Biotechnology / Tissue Engineering"", ""connection"": ""Co-founded by Paul F. Gratzer; commercializes decellularization technology from the research.""}]}",35:50.8
"Greer, John J",University of Alberta,Alberta,Proof of Principle Program - Phase II,201502PP2,Proof of Principle,Ampakine Therapy for Alleviating Respiratory Depression,145440,0,145440,1,1,Circulatory and Respiratory Health,RESPIRATION; NONE OF THE ABOVE; NERVOUS SYSTEM,2015-10-01,2016-09-30,2,2,,0,"{""level1_ip"": [{""title"": ""Use of AMPAKINE molecules for treatment or prevention of respiratory depression"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""University of Alberta / Cortex Pharmaceuticals"", ""description"": ""Patent protecting the use of AMPAKINE molecules for respiratory depression treatment, licensed exclusively to Cortex Pharmaceuticals, based on Dr. John J. Greer's research.""}, {""title"": ""Ampakine therapy for treating respiratory depression in neuromuscular disease"", ""type"": ""patent"", ""filing_year"": 2016, ""assignee"": ""John J. Greer"", ""description"": ""Patent held by Dr. Greer covering the use of ampakines for respiratory depression treatment in neuromuscular disease.""}], ""level2_companies"": []}",35:50.8
"Grierson, David S",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Development of Specific Inhibitors of HIV pre-mRNA Alternative Splicing: A New Anti-HIV/AIDS Strategy,160000,0,160000,1,1,Infection and Immunity,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; AIDS; DRUG RESEARCH; VIROLOGY,2015-04-01,2016-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Compounds inhibiting HIV replication by targeting HIV-1 pre-mRNA alternative splicing"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""University of Auckland"", ""description"": ""Patent covering benzopyridoindole and pyridocarbazole derivatives that inhibit HIV replication by modulating HIV-1 pre-mRNA alternative splicing.""}, {""title"": ""Diheteroarylamide-based compounds blocking HIV replication"", ""type"": ""patent"", ""filing_year"": 2016, ""assignee"": ""University of Auckland"", ""description"": ""Patent application describing novel diheteroarylamide compounds that inhibit HIV-1 pre-mRNA splicing and block HIV replication.""}], ""level2_companies"": []}",35:50.8
"Gross, Peter L",McMaster University,Ontario,Project Grant,202203PJT,Commercialization,Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants,279225,0,279225,2,2,Circulatory and Respiratory Health,"Cardiovascular, Respiratory and Circulatory Systems-Vascular and Endothelial Biology; Commercialization-Intellectual Property; Cardiovascular, Respiratory and Circulatory Systems-Hematology",2022-10-01,2024-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",35:50.8
"Grynpas, Marc D",Sinai Health System (Toronto),Ontario,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,"""Calcium Polyphosphate Bone Substitutes""",156022,0,156022,1,1,Musculoskeletal Health and Arthritis,"OSTEOPOROSIS; AGING; MUSCLE, BONE, OR JOINT",2011-04-01,2012-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Morphogenetically Active Amorphous Calcium Polyphosphate Nanoparticles Containing Retinol For Therapeutic Applications"", ""type"": ""patent application"", ""filing_year"": 2017, ""assignee"": ""Marc D. Grynpas et al."", ""description"": ""Patent application involving calcium polyphosphate nanoparticles relevant to bone substitute materials.""}, {""title"": ""Bone Substitute Material Involving Calcium Phosphates"", ""type"": ""patent application"", ""filing_year"": 2019, ""assignee"": ""Marc D. Grynpas et al."", ""description"": ""Patent application related to bone substitute materials using calcium phosphate compounds.""}], ""level2_companies"": []}",35:50.8
"Guertin, Pierre",Universite Laval,Quebec,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,First-in-class Therapeutic Against Urinary Retention (Continence) in Patients with Chronic Spinal Cord Injury and Related Disorders,160000,0,320000,1,2,"Neurosciences, Mental Health and Addiction","SPINAL CORD DISEASE; GENITO/URINARY SYSTEM; NERVOUS SYSTEM; RENAL FUNCTION, NEPHROLOGY, UROLOGY",2012-04-01,2013-03-31,1,2,"Nordic Life Science Pipeline Inc., Trienix Pharma",5,"{""level1_ip"": [{""title"": ""Compositions and methods for inducing and restoring locomotor functions in chronic spinal cord injured animals"", ""type"": ""patent application"", ""filing_year"": 2013, ""assignee"": ""Pierre Guertin"", ""description"": ""Patent application related to drug compositions and methods to improve locomotor functions in chronic spinal cord injury, including effects on defecation episodes.""}], ""level2_companies"": [{""company_name"": ""Nordic Life Science Pipeline Inc."", ""founding_year"": 2013, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Pierre Guertin; licensed technology related to SpinalonTM for clinical trials targeting spinal cord injury-related conditions including chronic constipation.""}, {""company_name"": ""Trienix Pharma"", ""founding_year"": 2015, ""industry"": ""Pharmaceuticals"", ""connection"": ""Founded by Pierre Guertin; involved in development and commercialization of drug candidates related to spinal cord injury treatment.""}]}",35:50.8
"Guertin, Pierre",Universite Laval,Quebec,Proof of Principle Program - Phase I,201302PPP,Proof of Principle,A Novel Class of Drug Treatment Against Chronic Constipation in Spinal Cord-Injured People,160000,0,,1,,"Neurosciences, Mental Health and Addiction",SPINAL CORD DISEASE; GASTRO-INTESTINAL DISEASE; NERVOUS SYSTEM; GASTROINTESTINAL (LIVER),2013-10-01,2014-09-30,1,,"Trienix Pharma, NeuroSpina Therapeutics, Eurymedon HealthCare, Nordic Life Science Pipeline Inc, Laboratoires Guertin",,"{""level1_ip"": [{""title"": ""Methods and compositions for improving locomotor function in spinal cord injured subjects"", ""type"": ""Patent"", ""filing_year"": 2005, ""assignee"": ""Pierre A. Guertin"", ""description"": ""Patent related to improving locomotor function in spinal cord injured subjects, granted September 6, 2011, just after the cutoff date. No newer patents specifically related to the project title were found after 2011-09.""}], ""level2_companies"": [{""company_name"": ""Trienix Pharma"", ""founding_year"": 2001, ""industry"": ""Biopharmaceutical"", ""connection"": ""Founded by Pierre Guertin, CEO""}, {""company_name"": ""NeuroSpina Therapeutics"", ""founding_year"": 2005, ""industry"": ""Biopharmaceutical"", ""connection"": ""Founded by Pierre Guertin, President and CEO 2005-2008; involved in drug development and clinical studies related to spinal cord injury""}, {""company_name"": ""Eurymedon HealthCare"", ""founding_year"": 2005, ""industry"": ""Biopharmaceutical"", ""connection"": ""Founded by Pierre Guertin, Chief Scientific Officer 2005-2008; involved in drug development and clinical studies related to spinal cord injury""}, {""company_name"": ""Nordic Life Science Pipeline Inc"", ""founding_year"": 2011, ""industry"": ""Biopharmaceutical"", ""connection"": ""Founded by Pierre Guertin, President and CEO; completed first clinical trial of Spinalon in 2016""}, {""company_name"": ""Laboratoires Guertin"", ""founding_year"": 2019, ""industry"": ""Biopharmaceutical"", ""connection"": ""Founded by Pierre Guertin; commercializing Spinalon, a tritherapy candidate for chronic spinal cord injury including urinary retention; launched funding campaign in 2019 to support phase IIb pilot study""}]}",35:50.8
"Haddad, Elie","Centre hospitalier universitaire Sainte-Justine (Montreal, Quebec)",Quebec,Project Grant - PA: Breast Cancer Research,202109PLL,Commercialization,Platform of synthetic specific promoters for immunotherapies and regenerative medicine,100000,0,260000,1,5,Cancer Research,Commercialization-Intellectual Property; Commercialization-Technology Transfer; Cancer-Cancer Drug Development and Therapeutics,2022-03-01,2023-03-31,1,1,Immugenia,1,"{""level1_ip"": [{""title"": ""Synthetic promoters for gene therapy and protein expression"", ""type"": ""Patent"", ""filing_year"": 2022, ""assignee"": ""Elias Haddad"", ""description"": ""Patent WO/2022/192687 covering synthetic specific promoters designed for applications in immunotherapies and regenerative medicine, filed after September 2021.""}], ""level2_companies"": [{""company_name"": ""Immugenia"", ""founding_year"": 2022, ""industry"": ""Biotechnology/Immunotherapy"", ""connection"": ""Co-founded by Elie Haddad to commercialize synthetic specific promoter technology developed in the research project.""}]}",53:59.0
"Haddad, Elie","Centre hospitalier universitaire Sainte-Justine (Montreal, Quebec)",Quebec,Project Grant,202209PJT,Commercialization,Empowering innovative hematopoietic stem cells (HSC)-based cancer immunotherapy through the creation of synthetic specific promoters,765000,0,,4,,Cancer Research,Commercialization-Intellectual Property; Commercialization-Technology Transfer; Cancer-Cancer Drug Development and Therapeutics,2023-04-01,2027-03-31,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",35:50.8
"Hancock, Robert Ernest W",University of British Columbia,British Columbia,Proof of Principle Program Phase I - Drug Development,201102PDD,Proof of Principle,Novel anti-inflammatory treatment for Amyotrophic Lateral Sclerosis,160000,0,320000,1,2,"Neurosciences, Mental Health and Addiction",DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; AMYOTROPHIC LATERAL SCLEROSIS (ALS); DRUG RESEARCH; NERVOUS SYSTEM,2011-10-01,2012-09-30,3,6,"Asep Medical Holdings Inc., ABT Innovations",2,"{""level1_ip"": [{""title"": ""Compositions for treating amyotrophic lateral sclerosis"", ""type"": ""US Patent"", ""filing_year"": 2018, ""assignee"": ""Hancock, Robert Ernest W"", ""description"": ""Patent covering novel compositions aimed at treating amyotrophic lateral sclerosis with anti-inflammatory properties.""}, {""title"": ""Treatment of amyotrophic lateral sclerosis"", ""type"": ""US Patent"", ""filing_year"": 2017, ""assignee"": ""Hancock, Robert Ernest W"", ""description"": ""Methods and compositions for treating ALS by modulating inflammatory pathways.""}, {""title"": ""Treatment of amyotrophic lateral sclerosis"", ""type"": ""EP Patent Application"", ""filing_year"": 2011, ""assignee"": ""Hancock, Robert Ernest W"", ""description"": ""European patent application for novel anti-inflammatory treatments for ALS.""}], ""level2_companies"": [{""company_name"": ""Asep Medical Holdings Inc."", ""founding_year"": 2012, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Hancock, Robert Ernest W; involved in development of anti-inflammatory treatments relevant to ALS research.""}, {""company_name"": ""ABT Innovations"", ""founding_year"": 2015, ""industry"": ""Biotechnology"", ""connection"": ""Founded by Hancock, Robert Ernest W; focuses on drug development including neurodegenerative disease therapies.""}]}",53:59.0
"Hancock, Robert Ernest W",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Anti-Biofilm Therapy,160000,0,,1,,Infection and Immunity,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; INFECTIOUS AND PARASITIC; BACTERIOLOGY; DRUG RESEARCH,2013-04-01,2014-03-31,3,,"ABT Innovations Inc., Asep Medical Holdings Inc. (Asep Inc.), ASEP Medical Holdings, Inc.",,"{""level1_ip"": [{""title"": ""Small cationic anti-biofilm and IDR peptides"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""Robert Ernest W. Hancock"", ""description"": ""US Patent Application #20190315823 filed on 2019-10-17 covering small cationic anti-biofilm and innate defense regulator peptides.""}, {""title"": ""Small cationic anti-biofilm and IDR peptides"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""Robert Ernest W. Hancock"", ""description"": ""WO2015038339A1 filed on 2014-08-27 for small cationic anti-biofilm and innate defense regulator peptides.""}, {""title"": ""Biofilm prevention, disruption, and treatment with bacteriophage lysin"", ""type"": ""Patent"", ""filing_year"": 2022, ""assignee"": ""Robert Ernest W. Hancock"", ""description"": ""US Patent #11,524,046 issued on 2022-12-13 for biofilm prevention, disruption, and treatment using bacteriophage lysin.""}], ""level2_companies"": [{""company_name"": ""ABT Innovations Inc."", ""founding_year"": 2015, ""industry"": ""Biotechnology/Anti-biofilm therapeutics"", ""connection"": ""Founded by Robert Ernest W. Hancock; licenses peptide technology for bacterial biofilm infections and related therapeutic applications.""}, {""company_name"": ""Asep Medical Holdings Inc. (Asep Inc.)"", ""founding_year"": 2014, ""industry"": ""Medical therapeutics/Anti-biofilm agents"", ""connection"": ""Founded by Robert Ernest W. Hancock; advancing research and innovations from Hancock's lab including broad-spectrum therapeutic agents addressing multi-drug resistant biofilm infections.""}, {""company_name"": ""ASEP Medical Holdings, Inc."", ""founding_year"": 2021, ""industry"": ""Medical therapeutics"", ""connection"": ""Founded by Robert Ernest W. Hancock; involved in commercialization of anti-biofilm therapies derived from Hancock's research.""}]}",53:59.0
"Hanrahan, John W",McGill University,Quebec,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,CFTR modulators as a potential new therapeutic paradigm to treat individuals with COPD,159665,0,159665,1,1,Circulatory and Respiratory Health,CHRONIC OBSTRUCTIVE LUNG DISEASE; RESPIRATION; HEALTH RESEARCH,2014-10-01,2015-09-30,5,5,Glantreo,1,"{""level1_ip"": [{""title"": ""Compound for treating diseases including COPD by modulating CFTR activity"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""John W. Hanrahan et al."", ""description"": ""WO2015173551A1 filed 2014-05-12, involving CFTR modulators for COPD treatment.""}, {""title"": ""Modulators of CFTR, pharmaceutical compositions, and methods of treatment"", ""type"": ""Patent"", ""filing_year"": 2023, ""assignee"": ""John W. Hanrahan et al."", ""description"": ""US Patent 11,591,350 issued 2023-02-28 covering CFTR modulators relevant to COPD.""}, {""title"": ""CFTR-modulating compositions and methods for gene editing related to CFTR"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""John W. Hanrahan et al."", ""description"": ""US Patent Application 20240093186 issued 2024-03-21 on CFTR modulator compositions and gene editing.""}, {""title"": ""Process of making CFTR modulators"", ""type"": ""Patent Application"", ""filing_year"": 2021, ""assignee"": ""John W. Hanrahan et al."", ""description"": ""WO2021030554A1 related to synthesis of CFTR modulators.""}, {""title"": ""Restoration of CFTR function by splicing modulation"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""John W. Hanrahan et al."", ""description"": ""US Patent Application 20220213479 issued 2022-07-07 covering CFTR modulators including ivacaftor.""}], ""level2_companies"": [{""company_name"": ""Glantreo"", ""founding_year"": 2015, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by John W. Hanrahan; company focused on CFTR modulator technology relevant to COPD.""}]}",53:59.0
"Hansen, Carl L",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,Pre-commercial development of single cell antibody selection process,154120,0,154120,1,1,Infection and Immunity,MULTIPLE DISEASE RELEVANCE; MULTIDISCIPLINARY; IMMUNOLOGY-TRANSPLANTATION; HEALTH RESEARCH,2012-10-01,2013-09-30,3,3,AbCellera Biologics Inc.,1,"{""level1_ip"": [{""title"": ""Methods for selecting single cells expressing heterogeneous combinations of antibodies"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Carl L. Hansen"", ""description"": ""Patent covering methods for single cell antibody selection relevant to the project.""}, {""title"": ""Methods for Assaying Cellular Binding Interactions"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""Carl L. Hansen"", ""description"": ""Patent related to microfluidic assays for antibody binding interactions from single cells.""}, {""title"": ""Humanized anti-CD19 antibodies and therapeutic uses"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""Carl L. Hansen"", ""description"": ""Patent on therapeutic antibodies derived from single cell selection methods.""}], ""level2_companies"": [{""company_name"": ""AbCellera Biologics Inc."", ""founding_year"": 2012, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Carl L. Hansen; commercializes technology from the single cell antibody selection research.""}]}",53:59.0
"Hassell, John A",McMaster University,Ontario,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Characterization of small molecule sensitizers to chemotherapy,160000,0,160000,1,1,Cancer Research,BREAST CANCER THERAPY; BREAST CANCER; CANCER; DRUG RESEARCH,2012-04-01,2013-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",53:59.0
"Hebert, Marc",Universite Laval,Quebec,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,"Diagnostic differentiel de la schizophrenie, la depression bipolaire et la depression majeure e l'aide de l'electroretinographie",159700,0,159700,1,1,"Neurosciences, Mental Health and Addiction",DEPRESSION; MENTAL HEALTH,2014-04-01,2015-03-31,0,0,"Chronophotonix, diaMentis",2,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""Chronophotonix"", ""founding_year"": 2014, ""industry"": ""Mental health diagnostics and neurotechnology"", ""connection"": ""Founded by Marc H\u00e9bert to commercialize technologies related to light effects on the brain and mental health diagnostics, directly relevant to the research on differential diagnosis of schizophrenia and mood disorders using electroretinography.""}, {""company_name"": ""diaMentis"", ""founding_year"": 2015, ""industry"": ""Personalized medicine and mental health diagnostics"", ""connection"": ""Co-founded by Marc H\u00e9bert to develop and commercialize diagnostic technologies in mental health, aligned with the project on differential diagnosis of psychiatric disorders using electroretinography.""}]}",53:59.0
"Hess, Robert F",McGill University,Quebec,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,Assessment and Treatment of Binocular Vision in Amblyopia,126802,0,126802,1,1,"Neurosciences, Mental Health and Addiction",DISEASES AFFECTING SPEECH/VISION/HEARING; VISION,2009-01-01,2009-12-31,4,4,,0,"{""level1_ip"": [{""title"": ""Binocular vision assessment and/or therapy"", ""type"": ""Patent Application"", ""filing_year"": 2010, ""assignee"": ""McGill University"", ""description"": ""US Patent Application 12/528934 filed on 2010-08-12 for binocular vision assessment and/or therapy, credited to Robert F. Hess.""}, {""title"": ""Game platform for assessment and/or treatment of binocular vision disorders such as amblyopia"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""Robert F. Hess"", ""description"": ""US8066372B2 granted in 2011 for a game platform for assessment and/or treatment of binocular vision disorders such as amblyopia by Robert F. Hess.""}, {""title"": ""Apparatus and methods for treatment of ocular disorders including amblyopia"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Robert F. Hess"", ""description"": ""US10251546B2 for apparatus and methods for treatment of ocular disorders including amblyopia.""}, {""title"": ""Binocular vision assessment and/or therapy"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""Robert F. Hess"", ""description"": ""US8057036B2 for binocular vision assessment and/or therapy by Robert F. Hess.""}], ""level2_companies"": []}",53:59.0
"Houde, Daniel",Universite de Sherbrooke,Quebec,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,Radiotherapie par filamentation laser femtoseconde,112602,0,112602,1,1,Cancer Research,CANCER THERAPY GENERAL; BRAIN TUMORS THERAPY; CANCER; BIOPHYSICS,2011-04-01,2012-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Method of material processing by laser filamentation"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Unknown"", ""description"": ""Involves femtosecond laser pulses to generate filaments inside transparent media, relevant to femtosecond laser filamentation technology.""}, {""title"": ""System performing laser filamentation within transparent materials using ultrafast laser pulses"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Unknown"", ""description"": ""A system designed for laser filamentation inside transparent materials using ultrafast laser pulses, directly relevant to femtosecond laser filamentation.""}], ""level2_companies"": []}",53:59.0
"Hunter, Graeme K",Western University (Ontario),Ontario,Proof of Principle Program - Phase I,200904PPP,Proof of Principle,Crystal-binding peptides for prevention of kidney stone disease,116350,6000,122350,1,1,"Nutrition, Metabolism and Diabetes",GENITO/URINARY SYSTEM; ATHEROSCLEROSIS; DRUG RESEARCH; BIOPHYSICS,2009-07-01,2010-06-30,3,3,,0,"{""level1_ip"": [{""title"": ""Peptides inhibiting calcium oxalate crystallization for kidney stone prevention"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""Hunter, Graeme K"", ""description"": ""Patents covering peptides derived from Matrix Gla Protein (MGP) that inhibit nucleation and growth of hydroxyapatite and calcium oxalate monohydrate crystals relevant to kidney stone disease prevention.""}, {""title"": ""Peptides for treatment of renal disorders including kidney failure"", ""type"": ""Patent Application US20220251153A1"", ""filing_year"": 2022, ""assignee"": ""Hunter, Graeme K"", ""description"": ""Patent application relating to peptides designed for treatment of renal disorders, including kidney failure and prevention of kidney stones.""}, {""title"": ""Crystal growth inhibitors for prevention of L-cystine kidney stones"", ""type"": ""Patent"", ""filing_year"": 2010, ""assignee"": ""Hunter, Graeme K"", ""description"": ""Patent covering molecular design of peptides as inhibitors of crystal growth to prevent L-cystine kidney stones.""}], ""level2_companies"": []}",53:59.0
"Huntsman, David G",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,A Diagnostic Test for Granulosa Cell Tumours of the Ovary,150000,0,304829,1,2,Cancer Research,CANCER,2010-04-01,2011-03-31,2,2,Contextual Genomics Inc.,1,"{""level1_ip"": [{""title"": ""Method for detecting granulosa-cell tumors by detecting FOXL2 gene mutation"", ""type"": ""Patent Application"", ""filing_year"": 2011, ""assignee"": ""University of British Columbia"", ""description"": ""A diagnostic method detecting granulosa cell tumors of the ovary by identifying the FOXL2 402C>G mutation.""}, {""title"": ""Diagnostic method for granulosa-cell tumors via FOXL2 mutation detection"", ""type"": ""Patent Application"", ""filing_year"": 2010, ""assignee"": ""University of British Columbia"", ""description"": ""A method for diagnosing granulosa cell tumors by detecting a specific FOXL2 gene mutation.""}], ""level2_companies"": [{""company_name"": ""Contextual Genomics Inc."", ""founding_year"": 2012, ""industry"": ""Genomic Diagnostics"", ""connection"": ""Co-founded by David G. Huntsman; involved in genomic diagnostics relevant to ovarian tumor research""}]}",53:59.0
"Huntsman, David G",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,PrOTYPE: An Enabling Technology to Improve Ovarian Cancer Care,154829,0,,1,,Cancer Research,"NEOPLASMS; NONE OF THE ABOVE; CANCER; GENOMICS, PROTEOMICS, AND BIOINFORMATICS",2013-04-01,2014-03-31,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",53:59.0
"Husain, Mansoor",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase II,201202PP2,Proof of Principle,Development of an anti-proliferative therapeutic that disrupts CaM-cyclin E interactions in vivo.,184100,10600,194700,1,1,Circulatory and Respiratory Health,ATHEROSCLEROSIS; CANCER THERAPY GENERAL; CARDIOVASCULAR; CELL BIOLOGY,2012-10-01,2013-09-30,3,3,"Blue Ocean Technologies Inc., Scientific Design Company, Inc., Unnamed Canadian biopharmaceutical company",3,"{""level1_ip"": [{""title"": ""Highly active anti-neoplastic and anti-proliferative agents"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""G1 Therapeutics, Inc."", ""description"": ""Patent WO2014144740A2 related to anti-proliferative therapeutics disrupting CaM-cyclin E interactions.""}, {""title"": ""Inhibitors of cyclin-dependent kinases (CDKs) including CDK7, CDK12, and CDK13"", ""type"": ""Patent"", ""filing_year"": 2022, ""assignee"": ""Not specified"", ""description"": ""US Patent 11,325,910 covering inhibitors relevant to cell cycle regulation and anti-proliferative therapy.""}, {""title"": ""Cell cycle disorder treatments involving inhibitors affecting cyclin interactions"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Not specified"", ""description"": ""US Patent Application 20130230458 related to treatments targeting cyclin interactions for anti-proliferative effects.""}], ""level2_companies"": [{""company_name"": ""Blue Ocean Technologies Inc."", ""founding_year"": null, ""industry"": ""Biotechnology"", ""connection"": ""Founded or co-founded by Husain, Mansoor""}, {""company_name"": ""Scientific Design Company, Inc."", ""founding_year"": null, ""industry"": ""Engineering/Scientific Services"", ""connection"": ""Husain, Mansoor is Chief Engineer""}, {""company_name"": ""Unnamed Canadian biopharmaceutical company"", ""founding_year"": null, ""industry"": ""Biopharmaceuticals"", ""connection"": ""Licensed a therapeutic patent held by Husain, Mansoor; Husain is not founder/co-founder, so excluded from list""}]}",53:59.0
"Hysi, Eno",Unity Health Toronto,Ontario,Project Grant,202403PJT,Commercialization,Commercialization of H-scan: a new tool for imaging kidney fibrosis,726750,0,726750,3,3,"Nutrition, Metabolism and Diabetes","Commercialization-Intellectual Property; Biomedical Engineering-Biomedical Imaging; Digestive, Endocrine and Excretory Systems-Nephrology and Urology",2024-10-01,2027-09-30,0,0,"ScarDx, Fibrocor Therapeutics",2,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""ScarDx"", ""founding_year"": 2024, ""industry"": ""Medical Imaging Software"", ""connection"": ""Founded by Hysi, Eno; commercializing H-scan technology for kidney fibrosis imaging""}, {""company_name"": ""Fibrocor Therapeutics"", ""founding_year"": 2024, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Hysi, Eno; involved in kidney fibrosis research and commercialization""}]}",53:59.0
"Jaffray, David A",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,Advanced Handheld SPECT System for Intraoperative Guidance,159845,0,159845,1,1,Cancer Research,CANCER THERAPY GENERAL; CANCER,2014-10-01,2015-09-30,4,4,"Acumyn, Inc., Nanovista Inc.",2,"{""level1_ip"": [{""title"": ""Systems and methods augmenting intraoperative video feed with virtual display features based on tracked medical instrument position"", ""type"": ""patent application"", ""filing_year"": 2021, ""assignee"": ""University Health Network"", ""description"": ""Patent application US20210153953 filed after 2014 related to intraoperative guidance systems enhancing video feeds with virtual displays.""}, {""title"": ""Surgical guidance system and method"", ""type"": ""patent application"", ""filing_year"": 2021, ""assignee"": ""University Health Network"", ""description"": ""Patent application US20210186632A1 filed after 2014 for surgical guidance systems relevant to intraoperative imaging.""}, {""title"": ""Systems and methods for registering intraoperative image data with an imaging probe and medical instrument reference frame"", ""type"": ""patent application"", ""filing_year"": 2021, ""assignee"": ""University Health Network"", ""description"": ""Patent application US20240153113 filed Mar 10, 2021 for intraoperative image registration methods.""}, {""title"": ""Systems and methods for performing intraoperative guidance"", ""type"": ""patent application"", ""filing_year"": 2018, ""assignee"": ""University Health Network"", ""description"": ""European patent application EP3773305A4 filed Apr 9, 2018 for intraoperative guidance systems.""}], ""level2_companies"": [{""company_name"": ""Acumyn, Inc."", ""founding_year"": 2015, ""industry"": ""Medical Imaging Technology"", ""connection"": ""Co-founded by David A. Jaffray; develops imaging systems relevant to intraoperative guidance.""}, {""company_name"": ""Nanovista Inc."", ""founding_year"": 2016, ""industry"": ""Nanoparticle-based Imaging Agents"", ""connection"": ""Co-founded by David A. Jaffray; focuses on image-guided cancer therapy, related to imaging guidance but not explicitly licensing handheld SPECT system.""}]}",53:59.0
"Jarvi, Keith A",Sinai Health System (Toronto),Ontario,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,"Novel semen biomarkers to identify sperm production in men with infertility: A non-invasive method to characterize men with azoospermia or no sperm in the semen, into those with and without testicular sperm production",152499,0,467159,1,3,"Human Development, Child and Youth Health",INFERTILITY MALE; GENITO/URINARY SYSTEM; ENDOCRINOLOGY; REPRODUCTION/PREGNANCY,2011-04-01,2012-03-31,0,1,,0,"{""level1_ip"": [], ""level2_companies"": []}",53:59.0
"Jarvi, Keith A",Sinai Health System (Toronto),Ontario,Proof of Principle Program - Phase I,201302PPP,Proof of Principle,Prediction of successful sperm retrieval in patients with non-obstructive azoospermia using a panel of protein biomarkers measured in seminal plasma,154660,0,,1,,"Human Development, Child and Youth Health","INFERTILITY MALE; PREGNANCY/BIRTH; GENOMICS, PROTEOMICS, AND BIOINFORMATICS; REPRODUCTION/PREGNANCY",2013-10-01,2014-09-30,1,,,,"{""level1_ip"": [{""title"": ""Markers of the male urogenital tract"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""Jarvi, Keith A et al."", ""description"": ""Patent covering biomarkers in semen to identify sperm production in men with infertility, directly related to non-invasive characterization of azoospermia.""}], ""level2_companies"": []}",53:59.0
"Jarvi, Keith A",Sinai Health System (Toronto),Ontario,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,Prediction of successful sperm retrieval in patients with non-obstructive azoospermia using TEX101 protein measured in seminal plasma by ELISA,160000,0,,1,,"Human Development, Child and Youth Health","INFERTILITY MALE; PREGNANCY/BIRTH; GENOMICS, PROTEOMICS, AND BIOINFORMATICS; REPRODUCTION/PREGNANCY",2016-04-01,2017-03-31,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",53:59.0
"Jarzem, Peter F",McGill University,Quebec,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,"Minimally Invasive Ready, Highly Expandable Vertebral Body Replacement Device",122826,0,122826,1,1,Cancer Research,"BONE CANCER; MUSCULO SKELETAL; NERVOUS SYSTEM; MUSCLE, BONE, OR JOINT",2010-04-01,2011-03-31,3,3,,0,"{""level1_ip"": [{""title"": ""Minimally Invasive Expandable Contained Vertebral Implant and Method"", ""type"": ""patent application"", ""filing_year"": 2009, ""assignee"": ""Peter F. Jarzem et al"", ""description"": ""Expandable implantable devices for vertebral body replacement designed for minimally invasive procedures, filed April 16, 2009, published October 21, 2010.""}, {""title"": ""Expandable Interbody Device for Use in the Spine"", ""type"": ""patent"", ""filing_year"": 2018, ""assignee"": ""Peter F. Jarzem et al"", ""description"": ""An expandable interbody device designed for minimally invasive operative access to the spine, issued December 29, 2020.""}, {""title"": ""Devices and Methods for Treating Vertebral Fractures"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""Peter F. Jarzem et al"", ""description"": ""Devices and methods related to expandable vertebral body replacement implants, filed after 2009.""}], ""level2_companies"": []}",53:59.0
"Juncker, David",McGill University,Quebec,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Clinical validation of an innovative multiplex antibody microarray platform,150000,0,150000,1,1,Cancer Research,"MULTIDISCIPLINARY; BREAST CANCER; GENOMICS, PROTEOMICS, AND BIOINFORMATICS; CANCER",2010-04-01,2011-03-31,2,2,Nomic,1,"{""level1_ip"": [{""title"": ""Nanoarray-in-Microarray Multiplexed Analysis Methods and Systems"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""David Juncker"", ""description"": ""Patent covering multiplex antibody microarray technology relevant to the project.""}, {""title"": ""Snap Chip for Multiplexed Sandwich Immunoassays"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""David Juncker"", ""description"": ""Patent application for a multiplex immunoassay platform related to antibody microarrays.""}], ""level2_companies"": [{""company_name"": ""Nomic"", ""founding_year"": 2017, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by David Juncker; no direct evidence of licensing or commercialization of the multiplex antibody microarray platform from the specified project.""}]}",53:59.0
"Kastrup, Christian J",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,Self-Propelling Hemostatic Particles that Treat Severe Bleeding,159788,0,159788,1,1,Circulatory and Respiratory Health,CLOTTING DEFECTS/THROMBOSIS; PREGNANCY/BIRTH; CARDIOVASCULAR; BLOOD,2014-10-01,2015-09-30,1,1,"NanoVation Therapeutics, SeraGene Therapeutics, CoMotion Drug Delivery Systems",3,"{""level1_ip"": [{""title"": ""Self-Fueled Particles for Propulsion Through Flowing Aqueous Fluids"", ""type"": ""Patent"", ""filing_year"": 2022, ""assignee"": ""Christian J. Kastrup et al."", ""description"": ""Patent covering self-propelling particle technology designed for hemostasis applications, granted March 8, 2022.""}], ""level2_companies"": [{""company_name"": ""NanoVation Therapeutics"", ""founding_year"": 2016, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Christian J. Kastrup, focusing on advanced therapeutic technologies.""}, {""company_name"": ""SeraGene Therapeutics"", ""founding_year"": 2018, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Christian J. Kastrup, involved in therapeutic development.""}, {""company_name"": ""CoMotion Drug Delivery Systems"", ""founding_year"": 2017, ""industry"": ""Medical Devices/Drug Delivery"", ""connection"": ""Co-founded by Christian J. Kastrup; actively commercializing self-propelling hemostatic particle technology from the research.""}]}",53:59.0
"Kazem-Moussavi, Zahra M",University of Manitoba,Manitoba,Project Grant,201803PJT,Commercialization,Acoustical Device for Obstructive Sleep Apnea Severity Prediction during Wakefulness,367200,0,367200,3,3,Circulatory and Respiratory Health,"Biomedical Engineering-Biophysics, Medical Technologies and Instrumentation; Health Determinants-Etiology of Disease and Conditions",2018-10-01,2021-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",53:59.0
"Kelley, Shana O",University of Toronto,Ontario,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,Clinical validation of low-cost ultrasensitive electronic molecular  diagnostics,150000,0,470000,1,3,Genetics,MULTIPLE DISEASE RELEVANCE; GENETICS,2009-01-01,2009-12-31,2,7,"Xagenic Inc., CTRL Therapeutics, Arma Biosciences",3,"{""level1_ip"": [{""title"": ""Ultrasensitive Electrochemical Biosensor for Molecular Diagnostics"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""University of Toronto"", ""description"": ""Patent covering ultrasensitive electrochemical biosensors for detecting biomolecules at low cost, directly related to electronic molecular diagnostics.""}, {""title"": ""Nucleic Acid Detection Assay Using Low-Cost Materials"", ""type"": ""Patent"", ""filing_year"": 2022, ""assignee"": ""University of Toronto"", ""description"": ""Patent application for ultrasensitive nucleic acid detection methods employing low-cost materials, relevant to clinical molecular diagnostics.""}], ""level2_companies"": [{""company_name"": ""Xagenic Inc."", ""founding_year"": 2010, ""industry"": ""Molecular Diagnostics"", ""connection"": ""Co-founded by Kelley, Shana O; focuses on rapid diagnostic testing technologies relevant to ultrasensitive molecular diagnostics.""}, {""company_name"": ""CTRL Therapeutics"", ""founding_year"": 2019, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Kelley, Shana O; develops technologies in molecular diagnostics aligned with ultrasensitive detection.""}, {""company_name"": ""Arma Biosciences"", ""founding_year"": 2020, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Kelley, Shana O; commercializes ultrasensitive molecular diagnostic technologies.""}]}",53:59.0
"Kelley, Shana O",University of Toronto,Ontario,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Preclinical testing of a mitochondrially-targeted anticancer agent,160000,0,,1,,Cancer Research,CANCER THERAPY GENERAL; CANCER; GENETICS,2012-04-01,2013-03-31,2,,"CTRL Therapeutics, Arma Biosciences",,"{""level1_ip"": [{""title"": ""In vitro capture and analysis of circulating tumor cells"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""Shana O Kelley et al."", ""description"": ""Patent US9250242B2 filed after 2014-02 related to tumor cell sorting and classification using microfluidic devices.""}, {""title"": ""Device for capture of particles in a flow"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""Shana O Kelley et al."", ""description"": ""Patent WO2014166000A1 filed after 2014-02 describing a device for capturing circulating tumor cells in fluid flow.""}], ""level2_companies"": [{""company_name"": ""CTRL Therapeutics"", ""founding_year"": 2019, ""industry"": ""Biotechnology / Molecular Diagnostics"", ""connection"": ""Co-founded by Shana O Kelley, relevant to tumor cell capture and diagnostics.""}, {""company_name"": ""Arma Biosciences"", ""founding_year"": 2021, ""industry"": ""Biotechnology / Molecular Diagnostics"", ""connection"": ""Co-founded by Shana O Kelley, working in related molecular diagnostic technologies.""}]}",53:59.0
"Kelley, Shana O",University of Toronto,Ontario,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,The xViva CTC capture chip: a device for tumor cell sorting and classification,160000,0,,1,,Genetics,PROSTATE AND BLADDER CANCER; CANCER THERAPY GENERAL; GENETICS; CANCER,2014-10-01,2015-09-30,3,,"CTRL Therapeutics, Arma Biosciences",,"{""level1_ip"": [{""title"": ""Mitochondrially-targeted anticancer agents using mitochondrial penetrating peptides"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""Kelley, Shana O"", ""description"": ""Compounds comprising mitochondrial targeting portions conjugated to anticancer agents for targeted delivery to mitochondria.""}, {""title"": ""Peptide-based conjugates for intracellular delivery of anticancer drugs"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Kelley, Shana O"", ""description"": ""Peptide conjugates designed to penetrate mitochondria and deliver anticancer drugs effectively.""}, {""title"": ""Mitochondrially targeted platinum-based anticancer agents"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""Kelley, Shana O"", ""description"": ""Platinum-based compounds modified for mitochondrial targeting to enhance anticancer efficacy.""}], ""level2_companies"": [{""company_name"": ""CTRL Therapeutics"", ""founding_year"": 2019, ""industry"": ""Biotechnology"", ""connection"": ""Founded by Shana O. Kelley; relevant to molecular diagnostics and cancer therapeutics.""}, {""company_name"": ""Arma Biosciences"", ""founding_year"": 2021, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Shana O. Kelley; focused on novel therapeutic agents.""}]}",53:59.0
"Kim, Peter K",Hospital for Sick Children (Toronto),Ontario,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,A novel therapeutic treatment for Zellweger Spectrum Disorder,160000,0,160000,1,1,"Human Development, Child and Youth Health",METABOLISM AND NUTRITION; CONGENITAL ANOMALIES; CELL BIOLOGY; GENETICS,2015-10-01,2016-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Therapeutic methods for Zellweger Spectrum Disorder"", ""type"": ""patent"", ""filing_year"": 2016, ""assignee"": ""Kim, Peter K"", ""description"": ""Patent covering novel therapeutic compounds and treatment methods for Zellweger Spectrum Disorder and related peroxisome biogenesis disorders.""}], ""level2_companies"": []}",53:59.0
"Kizhakkedathu, Jayachandran N",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,Novel Polymer Based Glucose-sparing Peritoneal Dialysis Solutions for End-stage Renal Disease,160000,0,764748,1,8,"Nutrition, Metabolism and Diabetes","RENAL FUNCTION, NEPHROLOGY, UROLOGY",2012-10-01,2013-09-30,3,8,,1,"{""level1_ip"": [{""title"": ""Peritoneal dialysis solution comprising carnitine, xylitol, and glucose polymers for end-stage renal disease"", ""type"": ""Patent"", ""filing_year"": 2023, ""assignee"": ""Kizhakkedathu, Jayachandran N"", ""description"": ""A novel peritoneal dialysis solution utilizing glucose polymers to improve treatment for end-stage renal disease.""}, {""title"": ""Solution for peritoneal dialysis with glucose polymers"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Kizhakkedathu, Jayachandran N"", ""description"": ""A peritoneal dialysis solution formulation incorporating glucose polymers to spare glucose usage.""}, {""title"": ""Novel glucose polymers for peritoneal dialysis"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""Kizhakkedathu, Jayachandran N"", ""description"": ""Application describing novel glucose polymers designed for improved peritoneal dialysis solutions.""}], ""level2_companies"": []}",53:59.0
"Kizhakkedathu, Jayachandran N",University of British Columbia,British Columbia,Proof of Principle Program - Phase II,201402PP2,Proof of Principle,Preclinical Development of a Glucose-Free Peritoneal Dialysis Solution,289799,5000,,1,,"Nutrition, Metabolism and Diabetes","RENAL FUNCTION, NEPHROLOGY, UROLOGY",2014-10-01,2015-09-30,1,,Avivo Biomedical Inc.,,"{""level1_ip"": [{""title"": ""Glucose-Free Peritoneal Dialysis Solution"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""University of British Columbia"", ""description"": ""Patent covering the formulation and use of a glucose-free peritoneal dialysis solution developed in the preclinical stage.""}], ""level2_companies"": [{""company_name"": ""Avivo Biomedical Inc."", ""founding_year"": 2020, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Kizhakkedathu, Jayachandran N; however, company focuses on enzyme technology for blood type conversion, not directly related to glucose-free peritoneal dialysis solution.""}]}",53:59.0
"Kizhakkedathu, Jayachandran N",University of British Columbia,British Columbia,Project Grant,202010PJT,Commercialization,Novel Infection Resistant Coating in an Era of Drug Resistant Bacteria for the Treatment and Prevention of Medical Device Infection,520199,0,,3,,Infection and Immunity,"Commercialization-Intellectual Property; Biomedical Engineering-Biomaterials, Nanotechnology and Biomechanics; Immunology and Infection-Antimicrobial Drug Resistance, Drug Discovery and Therapeutics (including vaccines)",2021-04-01,2024-03-31,2,,Avivo Labs Inc.,,"{""level1_ip"": [{""title"": ""Antimicrobial Peptide Coatings for Medical Devices"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""University of British Columbia"", ""description"": ""Compositions and methods for antimicrobial peptide coatings on medical devices to prevent bacterial adhesion and biofilm formation.""}, {""title"": ""Polymeric Catechol Binder Compositions for Durable Antimicrobial Coatings"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""University of British Columbia"", ""description"": ""Innovative polymeric binders with catechol groups for creating durable infection-resistant coatings on medical device surfaces.""}], ""level2_companies"": [{""company_name"": ""Avivo Labs Inc."", ""founding_year"": 2019, ""industry"": ""Biomedical Coatings and Medical Device Infection Prevention"", ""connection"": ""Co-founded by Kizhakkedathu, Jayachandran N; company commercializes antimicrobial coating technologies relevant to the research.""}]}",53:59.0
"Kizhakkedathu, Jayachandran N",University of British Columbia,British Columbia,Project Grant,202209PJT,Commercialization,Localized immuno-cloaking organ engineering approach to prevent transplant rejection without immunosuppressants,803250,0,,3,,Infection and Immunity,"Biomedical Engineering-Biomaterials, Nanotechnology and Biomechanics; Immunology and Infection-Transplantation, Immune Tolerance and Tumor Immunology; Commercialization-Intellectual Property",2023-04-01,2026-03-31,2,,,,"{""level1_ip"": [{""title"": ""CELL-SURFACE ENGINEERING COMPOSITIONS AND METHODS FOR IMMUNO-CLOAKING IN ORGAN TRANSPLANTATION"", ""type"": ""patent"", ""filing_year"": 2025, ""assignee"": ""University of British Columbia"", ""description"": ""This patent covers compositions and methods for cell-surface engineering using immune-deactivating polymers to locally cloak transplanted organs, preventing graft injury and transplant rejection without systemic immunosuppressants.""}, {""title"": ""ARTIFICIAL PLACENTA VACCINE FOR ORGAN TRANSPLANT IMMUNE MODULATION"", ""type"": ""patent"", ""filing_year"": 2023, ""assignee"": ""University of British Columbia"", ""description"": ""This patent describes devices and methods for an artificial placenta vaccine aimed at eliminating the need for chronic systemic immunosuppression in transplant recipients by localized immune modulation.""}], ""level2_companies"": []}",53:59.0
"Koeberle, Paulo D",University of Toronto,Ontario,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Peptide therapeutics for preventing retinal ganglion cell apoptosis,149949,0,149949,1,1,"Neurosciences, Mental Health and Addiction",GLAUCOMA; DISEASES AFFECTING SPEECH/VISION/HEARING,2015-04-01,2016-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Novel peptides and methods and uses thereof for preventing retinal disorders"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""University of British Columbia"", ""description"": ""This patent involves C-terminal peptides for inhibiting neuronal cell death or dysfunction, including retinal ganglion cell death or dysfunction, directly relevant to peptide therapeutics for preventing retinal ganglion cell apoptosis.""}], ""level2_companies"": []}",53:59.0
"Kotra, Lakshmi P",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,In vivo efficacy studies on KP-218 as a potential MS therapeutic agent,160000,0,160000,1,1,"Neurosciences, Mental Health and Addiction",MULTIPLE SCLEROSIS; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS,2014-10-01,2015-09-30,1,1,Lucid Psycheceuticals,1,"{""level1_ip"": [{""title"": ""Compounds and methods for treating multiple sclerosis"", ""type"": ""patent application"", ""filing_year"": 2015, ""assignee"": ""Kotra, Lakshmi P"", ""description"": ""Patent application covering novel compounds including KP-218 for treatment of multiple sclerosis filed after 2014-02.""}], ""level2_companies"": [{""company_name"": ""Lucid Psycheceuticals"", ""founding_year"": 2020, ""industry"": ""Biotechnology - Multiple Sclerosis Therapeutics"", ""connection"": ""Co-founded by Kotra, Lakshmi P; commercializes MS therapeutic agents related to KP-218 research.""}]}",53:59.0
"Kouassi, Edouard",CIUSSS Est-de-l'Ile-de- Montreal-Maisonneuve Rosemont,Quebec,Proof of Principle Program - Phase I,201003PPP,Proof of Principle,Novel methods and compounds for increasing red blood cell survival,160000,0,160000,1,1,Circulatory and Respiratory Health,BLOOD; ANAEMIAS; DRUG RESEARCH,2010-10-01,2011-09-30,5,5,,0,"{""level1_ip"": [{""title"": ""Methods and compounds for increasing red blood cell survival"", ""type"": ""patent application"", ""filing_year"": 2011, ""assignee"": ""Edouard Kouassi"", ""description"": ""Patent application published in 2011 describing methods and compounds to increase red blood cell survival, directly related to the project.""}, {""title"": ""Methods and compounds for increasing red blood cell survival"", ""type"": ""patent"", ""filing_year"": 2018, ""assignee"": ""Edouard Kouassi"", ""description"": ""Granted patent improving red blood cell survival and storage, relevant to the research area.""}, {""title"": ""Article of manufacture and methods for increasing survival of red blood cells"", ""type"": ""patent application"", ""filing_year"": 2017, ""assignee"": ""Edouard Kouassi"", ""description"": ""Patent application describing ex-vivo methods to increase red blood cell survival.""}, {""title"": ""Methods for increasing red blood cell half-life and treating anemia"", ""type"": ""patent application"", ""filing_year"": 2024, ""assignee"": ""Edouard Kouassi"", ""description"": ""Recent patent application involving polypeptide antagonists to increase red blood cell half-life.""}, {""title"": ""Activin-ActRII antagonists and uses for increasing red blood cell levels"", ""type"": ""patent"", ""filing_year"": 2018, ""assignee"": ""Edouard Kouassi"", ""description"": ""European patent related to compounds increasing red blood cell levels.""}], ""level2_companies"": []}",53:59.0
"Kremer, Richard B",Research Institute of the McGill University Health Centre,Quebec,Project Grant,202209PJT,Commercialization,Anti-parathyroid hormone-related protein (PTHrP) monoclonal antibodies against metastatic cancer,665550,0,665550,3,3,Cancer Research,"Commercialization-Technology Transfer; Musculoskeletal Health-Bone, Skin and Cartilage Sciences; Pharmacological, Toxicological and Pharmaceutical Sciences-Drug Discovery, Design and Delivery",2023-04-01,2026-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",53:59.0
"Kubow, Stanley",McGill University,Quebec,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Protective Effects of Potato Polyphenol-Rich Extracts Against Lung Damage Caused by Air Pollutants,150525,0,150525,1,1,Circulatory and Respiratory Health,ENVIRONMENTAL INFLUENCES ON HEALTH; RESPIRATION; NUTRITION,2012-04-01,2013-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Compositions and Methods for Preventing and Treating Diseases and Environmentally Induced Health Disorders"", ""type"": ""patent application"", ""filing_year"": 2014, ""assignee"": ""Stanley Kubow et al."", ""description"": ""Patent application filed on 2014-11-06 related to compositions and methods involving potato polyphenol-rich extracts for preventing and treating diseases and environmentally induced health disorders, relevant to protective effects against lung damage caused by air pollutants.""}], ""level2_companies"": []}",53:59.0
"Kumar, Rakesh",University of Alberta,Alberta,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Development of new class of antiviral drugs for influenza A virus infections,156590,0,316440,1,2,Infection and Immunity,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; INFECTIOUS AND PARASITIC; HEALTH RESEARCH; DRUG RESEARCH,2013-04-01,2014-03-31,3,6,,1,"{""level1_ip"": [{""title"": ""Peptides for treatment of viral infections including influenza A"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Kumar, Rakesh et al."", ""description"": ""U.S. Patent #11,304,989 issued April 19, 2022, covering novel peptides effective against influenza A virus.""}, {""title"": ""Antiviral agents for drug-resistant influenza A"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""Kumar, Rakesh et al."", ""description"": ""EP3389787A1 published February 26, 2020, describing antiviral compounds targeting drug-resistant influenza A strains.""}, {""title"": ""Antiviral drugs targeting virus retention genes"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""Kumar, Rakesh et al."", ""description"": ""U.S. Patent #10,709,727 issued July 14, 2020, on antiviral drugs targeting genes related to virus retention in host cells including influenza.""}], ""level2_companies"": []}",53:59.0
"Kumar, Rakesh",University of Alberta,Alberta,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,Development of novel chemotherapeutics for tuberculosis,159850,0,,1,,Infection and Immunity,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; INFECTIOUS AND PARASITIC; DRUG RESEARCH; BACTERIOLOGY,2014-04-01,2015-03-31,3,,Appstrail Technology,,"{""level1_ip"": [{""title"": ""Novel MmpL3 Inhibitors for Treatment of Drug-Resistant Tuberculosis"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""Kumar, Rakesh et al."", ""description"": ""Patent covering novel MmpL3 inhibitors effective against multi-drug resistant Mycobacterium tuberculosis strains.""}, {""title"": ""Diphenyl Ether-Based InhA Inhibitors for Tuberculosis Therapy"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Kumar, Rakesh et al."", ""description"": ""Patent on novel diphenyl ether derivatives targeting InhA enzyme in Mycobacterium tuberculosis, active against drug-resistant strains.""}, {""title"": ""Nucleoside Analog Compounds for Tuberculosis Treatment"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Kumar, Rakesh et al."", ""description"": ""Patent describing novel nucleoside analogs with potent activity against Mycobacterium tuberculosis.""}], ""level2_companies"": [{""company_name"": ""Appstrail Technology"", ""founding_year"": 2020, ""industry"": ""Salesforce Consulting and Digital Transformation"", ""connection"": ""Co-founded by Kumar, Rakesh; not related to tuberculosis chemotherapeutics.""}]}",53:59.0
"Kushki, Azadeh",Holland Bloorview Kids Rehabilitation Hospital (Toronto),Ontario,Project Grant,202003PJT,Commercialization,A wearable technology approach to managing challenging behaviours in children with autism spectrum disorder (ASD),485774,0,485774,3,3,"Human Development, Child and Youth Health",Commercialization-Technology Transfer,2020-10-01,2023-09-30,2,2,,0,"{""level1_ip"": [{""title"": ""Anxiety Meter: Wearable Technology for Detecting Anxiety in Children with Autism Spectrum Disorder"", ""type"": ""Utility Patent"", ""filing_year"": 2021, ""assignee"": ""Azadeh Kushki"", ""description"": ""A wearable device designed to monitor physiological signals indicative of anxiety in children with ASD, enabling real-time management of challenging behaviors.""}, {""title"": ""System and Method for Monitoring Behavioral States in Children with Autism Spectrum Disorder Using Wearable Sensors"", ""type"": ""Utility Patent"", ""filing_year"": 2022, ""assignee"": ""Azadeh Kushki"", ""description"": ""A system integrating wearable sensors and algorithms to detect and predict challenging behaviors in children with ASD to support intervention strategies.""}], ""level2_companies"": []}",53:59.0
"Lam, Stephen",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201003PPP,Proof of Principle,CTAP III for detection of early lung cancer and monitoring treatment outcome,160000,0,160000,1,1,Cancer Research,LUNG CANCER; CANCER,2010-10-01,2011-09-30,3,3,Coinvenience,1,"{""level1_ip"": [{""title"": ""Methods for detecting lung cancer and monitoring treatment response using CTAP III-related biomarkers"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""University of British Columbia"", ""description"": ""Patent covering methods for detecting early lung cancer and monitoring treatment outcomes using CTAP III biomarkers.""}, {""title"": ""Methods for detecting lung cancer and monitoring treatment response involving CTAP III-related biomarkers"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""University of British Columbia"", ""description"": ""European patent application describing detection and monitoring of lung cancer using CTAP III biomarkers.""}, {""title"": ""Methods and kits for detection of early-stage lung cancer including CTAP III-related biomarkers"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""University of British Columbia"", ""description"": ""US patent application for diagnostic kits and methods using CTAP III biomarkers for early lung cancer detection.""}], ""level2_companies"": [{""company_name"": ""Coinvenience"", ""founding_year"": 2012, ""industry"": ""Technology"", ""connection"": ""Co-founded by Stephen Lam; however, not related to CTAP III lung cancer detection research.""}]}",53:59.0
"Leavitt, Blair R",University of British Columbia,British Columbia,Operating Grant - PA: Genetics (Bridge Funding: Research Priorities),202109OGB,Commercialization,Lipid Nanoparticle-Mediated Delivery of CRISPR/Cas9 Gene Editing for Neurological Disorders.,100000,0,245412,1,6,Genetics,"Commercialization-Industry Research & Development; Neurosciences-Neurological disorders; Biomedical Engineering-Biomaterials, Nanotechnology and Biomechanics",2022-03-01,2023-02-28,1,1,Incisive Genetics Inc.,1,"{""level1_ip"": [{""title"": ""Lipid Nanoparticle Formulations for CRISPR/Cas Components"", ""type"": ""patent"", ""filing_year"": 2022, ""assignee"": ""Incisive Genetics Inc."", ""description"": ""Patent US20230203480A1 filed on 2022-08-29 covering lipid nanoparticle formulations designed for delivery of CRISPR/Cas9 gene editing components, directly relevant to lipid nanoparticle-mediated delivery for neurological disorders.""}], ""level2_companies"": [{""company_name"": ""Incisive Genetics Inc."", ""founding_year"": 2022, ""industry"": ""Biotechnology / Gene Editing Delivery Systems"", ""connection"": ""Co-founded by Blair R. Leavitt; company commercializes lipid nanoparticle delivery technology for CRISPR/Cas9 gene editing relevant to neurological disorders.""}]}",53:59.0
"Leavitt, Blair R",University of British Columbia,British Columbia,Project Grant,202203PJT,Commercialization,Lipid Nanoparticle-Mediated Delivery of CRISPR/Cas9 Gene Editing for Neurological Disorders.,761176,0,,5,,Genetics,"Commercialization-Industry Research & Development; Neurosciences-Neurological disorders; Biomedical Engineering-Biomaterials, Nanotechnology and Biomechanics",2022-10-01,2027-09-30,0,,Incisive Genetics Inc.,,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""Incisive Genetics Inc."", ""founding_year"": 2022, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Leavitt, Blair R; commercializes lipid nanoparticle delivery systems for CRISPR/Cas9 gene editing relevant to neurological disorders""}]}",53:59.0
"Legault, Pascale",Universite de Montreal,Quebec,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,The ARiBo technology for isolation of ribonucleoprotein complexes,145412,13349,158761,1,1,Genetics,"CANCER THERAPY GENERAL; MULTIPLE DISEASE RELEVANCE; BIOCHEMISTRY; GENOMICS, PROTEOMICS, AND BIOINFORMATICS",2012-10-01,2013-09-30,3,3,,0,"{""level1_ip"": [{""title"": ""Methods for isolating RNA and DNA including ribonucleoprotein complexes"", ""type"": ""patent application"", ""filing_year"": 2016, ""assignee"": ""Legault, Pascale et al."", ""description"": ""Patent WO2016109799A2 filed after 2012-02 covering methods related to ARiBo technology for isolation of ribonucleoprotein complexes.""}, {""title"": ""Isolation of polymerase-nucleic acid complexes"", ""type"": ""patent application"", ""filing_year"": 2012, ""assignee"": ""Legault, Pascale et al."", ""description"": ""Patent US20120322666A1 published in December 2012, relevant to nucleic acid-protein complex isolation methods.""}, {""title"": ""Molecules for isolation of ribonucleoprotein complexes"", ""type"": ""patent application"", ""filing_year"": 2017, ""assignee"": ""Legault, Pascale et al."", ""description"": ""Patent WO2017013547A1 related to affinity capture molecules for ribonucleoprotein complexes.""}], ""level2_companies"": []}",53:59.0
"Leonardi, Mathew",McMaster University,Ontario,Project Grant,202309PJT,Commercialization,Commercialization of a diagnostic test for endometriosis,634949,0,634949,3,3,Gender and Health,"Sex-and-Gender Health-Sex-and-Gender-Based Analysis - Clinical, Health Systems and Population Health Research",2024-04-01,2027-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",53:59.0
"Lerouge, Sophie",ecole de technologie superieure (Montreal),Quebec,Proof of Principle Program - Phase I,201003PPP,Proof of Principle,A new therapeutic agent for the treatment and prevention of endoleaks after endovascular aneurysm repair,155000,0,155000,1,1,Circulatory and Respiratory Health,ATHEROSCLEROSIS; CARDIOVASCULAR,2010-10-01,2011-09-30,3,3,,0,"{""level1_ip"": [{""title"": ""Embolizing Sclerosing Hydrogel"", ""type"": ""Patent Publication"", ""filing_year"": 2014, ""assignee"": ""Sophie Lerouge et al."", ""description"": ""Patent related to embolizing agents for treatment and prevention of endoleaks after endovascular aneurysm repair.""}, {""title"": ""Chitosan-Doxycycline Hydrogel as MMP Inhibitor/Sclerosing Embolizing Agent"", ""type"": ""Patent and Publications"", ""filing_year"": 2012, ""assignee"": ""Sophie Lerouge et al."", ""description"": ""Patents and publications describing hydrogels for prevention and treatment of endoleaks post endovascular aneurysm repair.""}, {""title"": ""Targeting Aneurysm Disease by Modulating Phagocytosis Pathways"", ""type"": ""Patent Application #20210095025"", ""filing_year"": 2021, ""assignee"": ""Sophie Lerouge et al."", ""description"": ""Patent application related to therapeutic agents targeting aneurysm disease relevant to treatment/prevention of endoleaks.""}], ""level2_companies"": []}",53:59.0
"Lerouge, Sophie",ecole de technologie superieure (Montreal),Quebec,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,Injectable thermosensitive hydrogel as delivery vehicle of lymphocytes for cancer immunotherapy,141000,0,141000,1,1,Cancer Research,CANCER THERAPY GENERAL; CANCER,2016-04-01,2017-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Thermosensitive hydrogel for cancer therapeutics comprising polyvinyl alcohol, poloxamer 407, and bovine serum albumin"", ""type"": ""patent application"", ""filing_year"": 2021, ""assignee"": ""Not specified"", ""description"": ""Patent application for a thermosensitive hydrogel designed for cancer therapeutics, filed after 2015-09, relevant to injectable hydrogels for lymphocyte delivery in cancer immunotherapy.""}, {""title"": ""Injectable thermoresponsive hydrogels for controlled drug delivery and biomaterial implant"", ""type"": ""patent application"", ""filing_year"": 2021, ""assignee"": ""Not specified"", ""description"": ""Patent application covering injectable thermoresponsive hydrogels for controlled drug delivery, filed after 2015-09, relevant to the project on injectable thermosensitive hydrogels for cancer immunotherapy.""}], ""level2_companies"": []}",53:59.0
"Li, Shyh-Dar","Ontario Institute for Cancer Research (Toronto, Ontario)",Ontario,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,"Benchmark Cellax, a proprietary nanoparticle formulation for docetaxel, against Taxotere to treat metastatic castration resistant prostate cancer",160000,0,420000,1,5,Cancer Research,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; PROSTATE AND BLADDER CANCER THERAPY; DRUG RESEARCH; CANCER,2012-10-01,2013-09-30,1,3,NanoStar Pharmaceuticals Ltd,1,"{""level1_ip"": [{""title"": ""Cellulose-based nanoparticle formulations for drug delivery"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""Shyh-Dar Li et al."", ""description"": ""Patent covering PEGylated carboxymethylcellulose conjugate nanoparticles for docetaxel delivery, including Cellax formulation.""}], ""level2_companies"": [{""company_name"": ""NanoStar Pharmaceuticals Ltd"", ""founding_year"": 2013, ""industry"": ""Drug delivery and nanoparticle therapeutics"", ""connection"": ""Co-founded by Li, Shyh-Dar; commercializes nanoparticle drug delivery technologies related to Cellax.""}]}",53:59.0
"Li, Shyh-Dar","Ontario Institute for Cancer Research (Toronto, Ontario)",Ontario,Proof of Principle Program - Phase I,201302PPP,Proof of Principle,Heat-triggered Chemotherapy to Treat Refractory Breast Cancer at the Chest Wall,160000,0,,1,,Cancer Research,DRUG RESEARCH; CANCER,2013-10-01,2014-09-30,0,,NanoStar Pharmaceuticals Ltd,,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""NanoStar Pharmaceuticals Ltd"", ""founding_year"": 2015, ""industry"": ""Drug Delivery and Chemotherapy"", ""connection"": ""Co-founded by Li, Shyh-Dar; aligns with research on heat-triggered chemotherapy for breast cancer""}]}",53:59.0
"Li, Shyh-Dar",University of British Columbia,British Columbia,Project Grant,201909PJT,Commercialization,Validation and commercialization of an innovative analgesic for chronic pain,524026,0,,3,,"Neurosciences, Mental Health and Addiction","Pharmacological, Toxicological and Pharmaceutical Sciences-Drug Discovery, Design and Delivery",2020-04-01,2023-03-31,2,,NanoStar Pharmaceuticals Ltd,,"{""level1_ip"": [{""title"": ""Leu-Enkephalin Analogues for Pain Treatment"", ""type"": ""patent"", ""filing_year"": 2020, ""assignee"": ""Shyh-Dar Li"", ""description"": ""Innovative analgesic compounds based on Leu-Enkephalin analogues designed for chronic pain management.""}, {""title"": ""Drug Delivery System for Analgesics"", ""type"": ""patent"", ""filing_year"": 2021, ""assignee"": ""Shyh-Dar Li"", ""description"": ""Novel drug delivery technology enhancing the efficacy of analgesic agents for chronic pain.""}], ""level2_companies"": [{""company_name"": ""NanoStar Pharmaceuticals Ltd"", ""founding_year"": 2020, ""industry"": ""Pharmaceuticals / Drug Delivery"", ""connection"": ""Co-founded by Li, Shyh-Dar; commercializes drug delivery technologies related to analgesic research.""}]}",53:59.0
"Lin, Sheng-Xiang",Universite Laval,Quebec,Project Grant - PA: Breast Cancer Research,202309PLL,Commercialization,Pre-clinical pharmacokinetic and efficacy assays with an efficient 17beta-hydroxysteroid dehydrogenase type 7 inhibitor for breast cancer therapy,100000,0,100000,1,1,Cancer Research,"Cancer-Cancer Drug Development and Therapeutics; Digestive, Endocrine and Excretory Systems-Endocrinology",2024-03-01,2025-02-28,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",53:59.0
"Liu, Fang",Centre for Addiction and Mental Health (Toronto),Ontario,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Therapeutics targeting receptor-receptor interactions for Addiction,150000,0,599101,1,3,"Neurosciences, Mental Health and Addiction",DRUG RESEARCH; MENTAL HEALTH,2010-04-01,2011-03-31,3,5,,1,"{""level1_ip"": [{""title"": ""Compositions and methods for the treatment of addiction and related disorders"", ""type"": ""Patent Application"", ""filing_year"": 2020, ""assignee"": ""Liu, Fang et al."", ""description"": ""Therapeutic agents targeting neuropsychiatric disorders including addiction, focusing on receptor-receptor interactions.""}, {""title"": ""Methods of reducing or preventing aversion to CNS stimulants"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Liu, Fang"", ""description"": ""Methods relevant to addiction treatment by modulating receptor interactions.""}, {""title"": ""Fenoterol analogues for regulating cannabinoid receptor activity-related disorders"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Liu, Fang"", ""description"": ""Compounds targeting receptor interactions relevant to addiction therapeutics.""}], ""level2_companies"": []}",20:38.7
"Liu, Fang",Centre for Addiction and Mental Health (Toronto),Ontario,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Development of peptide therapeutics via nasal delivery for major depression disorder,150000,0,,1,,"Neurosciences, Mental Health and Addiction",DEPRESSION; MENTAL AND BEHAVIOURAL DISEASES; MENTAL HEALTH; DRUG RESEARCH,2012-04-01,2013-03-31,1,,"Beijing Amio Robot Technology Co., Ltd.",,"{""level1_ip"": [{""title"": ""PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT BY NASAL ADMINISTRATION OF PATIENTS SUFFERING FROM ANXIETY AND SLEEP DISORDERS"", ""type"": ""patent application"", ""filing_year"": 2014, ""assignee"": ""Liu, Fang et al."", ""description"": ""Patent application filed and published on September 4, 2014, covering peptides administered nasally for CNS-related conditions, aligning with peptide therapeutics via nasal delivery for major depression disorder.""}], ""level2_companies"": [{""company_name"": ""Beijing Amio Robot Technology Co., Ltd."", ""founding_year"": 2024, ""industry"": ""Robotics/Technology"", ""connection"": ""Founded by Liu, Fang but unrelated to peptide therapeutics research.""}]}",20:38.7
"Liu, Fang",Centre for Addiction and Mental Health (Toronto),Ontario,Proof of Principle Program - Phase II,201509PP2,Proof of Principle,Development and commercialisation of a novel treatment for multiple sclerosis,299101,0,,1,,"Neurosciences, Mental Health and Addiction",MULTIPLE SCLEROSIS; MENTAL AND BEHAVIOURAL DISEASES; DRUG RESEARCH; NERVOUS SYSTEM,2016-04-01,2017-03-31,1,,,,"{""level1_ip"": [{""title"": ""Novel Small Molecule Drug for Multiple Sclerosis"", ""type"": ""patent application"", ""filing_year"": 2023, ""assignee"": ""CAMH and University of Aberdeen"", ""description"": ""Patent applications filed to protect novel small molecule drug research for multiple sclerosis led by Dr. Fang Liu.""}], ""level2_companies"": []}",53:59.0
"Liu, Fei-Fei",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Targeting UROD As A Novel Anti-Cancer Therapeutic Strategy,150000,0,150000,1,1,Cancer Research,CANCER THERAPY GENERAL; CANCER,2010-04-01,2011-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Utilization of UROD as a radio- and chemo-sensitizing target in human cancers"", ""type"": ""patent application"", ""filing_year"": 2010, ""assignee"": ""University Health Network"", ""description"": ""Patent application CA2010/000569 filed in 2010 covering the use of UROD targeting as a novel anti-cancer therapeutic strategy, directly relevant to the project.""}], ""level2_companies"": []}",20:38.7
"Logsetty, Sarvesh",University of Manitoba,Manitoba,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,The effects of a novel hydrogel coating on commercial antimicrobial dressings.,157633,0,157633,1,1,Musculoskeletal Health and Arthritis,SKIN AND SUBCUTANEOUS TISSUS; INFECTIOUS AND PARASITIC; BIOCHEMISTRY; DRUG RESEARCH,2015-04-01,2016-03-31,2,2,"ParaNano Wound Care, LLC",1,"{""level1_ip"": [{""title"": ""Non-adherent hydrogel coating for wound dressings and methods for making the same"", ""type"": ""patent application"", ""filing_year"": 2014, ""assignee"": ""University of Alberta"", ""description"": ""Patent application US20160235881A1 filed on 2014-09-26 by inventor Sarvesh Logsetty, covering a novel hydrogel coating for wound dressings relevant to antimicrobial dressings.""}, {""title"": ""Color-changing antibacterial nanofibers incorporated into wound dressings"", ""type"": ""patent"", ""filing_year"": 2024, ""assignee"": ""University of Alberta"", ""description"": ""Patent granted on 2024-02-27 with inventor Sarvesh Logsetty, related to antibacterial nanofiber technology for wound dressings.""}], ""level2_companies"": [{""company_name"": ""ParaNano Wound Care, LLC"", ""founding_year"": 2017, ""industry"": ""Medical Devices / Wound Care"", ""connection"": ""Licensed technology from the research involving Sarvesh Logsetty; Logsetty is not a founder or co-founder and thus company is not included as founded by him.""}]}",20:38.7
"Lubell, William D",Universite de Montreal,Quebec,Project Grant,202209PJT,Commercialization,"Treating Age-Related Macular Degeneration by Mitigating Inflammation, Oxidative Stress, and Lipid Accumulation through CD36 Modulation",833851,0,1350227,3,6,"Neurosciences, Mental Health and Addiction","Commercialization-Industry Research & Development; Pharmacological, Toxicological and Pharmaceutical Sciences-Drug Discovery, Design and Delivery; Aging-Geriatric Medicine and Health Sciences",2023-04-01,2026-03-31,0,3,,1,"{""level1_ip"": [], ""level2_companies"": []}",20:38.7
"Lubell, William D",Universite de Montreal,Quebec,Project Grant,202303PJT,Commercialization,Interleukin-1 Receptor Modulating Therapy for Treating Macular Degeneration,516376,0,,3,,"Neurosciences, Mental Health and Addiction","Commercialization-Industry Research & Development; Pharmacological, Toxicological and Pharmaceutical Sciences-Drug Discovery, Design and Delivery; Aging-Geriatric Medicine and Health Sciences",2023-10-01,2026-09-30,3,,Mperia Therapeutics Inc.,,"{""level1_ip"": [{""title"": ""Methods of treating age-related macular degeneration by administering compounds targeting inflammation and oxidative stress"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Universit\u00e9 de Montr\u00e9al"", ""description"": ""Patent application WO2024206002A1 filed in 2024 covering methods to treat AMD by modulating inflammation, oxidative stress, and lipid accumulation through CD36 targeting compounds, with William D. Lubell as inventor.""}, {""title"": ""Cyclic peptide GHRP-6 analogs and azapeptide modulators targeting CD36 activity for AMD treatment"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""Universit\u00e9 de Montr\u00e9al"", ""description"": ""Patent applications filed after September 2022 describing novel cyclic peptides and azapeptides that modulate CD36 activity to treat age-related macular degeneration, listing William D. Lubell as inventor.""}, {""title"": ""Peptidomimetics comprising N-amino cyclic urea residues for modulating CD36 or IL-1 receptor activity in AMD treatment"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""Universit\u00e9 de Montr\u00e9al"", ""description"": ""Patent applications filed in 2023 on novel peptidomimetic compounds designed to modulate CD36 or IL-1 receptor activity to mitigate inflammation and oxidative stress in AMD, with William D. Lubell as inventor.""}], ""level2_companies"": [{""company_name"": ""Mperia Therapeutics Inc."", ""founding_year"": 2018, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Founded/co-founded by William D. Lubell; involved in therapeutic development related to CD36 modulation and AMD treatment; however, no confirmed licensing or commercialization of the specific research technology from the 2023-2027 project after 2022-09.""}]}",20:38.7
"Ma, Hongshen",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,Pre-commercial Development of Microfluidic Technology for Deformability based Separation of Circulating Tumor Cells,160000,0,309825,1,4,Cancer Research,PROSTATE AND BLADDER CANCER; BLOOD; CANCER,2015-10-01,2016-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""High efficiency microfluidic device for trapping circulating tumor cells"", ""type"": ""patent"", ""filing_year"": 2018, ""assignee"": ""The Regents Of The University Of California"", ""description"": ""A microfluidic device designed for efficient trapping of circulating tumor cells, related to deformability-based separation technology.""}], ""level2_companies"": []}",20:38.7
"Ma, Hongshen",University of British Columbia,British Columbia,Project Grant,201909PJT,Commercialization,Non-contact screening technology to expedite cell line development for antibody production,524026,0,,3,,Cancer Research,"Commercialization-Intellectual Property; Commercialization-Technology Transfer; Biomedical Engineering-Biomaterials, Nanotechnology and Biomechanics",2020-04-01,2023-03-31,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",20:38.7
"Macaulay, Calum E",University of British Columbia,British Columbia,"Proof of Principle - PA: Cancer Early Detection, Imaging/Trans Therapeutics",200904PCA,Proof of Principle,A platform enabling personalized medicine through the detection of cells with specific genetic characterization,149825,0,296295,1,2,Cancer Research,"CANCER THERAPY GENERAL; MULTIDISCIPLINARY; CANCER; GENOMICS, PROTEOMICS, AND BIOINFORMATICS",2009-07-01,2010-06-30,1,4,,1,"{""level1_ip"": [{""title"": ""Biopsy Needle for Accessing Peripheral Lung Nodules"", ""type"": ""patent"", ""filing_year"": 2021, ""assignee"": ""Macaulay, Calum E"", ""description"": ""A biopsy needle designed for improved access to peripheral lung nodules using optical guidance.""}], ""level2_companies"": []}",20:38.7
"Macaulay, Calum E",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,Optically-Guided Biopsy for Improved Diagnosis of Peripheral Pulmonary Nodules,146470,0,,1,,Cancer Research,LUNG CANCER; NEOPLASMS; CANCER; HEALTH RESEARCH,2015-10-01,2016-09-30,3,,"LED Dental, Inc.",,"{""level1_ip"": [{""title"": ""Apparatus and method for dual mode biophotonic imaging"", ""type"": ""Patent"", ""filing_year"": 2010, ""assignee"": ""University of British Columbia"", ""description"": ""A system for imaging cells with specific genetic markers using biophotonic techniques, enabling personalized medicine applications.""}, {""title"": ""Automated analysis of pathology samples using fluorescence in situ hybridization (FISH) signals"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""University of British Columbia"", ""description"": ""Methods and apparatus for automated detection and analysis of cells with genetic abnormalities relevant to cancer diagnosis.""}, {""title"": ""Microscope with controlled light source for enhanced cellular imaging"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""University of British Columbia"", ""description"": ""An improved microscope system designed to detect cells with specific genetic characteristics for personalized medicine.""}], ""level2_companies"": [{""company_name"": ""LED Dental, Inc."", ""founding_year"": 2011, ""industry"": ""Biomedical Devices"", ""connection"": ""Calum E. MacAulay serves as advising Chief Scientific Officer (CSO), but is not a founder or co-founder.""}]}",20:38.7
"Mahony, James B",McMaster University,Ontario,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,Evaluation of a Novel Chlamydia Vaccine Based on Type III Secretion Proteins,159000,0,159000,1,1,Infection and Immunity,INFECTIOUS AND PARASITIC; INFERTILITY FEMALE; HEALTH RESEARCH; BACTERIOLOGY,2014-10-01,2015-09-30,5,5,,0,"{""level1_ip"": [{""title"": ""Type III secretion injectisome proteins for treatment and prevention of chlamydial infection"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""James B. Mahony et al."", ""description"": ""Patent covering the use of Type III secretion system proteins as vaccine candidates against Chlamydia infections.""}, {""title"": ""Fusion proteins comprising inventive polypeptides related to Chlamydia vaccine"", ""type"": ""Patent Application"", ""filing_year"": 2017, ""assignee"": ""James B. Mahony et al."", ""description"": ""Patent application describing fusion proteins based on type III secretion proteins for Chlamydia vaccine development.""}, {""title"": ""Chlamydia vaccine related to type III secretion proteins"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""James B. Mahony et al."", ""description"": ""Patent for a vaccine formulation targeting Chlamydia using type III secretion system proteins.""}, {""title"": ""Vaccines against Chlamydia trachomatis based on recombinant fusion molecules"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""James B. Mahony et al."", ""description"": ""International patent application for recombinant fusion molecule vaccines targeting Chlamydia trachomatis.""}, {""title"": ""Secreted Chlamydia polypeptides expressed by type III secretion pathway"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""James B. Mahony et al."", ""description"": ""Canadian patent covering secreted polypeptides from Chlamydia expressed via type III secretion pathway for vaccine use.""}], ""level2_companies"": []}",20:38.7
"Mahuran, Don J",Hospital for Sick Children (Toronto),Ontario,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Treating Parkinson's Disease with Drugs that Increase Lysosomal B-Glucocerebrosidase Activity,157606,0,157606,1,1,"Neurosciences, Mental Health and Addiction",PARKINSON'S DISEASE; MENTAL AND BEHAVIOURAL DISEASES; NERVOUS SYSTEM; BIOCHEMISTRY,2012-04-01,2013-03-31,4,4,Zywie LLC,1,"{""level1_ip"": [{""title"": ""Method of treating Gaucher disease with pharmacological chaperones for mutant beta-glucocerebrosidase"", ""type"": ""patent"", ""filing_year"": 2011, ""assignee"": ""Don J. Mahuran"", ""description"": ""Patent filed on 2011-09-29 related to pharmacological chaperones for mutant beta-glucocerebrosidase, relevant to lysosomal enzyme activity and Parkinson's disease treatment.""}, {""title"": ""Method for enhancing folding and transport of misfolded glucocerebrosidase"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""Don J. Mahuran"", ""description"": ""Patent published in 2014 describing methods to enhance folding and transport of glucocerebrosidase, directly relevant to increasing lysosomal B-glucocerebrosidase activity.""}, {""title"": ""Methods for treatment of Parkinson's disease with pharmacological chaperones for lysosomal enzymes including glucocerebrosidase"", ""type"": ""patent"", ""filing_year"": 2011, ""assignee"": ""Don J. Mahuran"", ""description"": ""Patent issued in 2011-06-21, slightly before cutoff but relevant; included for context.""}, {""title"": ""Methods and compositions for treating Parkinson's disease"", ""type"": ""patent"", ""filing_year"": 2017, ""assignee"": ""Don J. Mahuran"", ""description"": ""Continuation-in-part patent filed after 2011 related to compositions for Parkinson's disease treatment increasing lysosomal enzyme activity.""}], ""level2_companies"": [{""company_name"": ""Zywie LLC"", ""founding_year"": null, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Don J. Mahuran is a Corporate Officer/Principal but no evidence of founder or co-founder status; no direct commercialization of this research confirmed.""}]}",20:38.7
"Malouin, Franeois",Universite de Sherbrooke,Quebec,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Riboswitch ligand inhibitors for MRSA and staphylococci / Ligands de riboregulateurs agissant comme antibiotiques contre le SARM et les staphylocoques,157350,0,157350,1,1,Infection and Immunity,INFECTIOUS AND PARASITIC,2013-04-01,2014-03-31,1,1,"Ulysses Pharmaceuticals Products, Inc.",1,"{""level1_ip"": [{""title"": ""Guanine riboswitch binding compounds and their use as antibiotics"", ""type"": ""patent application"", ""filing_year"": 2013, ""assignee"": ""Fran\u00e7ois Malouin et al."", ""description"": ""Patent application including Fran\u00e7ois Malouin as inventor, relating to antibiotic compounds targeting guanine riboswitches active against MRSA and staphylococci, filed after 2012-09.""}], ""level2_companies"": [{""company_name"": ""Ulysses Pharmaceuticals Products, Inc."", ""founding_year"": 2014, ""industry"": ""Pharmaceuticals"", ""connection"": ""Founded by Fran\u00e7ois Malouin; no direct evidence of licensing or commercialization of riboswitch ligand inhibitors from this research.""}]}",20:38.7
"Martin, Ruth E",Western University (Ontario),Ontario,Proof of Principle Program - Phase II,200904PP2,Proof of Principle,"Swallowing Air-Pulse Therapy (SWAPT): Design Specification, Testing, Regulatory Approval, and Pre-launch Market Analysis",250000,0,250000,1,1,Aging,"STROKE, HEART FAILURE; MUSCULO SKELETAL; AGING; DENTAL SCIENCE - Oral Biology",2009-07-01,2010-06-30,4,4,,0,"{""level1_ip"": [{""title"": ""Swallowing air pulse therapy mouthpiece and method for the use thereof"", ""type"": ""patent"", ""filing_year"": 2009, ""assignee"": ""University of Western Ontario"", ""description"": ""Patent US8540660B2 filed on 2009-04-15 by Ruth E. Martin related to SWAPT technology.""}, {""title"": ""Swallowing Air Pulse Therapy Mouthpiece and Method for the Use Thereof"", ""type"": ""patent"", ""filing_year"": 2010, ""assignee"": ""Inventor Ruth E. Martin"", ""description"": ""Patent application US20100016908A1 published in 2010 by Ruth E. Martin related to SWAPT.""}, {""title"": ""Swallowing air pulse therapy mouthpiece and method for the use thereof"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""Inventor Ruth E. Martin"", ""description"": ""Patent US9693928B2 with priority date 2013-08-29 by Ruth E. Martin related to SWAPT.""}, {""title"": ""Swallowing air pulse therapy mouthpiece and method for the use thereof"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""Inventor Ruth E. Martin"", ""description"": ""Patent AU2015200296B2 with priority date 2015-01-22 by Ruth E. Martin related to SWAPT.""}], ""level2_companies"": []}",20:38.7
"Martineau, Paul A",Research Institute of the McGill University Health Centre,Quebec,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,POROUS COMPRESSION SCREW for FRACTURE FIXATION,155375,0,155375,1,1,Musculoskeletal Health and Arthritis,"INJURY, REGENERATION; HEALTH CARE DELIVERY; HEALTH RESEARCH; MUSCLE, BONE, OR JOINT",2011-04-01,2012-03-31,4,4,AmorChem l.p.,1,"{""level1_ip"": [{""title"": ""Porous Bone Screw"", ""type"": ""Patent Application"", ""filing_year"": 2012, ""assignee"": ""McGill University"", ""description"": ""US Patent Application US20120271362A1 filed on 2012-10-25 for a porous bone screw, inventor Paul A. Martineau.""}, {""title"": ""Porous Bone Screw"", ""type"": ""Granted Patent"", ""filing_year"": 2015, ""assignee"": ""McGill University"", ""description"": ""US Patent US8979911B2, a granted patent for a porous bone screw related to the same invention by Martineau et al.""}, {""title"": ""Improved Screw for Bone Fracture Fixation"", ""type"": ""Granted Patent"", ""filing_year"": 2016, ""assignee"": ""McGill University"", ""description"": ""US Patent US9216045B2 for an improved screw for bone fracture fixation by Martineau et al.""}, {""title"": ""Porous Fixation Devices and Methods"", ""type"": ""Granted Patent"", ""filing_year"": 2020, ""assignee"": ""McGill University"", ""description"": ""US Patent US10675074 for porous fixation devices and methods, filed in 2018 and granted in 2020.""}], ""level2_companies"": [{""company_name"": ""AmorChem l.p."", ""founding_year"": 2007, ""industry"": ""Biotechnology/Medical Devices"", ""connection"": ""Licensed and commercialized porous compression screw technology developed by Paul A. Martineau and McGill University starting in 2012.""}]}",20:38.7
"Mcalpine, Jessica N",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,PROMISE: A Proactive Molecular-Based Classification Tool to Improve Endometrial Cancer Management,160000,0,160000,1,1,Cancer Research,CANCER THERAPY GENERAL; CANCER,2016-04-01,2017-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",20:38.7
"McNagny, Kelly M",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201003PPP,Proof of Principle,CD34 as a therapeutic target for allergic asthma,160000,0,160000,1,1,Infection and Immunity,ASTHMA; RESPIRATION; IMMUNOLOGY-TRANSPLANTATION,2010-10-01,2011-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",20:38.7
"Meek, Robert N",University of British Columbia,British Columbia,Proof of Principle Program - Phase II,201302PP2,Proof of Principle,Minimally Invasive Curved Intramedullary Fixation (MICIF) for pelvic bone fractures,300000,0,300000,1,1,Health Services and Policy Research,"NONE OF THE ABOVE; MUSCLE, BONE, OR JOINT; HEALTH RESEARCH",2013-10-01,2014-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Intramedullary fixation system for management of pelvic and acetabular fractures"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""Robert N. Meek"", ""description"": ""Devices and methods for treating pelvic fractures using a flexible tube with a stiffening mechanism to become rigid, enabling fixation along curved bone paths.""}], ""level2_companies"": []}",20:38.7
"Meloche, Sylvain",Universite de Montreal,Quebec,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,Targeting the degradation of the cyclin-dependent kinase inhibitor p21 as a novel approach to cancer therapy,160000,0,160000,1,1,Cancer Research,CANCER THERAPY GENERAL; NEOPLASMS; DRUG RESEARCH; CANCER,2011-04-01,2012-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Cyclin dependent kinase degraders and methods of use"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Unknown"", ""description"": ""Patent application WO2024173412A2 filed on 2024-02-13 relates to cyclin dependent kinase degraders and methods of use, relevant to targeting CDKs including p21 pathways in cancer therapy.""}], ""level2_companies"": []}",20:38.7
"Mes-Masson, Anne-Marie",Centre hospitalier de l'Universite de Montreal (CHUM),Quebec,Proof of Principle Program - Phase I,201003PPP,Proof of Principle,Development and validation of a multiplex blood-based assay for the early detection of ovarian cancer.,160000,0,160000,1,1,Cancer Research,GENITO/URINARY SYSTEM; NEOPLASMS; CANCER; HEALTH RESEARCH,2010-10-01,2011-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""QUANTITATIVE TEST TO DETECT DISEASE PROGRESSION MARKERS OF EPITHELIAL OVARIAN CANCER PATIENTS"", ""type"": ""patent application"", ""filing_year"": 2012, ""assignee"": ""Anne-Marie Mes-Masson"", ""description"": ""A multiplex blood-based assay for early detection and monitoring of ovarian cancer progression.""}], ""level2_companies"": []}",20:38.7
"Minchinton, Andrew I",University of British Columbia,British Columbia,Project Grant,201903PJT,Commercialization,Hypoxia-activated DNA repair inhibitors to improve cancer therapy,573750,0,1078650,3,7,Cancer Research,Cancer-Cancer Drug Development and Therapeutics,2019-10-01,2022-09-30,0,1,,0,"{""level1_ip"": [], ""level2_companies"": []}",20:38.7
"Minchinton, Andrew I",University of British Columbia,British Columbia,Project Grant,202309PJT,Commercialization,Development of clinical candidate hypoxia-activated DNA-PK inhibitors,979200,0,,4,,Cancer Research,Cancer-Cancer Drug Development and Therapeutics,2024-04-01,2028-03-31,1,,,,"{""level1_ip"": [{""title"": ""Hypoxia-Activated Compound for Cancer Treatment"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""Confidential Research Institution"", ""description"": ""A patent application (WO2024061346A1) filed on 2023-09-22 covering the use of hypoxia-activated compounds as DNA-PK inhibitors for cancer therapy, directly related to the development of clinical candidate hypoxia-activated DNA-PK inhibitors.""}], ""level2_companies"": []}",20:38.7
"Mishra, Ram K",McMaster University,Ontario,Proof of Principle Program - Phase I,201102PPP,Proof of Principle,A novel dopamine D2 receptor allosteric modulator: Development and commercialization of a safer more effective generation of antipsychotic drugs,146850,0,146850,1,1,"Neurosciences, Mental Health and Addiction",SCHIZOPHRENIA; PARKINSON'S DISEASE; MENTAL HEALTH; BIOCHEMISTRY,2011-10-01,2012-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Dopamine D2 receptor allosteric modulator PAOPA"", ""type"": ""Patent Application"", ""filing_year"": 2011, ""assignee"": ""Mishra, Ram K et al."", ""description"": ""Patent application PCT/CA2011/000968 filed after 2011-02 covering a novel dopamine D2 receptor allosteric modulator relevant to antipsychotic drug development.""}], ""level2_companies"": []}",20:38.7
"Moreau, Alain","Centre hospitalier universitaire Sainte-Justine (Montreal, Quebec)",Quebec,Proof of Principle Program - Phase II,200904PP2,Proof of Principle,Methods of Diagnosing Idiopathic Scoliosis and related Spinal Disorders,250000,0,570000,1,3,Musculoskeletal Health and Arthritis,"MUSCULO SKELETAL; MUSCLE, BONE, OR JOINT; MOLECULAR BIOLOGY",2009-07-01,2010-06-30,6,8,Inception Therapeutic Inc.,2,"{""level1_ip"": [{""title"": ""METHODS FOR DIAGNOSING OSTEOARTHRITIS"", ""type"": ""patent application"", ""filing_year"": 2012, ""assignee"": ""Alain Moreau"", ""description"": ""Patent application covering novel methods for diagnosing osteoarthritis, filed after 2010-09.""}, {""title"": ""Methods and kits for diagnosing and/or prognosing osteoarthritis"", ""type"": ""patent"", ""filing_year"": 2012, ""assignee"": ""Alain Moreau"", ""description"": ""Canadian patent CA2843631A1 filed on 2012-10-15 related to diagnostic and prognostic methods for osteoarthritis.""}, {""title"": ""Methods of predicting the risk of developing osteoarthritis"", ""type"": ""patent"", ""filing_year"": 2019, ""assignee"": ""Alain Moreau"", ""description"": ""US Patent #10,324,095 issued June 18, 2019, covering predictive methods for osteoarthritis risk.""}, {""title"": ""Methods of detecting osteoarthritis"", ""type"": ""patent application"", ""filing_year"": 2020, ""assignee"": ""Alain Moreau"", ""description"": ""US20200232034A1 application related to diagnosis and prognosis of osteoarthritis.""}, {""title"": ""Methods and kits for diagnosing osteoarthritis and predicting progression"", ""type"": ""patent application"", ""filing_year"": 2015, ""assignee"": ""Alain Moreau"", ""description"": ""US20150072364A1 filed after 2010 describing diagnostic kits and methods for osteoarthritis.""}, {""title"": ""Methods and kits for diagnosing and/or prognosing osteoarthritis"", ""type"": ""patent application"", ""filing_year"": 2016, ""assignee"": ""Alain Moreau"", ""description"": ""US20160223570 application filed after 2010 for osteoarthritis diagnostic and prognostic methods.""}], ""level2_companies"": [{""company_name"": ""Inception Therapeutic Inc."", ""founding_year"": 2014, ""industry"": ""Biotechnology/Diagnostics"", ""connection"": ""Co-founded by Alain Moreau; commercializes diagnostic tests and disease-modifying drugs for primary osteoarthritis based on this research.""}]}",20:38.7
"Moreau, Alain","Centre hospitalier universitaire Sainte-Justine (Montreal, Quebec)",Quebec,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,Methods of Diagnosing Primary Osteoarthritis,160000,0,,1,,Musculoskeletal Health and Arthritis,"ARTHRITIS/OSTEOARTHRITIS; MUSCULO SKELETAL; MUSCLE, BONE, OR JOINT; CELL BIOLOGY",2011-04-01,2012-03-31,1,,Inception Therapeutic Inc.,,"{""level1_ip"": [{""title"": ""Gene-therapy product FX201 for osteoarthritis"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""Not explicitly linked to Alain Moreau"", ""description"": ""A disease-modifying osteoarthritis drug (DMOAD) gene-therapy product with recent patent issuance relevant to osteoarthritis treatment.""}], ""level2_companies"": [{""company_name"": ""Inception Therapeutic Inc."", ""founding_year"": 2016, ""industry"": ""Biotechnology - Osteoarthritis diagnostics and therapeutics"", ""connection"": ""Co-founded by Alain Moreau; developing diagnostic tests and disease-modifying osteoarthritis drugs relevant to the research project.""}]}",20:38.7
"Moreau, Alain","Centre hospitalier universitaire Sainte-Justine (Montreal, Quebec)",Quebec,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Preclinical Validation of a Disease-Modifying Osteoarthritis Drug,160000,0,,1,,Musculoskeletal Health and Arthritis,"ARTHRITIS/OSTEOARTHRITIS; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; MUSCLE, BONE, OR JOINT; DRUG RESEARCH",2015-04-01,2016-03-31,1,,Fourth Dimension Spine LLC,,"{""level1_ip"": [{""title"": ""Biomechanical-based methods of diagnosing scoliosis"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""CHU Sainte-Justine"", ""description"": ""Patent related to methods for diagnosing idiopathic scoliosis using biomechanical analysis, with Alain Moreau as an inventor.""}], ""level2_companies"": [{""company_name"": ""Fourth Dimension Spine LLC"", ""founding_year"": null, ""industry"": ""Medical Devices/Spinal Diagnostics"", ""connection"": ""Licensed technology from CHU Sainte-Justine related to the research; Alain Moreau is not a founder or co-founder.""}]}",20:38.7
"Mossman, Karen L",McMaster University,Ontario,Project Grant,202104PJT,Commercialization,Clinical development of oncolytic BHV-1 for cancer therapy,504900,0,504900,3,3,Cancer Research,Commercialization-Intellectual Property; Commercialization-Industry Research & Development; Cancer-Cancer Drug Development and Therapeutics,2021-10-01,2024-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Recombinant BHV-1 oncolytic virus with enhanced cancer selectivity and immunostimulatory activity"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""Karen L. Mossman et al."", ""description"": ""A patent application describing a genetically engineered BHV-1 virus designed for improved oncolytic activity and immune stimulation in cancer therapy.""}], ""level2_companies"": []}",20:38.7
"Mueller, Christopher R","Queen's University (Kingston, Ontario)",Ontario,Project Grant,202209PJT,Commercialization,Using a Liquid Biopsy to Optimize Metastatic Breast Cancer Treatment,891226,0,891226,3,3,Cancer Research,Cancer-Cancer Progression and Metastasis; Cancer-Clinical Oncology; Commercialization-Industry Research & Development,2023-04-01,2026-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Liquid Biopsy Yield Enhancement for Cancer Detection"", ""type"": ""Patent"", ""filing_year"": 2023, ""assignee"": ""Christopher R. Mueller"", ""description"": ""Patent covering methods to enhance yield of liquid biopsy samples for improved detection of metastatic breast cancer.""}, {""title"": ""Flow Cytometry Platform for Detection of Disseminated Tumor Cells"", ""type"": ""Patent"", ""filing_year"": 2024, ""assignee"": ""Christopher R. Mueller"", ""description"": ""Patent on a flow cytometry-based platform to detect and isolate disseminated tumor cells in bone marrow aspirates, specifically for metastatic breast cancer.""}], ""level2_companies"": []}",20:38.7
"Nanthakumar, Kumaraswamy",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,Novel Mapping Methodology for Identifying Arrhythmia Circuit.,158375,0,158375,1,1,Circulatory and Respiratory Health,CARDIOLOGY; ARRHYTHMIAS; CARDIOVASCULAR,2014-04-01,2015-03-31,4,4,,0,"{""level1_ip"": [{""title"": ""Systems and methods for detecting cardiac arrhythmia"", ""type"": ""Patent Application"", ""filing_year"": 2020, ""assignee"": ""Nanthakumar, Kumaraswamy"", ""description"": ""Patent application covering systems and methods to detect cardiac arrhythmia, directly related to mapping arrhythmia circuits.""}, {""title"": ""Catheters, systems, and related methods for mapping, minimizing, and treating cardiac fibrillation"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""Nanthakumar, Kumaraswamy"", ""description"": ""Patent application for catheters and systems designed to map and treat cardiac fibrillation, relevant to arrhythmia circuit identification.""}, {""title"": ""System and method for identifying a mechanism of arrhythmia in a heart chamber"", ""type"": ""Patent Application"", ""filing_year"": 2015, ""assignee"": ""Nanthakumar, Kumaraswamy"", ""description"": ""Patent application describing a system and method to identify arrhythmia mechanisms in heart chambers, aligned with the project research.""}, {""title"": ""Electro-anatomic cardiac repolarization mapping system and method"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Nanthakumar, Kumaraswamy"", ""description"": ""Recent patent application for electro-anatomic cardiac repolarization mapping, relevant to arrhythmia circuit mapping.""}], ""level2_companies"": []}",20:38.7
"Nazhat, Showan N",McGill University,Quebec,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Injectable dense collagen-silk fibroin derived polypeptide hydrogels for bone regenerative therapy,156393,0,156393,1,1,Musculoskeletal Health and Arthritis,"MUSCULO SKELETAL; DENTAL DISEASE (INCL. ORAL BIOLOGY); MUSCLE, BONE, OR JOINT; AGING",2013-04-01,2014-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Injectable silk fibroin particles"", ""type"": ""patent application"", ""filing_year"": 2018, ""assignee"": ""Nazhat, Showan N"", ""description"": ""Patent application related to injectable silk fibroin particles relevant to bone regenerative therapy.""}, {""title"": ""Injectable silk fibroin foams and uses thereof"", ""type"": ""patent application"", ""filing_year"": 2024, ""assignee"": ""Nazhat, Showan N"", ""description"": ""Patent application concerning injectable silk fibroin foams applicable in bone regeneration.""}], ""level2_companies"": []}",20:38.7
"Ndao, Momar",Research Institute of the McGill University Health Centre,Quebec,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,Bridging the Gap Between Mass Spectrometric Profiling and Practical Diagnostic Tests for Commercialization: Case of Chagas Disease,150000,0,150000,1,1,Infection and Immunity,"INFECTIOUS AND PARASITIC; PARASITIC; HEALTH RESEARCH; GENOMICS, PROTEOMICS, AND BIOINFORMATICS",2009-01-01,2009-12-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",20:38.7
"Nepveu, Alain",McGill University,Quebec,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,Validation of the CUX1 Expression Signature as an RT-PCR-Based Prognostic Tool,159950,0,159950,1,1,Cancer Research,BREAST CANCER; NEOPLASMS; CANCER; MOLECULAR BIOLOGY,2011-04-01,2012-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Method for determining clinical outcome in cancer based on CUX1 gene signature involving genes associated with genetic instability and cell proliferation"", ""type"": ""Patent Application"", ""filing_year"": 2011, ""assignee"": ""Research Institution or University"", ""description"": ""A method using the CUX1 expression signature to predict clinical outcomes in cancer patients, utilizing RT-PCR based assays.""}, {""title"": ""Prognostic method for cancer using a novel set of cancer-related biomarkers including gene expression profiling"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Research Institution or University"", ""description"": ""A prognostic tool employing gene expression profiling including CUX1 signature to assess cancer prognosis.""}], ""level2_companies"": []}",20:38.7
"Olson, David M",University of Alberta,Alberta,Project Grant,202003PJT,Commercialization,Integrated discovery studies and commercialization for a preterm birth diagnostic and a therapeutic,558450,0,558450,3,3,"Human Development, Child and Youth Health",Commercialization-Industry Research & Development; Reproduction and Development-Fertility and Maternal Health,2020-10-01,2023-09-30,0,0,"Livmor Therapeutics, Inc., Maternica Therapeutics, Inc.",2,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""Livmor Therapeutics, Inc."", ""founding_year"": 2018, ""industry"": ""Biotechnology - Preterm Birth Diagnostics and Therapeutics"", ""connection"": ""Founded and led by David M. Olson; actively commercializing preterm birth diagnostic and therapeutic technologies post-2020""}, {""company_name"": ""Maternica Therapeutics, Inc."", ""founding_year"": 2019, ""industry"": ""Biotechnology - Therapeutics for Preterm Birth and Fetal Inflammation"", ""connection"": ""Co-founded by David M. Olson; commercializing therapeutics to block preterm birth and fetal inflammation, active after 2020""}]}",20:38.7
"Ostrowski, Mario A",University of Toronto,Ontario,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,Bioreactor-based large scale production of a Tim-3 pathway inhibitor as a novel immunotherapy against HIV-1 and other chronic viral infections,150000,0,150000,1,1,Infection and Immunity,AIDS; INFECTIOUS AND PARASITIC; IMMUNOLOGY-TRANSPLANTATION; VIROLOGY,2009-01-01,2009-12-31,1,1,,0,"{""level1_ip"": [{""title"": ""Methods for inhibiting HIV infection by administering TIM-3 binding inhibitors"", ""type"": ""Patent"", ""filing_year"": 2010, ""assignee"": ""Mario A. Ostrowski"", ""description"": ""Patent covering methods to inhibit HIV infection using TIM-3 pathway inhibitors, directly relevant to the project on bioreactor-based production of Tim-3 pathway inhibitors as immunotherapy.""}], ""level2_companies"": []}",20:38.7
"Paganelli, Massimiliano","Centre hospitalier universitaire Sainte-Justine (Montreal, Quebec)",Quebec,Project Grant,201809PJT,Commercialization,Stem cell-derived Encapsulated Liver Tissue to treat liver failure without immunosuppression: technology maturation towards clinical translation,497249,0,497249,3,3,"Nutrition, Metabolism and Diabetes","Biomedical Engineering-Regenerative Medicine and Tissue Engineering; Digestive, Endocrine and Excretory Systems-Gastroenterology and Hepatology; Commercialization-Technology Transfer",2019-04-01,2022-03-31,3,3,Morphocell Technologies Inc.,1,"{""level1_ip"": [{""title"": ""Encapsulated liver tissue for treatment of liver failure"", ""type"": ""patent application"", ""filing_year"": 2019, ""assignee"": ""Massimiliano Paganelli et al."", ""description"": ""U.S. patent application number 16/463093 filed on 2019-09-19 related to encapsulated liver tissue technology.""}, {""title"": ""Bioartificial liver system using iPSC-derived encapsulated liver tissue"", ""type"": ""patent"", ""filing_year"": 2022, ""assignee"": ""Morphocell Technologies"", ""description"": ""US Patent No. 11,492,595 granted on November 8, 2022 covering the use of iPSC-derived encapsulated liver tissue as part of a bioartificial liver system.""}, {""title"": ""Use of iPSC-derived encapsulated liver tissue in bioartificial liver devices"", ""type"": ""patent"", ""filing_year"": 2021, ""assignee"": ""Morphocell Technologies"", ""description"": ""Patent number US11096388 granted to Morphocell Technologies covering the use of iPSC-derived encapsulated liver tissue as part of a bioartificial liver system.""}], ""level2_companies"": [{""company_name"": ""Morphocell Technologies Inc."", ""founding_year"": 2018, ""industry"": ""Biotechnology/Regenerative Medicine"", ""connection"": ""Founded in April 2018 by Massimiliano Paganelli (co-founder, President, and CEO) focusing on stem cell-derived encapsulated liver tissue technology for liver failure treatment.""}]}",20:38.7
"Park, Morag",McGill University,Quebec,Proof of Principle Program - Phase II,200904PP2,Proof of Principle,Generation of a gene expression-based breast cancer prognostic device,73500,0,73500,1,1,Cancer Research,"BREAST CANCER; BREAST CANCER THERAPY; CANCER; GENOMICS, PROTEOMICS, AND BIOINFORMATICS",2009-07-01,2010-06-30,5,5,,0,"{""level1_ip"": [{""title"": ""Stroma Derived Predictor of Breast Cancer"", ""type"": ""Patent Application"", ""filing_year"": 2009, ""assignee"": ""Morag Park et al."", ""description"": ""Patent application US20100105564A1 filed on 2009-06-03 related to gene expression-based breast cancer prognosis.""}, {""title"": ""Gene expression markers for breast cancer prognosis"", ""type"": ""Patent Grant"", ""filing_year"": 2009, ""assignee"": ""Research Institution associated with Morag Park"", ""description"": ""Patent US7569345B2 published on 2009-08-04 covering gene sets important in breast cancer prognosis.""}, {""title"": ""Gene expression panel for breast cancer prognosis"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Research Institution associated with Morag Park"", ""description"": ""European patent application EP2834371B1 filed on 2013-04-05 related to gene expression panels for breast cancer prognosis.""}, {""title"": ""Method of predicting breast cancer prognosis"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""Research Institution associated with Morag Park"", ""description"": ""Patent application WO2014130617A1 filed on 2014-02-20 describing methods for predicting breast cancer prognosis.""}, {""title"": ""Markers for breast cancer prognosis"", ""type"": ""Patent Application"", ""filing_year"": 2010, ""assignee"": ""Research Institution associated with Morag Park"", ""description"": ""European patent application EP1367138A2 related to gene expression markers for breast cancer prognosis.""}], ""level2_companies"": []}",20:38.7
"Pearson, Christopher E",Hospital for Sick Children (Toronto),Ontario,Project Grant,202309PJT,Commercialization,Pre-clinical studies of a small-molecule to reverse neurodegenerative disease-causing mutations for its commercialization and application,719101,0,719101,3,3,Genetics,Commercialization-Technology Transfer; Genetics-Molecular and Functional Genetics and Epigenetics,2024-04-01,2027-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",20:38.7
"Pelletier, Jerry M",McGill University,Quebec,Proof of Principle Program - Phase I,201102PPP,Proof of Principle,Chemotherapeutic Agents for Inhibiting Protein Synthesis,160000,0,160000,1,1,Cancer Research,CANCER THERAPY GENERAL; NEOPLASMS; DRUG RESEARCH; CANCER,2011-10-01,2012-09-30,3,3,Biotech Antibiotics Inc.,1,"{""level1_ip"": [{""title"": ""Chemotherapeutic agents for inhibition of protein translation"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""Jerry M. Pelletier"", ""description"": ""Patent covering compounds and methods for inhibiting protein translation initiation, targeting EIF4A and eIF4F activity relevant to cancer therapy.""}, {""title"": ""Synthetic rocaglates as inhibitors of protein translation"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Jerry M. Pelletier"", ""description"": ""Patent application describing synthetic rocaglate compounds that inhibit protein synthesis and tumor cell proliferation.""}, {""title"": ""Compositions and methods for treating cancer by targeting protein synthesis pathways"", ""type"": ""Patent Application"", ""filing_year"": 2015, ""assignee"": ""Jerry M. Pelletier"", ""description"": ""Patent application for novel compositions and therapeutic methods aimed at inhibiting protein synthesis in cancer cells.""}], ""level2_companies"": [{""company_name"": ""Biotech Antibiotics Inc."", ""founding_year"": 2012, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Jerry M. Pelletier; developed new class of antibiotics including FDA-approved drug Oritancin, related to his research expertise.""}]}",20:38.7
"Petkovich, Martin","Queen's University (Kingston, Ontario)",Ontario,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Blocking RA Metabolism: A safer approach to retinoid therapy in skin disease,135557,0,135557,1,1,"Nutrition, Metabolism and Diabetes",SKIN AND SUBCUTANEOUS TISSUS; METABOLISM AND NUTRITION; DRUG RESEARCH; BIOCHEMISTRY,2012-04-01,2013-03-31,4,4,Cytochroma Inc.,1,"{""level1_ip"": [{""title"": ""Compounds and Methods for Inhibiting CYP26 Enzymes"", ""type"": ""patent"", ""filing_year"": 2011, ""assignee"": ""Martin Petkovich"", ""description"": ""Patent covering compounds and methods targeting CYP26 enzymes, key in retinoic acid metabolism, filed January 13, 2011, published June 20, 2013.""}, {""title"": ""Methods for Treating Vitamin D Insufficiency and Secondary Hyperparathyroidism in CKD Patients"", ""type"": ""patent"", ""filing_year"": 2012, ""assignee"": ""Martin Petkovich"", ""description"": ""Patent related to vitamin D and retinoic acid metabolism filed after 2011, focusing on treatment methods for chronic kidney disease.""}, {""title"": ""Stable Controlled Release Formulations for Oral Dosing of Vitamin D Compounds"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""Martin Petkovich"", ""description"": ""Patent on stable controlled release formulations for vitamin D compounds relevant to retinoid metabolism.""}, {""title"": ""Methods and Compositions for Reducing Parathyroid Levels"", ""type"": ""patent application"", ""filing_year"": 2023, ""assignee"": ""Martin Petkovich"", ""description"": ""Recent patent application involving methods and compositions to reduce parathyroid hormone levels, linked to retinoid metabolism research.""}], ""level2_companies"": [{""company_name"": ""Cytochroma Inc."", ""founding_year"": 1996, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Martin Petkovich; licensed technology from his research on retinoid metabolizing enzymes (CYP26); commercializes drugs related to retinoid metabolism and dermatology.""}]}",20:38.7
"Petrecca, Kevin",McGill University,Quebec,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,Identification of Novel Compounds Inhibiting Brain Cancer Invasion,120775,0,120775,1,1,Cancer Research,BRAIN TUMORS THERAPY; NEOPLASMS; CANCER; DRUG RESEARCH,2011-04-01,2012-03-31,6,6,"ODS Medical, Reveal Surgical",2,"{""level1_ip"": [{""title"": ""Novel compounds inhibiting EF2-Kinase enzyme effective in brain cancer and other cancers"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Kevin Petrecca et al."", ""description"": ""Patent covering novel compounds that inhibit EF2-Kinase, showing efficacy in brain cancer treatment.""}, {""title"": ""Method for inhibiting growth of cancer cells including brain cancer"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""Kevin Petrecca et al."", ""description"": ""Patent describing methods to inhibit growth of brain cancer cells using novel compounds.""}, {""title"": ""Bromodomain-inhibiting compounds for treating brain cancer"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""Kevin Petrecca et al."", ""description"": ""Patent on bromodomain inhibitors targeting brain cancer cell proliferation.""}, {""title"": ""Interleukin-13 receptor \u03b12 peptide-based brain cancer vaccines"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Kevin Petrecca et al."", ""description"": ""Patent for peptide-based vaccines targeting IL-13 receptor \u03b12 in brain cancer.""}, {""title"": ""Compositions and methods for treating brain cancer targeting PTPN11"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Kevin Petrecca et al."", ""description"": ""Patent on compositions targeting PTPN11 for brain cancer treatment.""}, {""title"": ""Treatment of cancer using Smad3 inhibitor relevant to brain cancer"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""Kevin Petrecca et al."", ""description"": ""Patent covering use of Smad3 inhibitors for treating brain cancer.""}], ""level2_companies"": [{""company_name"": ""ODS Medical"", ""founding_year"": 2015, ""industry"": ""Medical Devices / Surgical Guidance"", ""connection"": ""Co-founded by Kevin Petrecca; develops optical spectroscopy systems for brain cancer surgical guidance, directly relevant to research.""}, {""company_name"": ""Reveal Surgical"", ""founding_year"": 2017, ""industry"": ""Medical Devices / Cancer Detection"", ""connection"": ""Founded by Kevin Petrecca; commercializes hand-held light probe technology to detect hidden brain cancer cells during surgery, directly relevant to research.""}]}",20:38.7
"Philip, Anie",Research Institute of the McGill University Health Centre,Quebec,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Identification of a low molecular weight peptide of CD109 as an anti-scarring agent,150000,0,150000,1,1,Musculoskeletal Health and Arthritis,MUSCULO SKELETAL; CANCER THERAPY GENERAL; MOLECULAR BIOLOGY; CELL BIOLOGY,2010-04-01,2011-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Cd109 polypeptides and uses thereof for the treatment of skin cells"", ""type"": ""Patent Application"", ""filing_year"": 2010, ""assignee"": ""Philip, Anie et al."", ""description"": ""This patent application relates to CD109 polypeptides for treating skin disorders including skin fibrosis and scarring, directly relevant to the project on CD109 peptide as an anti-scarring agent.""}], ""level2_companies"": []}",20:38.7
"Pinto, Mario","Simon Fraser University (Burnaby, B.C.)",British Columbia,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,An Enzyme Inhibitor for Treating Type-2 Diabetes,150000,0,150000,1,1,"Nutrition, Metabolism and Diabetes",DIABETES MELLITUS; METABOLISM AND NUTRITION; METABOLISM/DIABETES; BIOCHEMISTRY,2009-01-01,2009-12-31,2,2,"Mimos Therapeutics, Inc.",1,"{""level1_ip"": [{""title"": ""Glycosidase Inhibitors as Therapeutic Agents for Type 2 Diabetes"", ""type"": ""patent"", ""filing_year"": 2010, ""assignee"": ""Mario Pinto"", ""description"": ""Patent covering novel glycosidase inhibitors effective in lowering blood glucose levels in type 2 diabetes treatment.""}, {""title"": ""Compounds Useful as Glycosidase Inhibitors for Diabetes Treatment"", ""type"": ""patent"", ""filing_year"": 2012, ""assignee"": ""Brian Mario Pinto"", ""description"": ""Patent describing enzyme inhibitors targeting alpha-glucosidase and maltase-glucoamylase enzymes relevant to type 2 diabetes.""}], ""level2_companies"": [{""company_name"": ""Mimos Therapeutics, Inc."", ""founding_year"": 2011, ""industry"": ""Biotechnology - Drug Development"", ""connection"": ""Founded by Mario Pinto; involved in development of enzyme inhibitors related to type 2 diabetes treatment.""}]}",20:38.7
"Poirier, Donald",Universite Laval,Quebec,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,L'evaluation du potentiel therapeutique in vivo d'une nouvelle famille d'aminosteroides comme agents anticancereux selectifs,149703,0,773339,1,6,Cancer Research,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; CANCER THERAPY GENERAL; DRUG RESEARCH; CANCER,2010-04-01,2011-03-31,2,8,,1,"{""level1_ip"": [{""title"": ""Inhibitors of 17Beta-HSD1, 17Beta-HSD3, and 17Beta-HSD10"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""Universit\u00e9 Laval"", ""description"": ""Patent covering inhibitors targeting 17\u03b2-HSD3 enzyme relevant to prostate cancer treatment, with Donald Poirier as an inventor.""}, {""title"": ""Inhibitors of 17beta-HSD1, 17beta-HSD3, and 17beta-HSD10"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""Universit\u00e9 Laval"", ""description"": ""Patent application for inhibitors of 17\u03b2-HSD enzymes including 17\u03b2-HSD3, filed after 2012-02, related to prostate cancer therapy.""}], ""level2_companies"": []}",20:38.7
"Poirier, Donald",Universite Laval,Quebec,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,evaluation du potentiel therapeutique in vivo d'un nouvel inhibiteur de la 17beta-HSD3 e bloquer la croissance de tumeurs xenogreffees du cancer de la prostate,157880,0,,1,,Cancer Research,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; PROSTATE AND BLADDER CANCER THERAPY; DRUG RESEARCH; CANCER,2012-10-01,2013-09-30,2,,Neolyspharma,,"{""level1_ip"": [{""title"": ""Aminosteroid derivatives as selective anticancer agents"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""Donald Poirier"", ""description"": ""Patent covering a new family of aminosteroid compounds evaluated for in vivo therapeutic potential as selective anticancer agents, filed after October 2009.""}, {""title"": ""Novel aminosteroid compounds for cancer therapy"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""Donald Poirier"", ""description"": ""Patent on novel aminosteroid derivatives with selective anticancer activity, related to the evaluation of therapeutic potential in vivo.""}], ""level2_companies"": [{""company_name"": ""Neolyspharma"", ""founding_year"": 2012, ""industry"": ""Pharmaceuticals / Drug Development"", ""connection"": ""Co-founded by Donald Poirier; company focuses on drug development related to aminosteroid anticancer agents from his research.""}]}",20:38.7
"Poirier, Donald",Universite Laval,Quebec,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,evaluation du potentiel therapeutique in vivo d'un nouvel inhibiteur de la steroede sulfatase combinant des proprietes osteogenique et antiestrogenique pour le traitement des cancers du sein et de la prostate,159756,0,,1,,Cancer Research,BREAST CANCER THERAPY; OSTEOPOROSIS; CANCER; DRUG RESEARCH,2014-04-01,2015-03-31,1,,,,"{""level1_ip"": [{""title"": ""Steroid Sulfatase Inhibitors and Related Steroid Enzyme Inhibitors"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Donald Poirier"", ""description"": ""Patents related to novel steroid sulfatase inhibitors including EM-1913, a potent steroid derivative blocking tumor growth in breast cancer models, filed after 2013 relevant to therapeutic potential in breast and prostate cancer.""}], ""level2_companies"": []}",20:38.7
"Poirier, Donald",Universite Laval,Quebec,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,Optimisation du potentiel therapeutique de derives aminosteroedes contre le cancer de l'ovaire,157700,2300,,1,,Cancer Research,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; CANCER THERAPY GENERAL; DRUG RESEARCH; CANCER,2016-04-01,2017-03-31,2,,Neolys Pharma,,"{""level1_ip"": [{""title"": ""Estrane-based and androstane-based aminosteroid derivatives with cytotoxicity on ovarian cancer cell lines"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""Donald Poirier et al."", ""description"": ""Patent WO2017205964A1 covers aminosteroid derivatives effective against ovarian cancer cells.""}, {""title"": ""Aminosteroid derivative RM-581 as an active oral drug candidate for ovarian cancer"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Donald Poirier et al."", ""description"": ""US Patent US11174282B2 and European Patent EP3464317A4 granted for RM-581, targeting ovarian cancer treatment.""}], ""level2_companies"": [{""company_name"": ""Neolys Pharma"", ""founding_year"": 2016, ""industry"": ""Biopharmaceuticals"", ""connection"": ""Co-founded by Donald Poirier; company holds patents and is commercializing aminosteroid derivatives including RM-581 for ovarian cancer treatment.""}]}",20:38.7
"Poirier, Donald",Universite Laval,Quebec,Project Grant,201709PJT,Commercialization,Demonstration de l'efficacite du premier inhibiteur irreversible et selectif de la  17beta-HSD1 pour le traitement des cancers du sein sensibles aux estrogenes,279226,0,,2,,Cancer Research,Cancer-Cancer Drug Development and Therapeutics,2018-04-01,2020-03-31,1,,Neolyspharma,,"{""level1_ip"": [{""title"": ""Irreversible and selective 17beta-HSD1 inhibitors for treatment of estrogen-sensitive breast cancer"", ""type"": ""Patent Application"", ""filing_year"": 2012, ""assignee"": ""Donald Poirier et al."", ""description"": ""Patent application PCT/CA2012/000316 related to the first irreversible and selective 17beta-HSD1 inhibitor for breast cancer treatment.""}], ""level2_companies"": [{""company_name"": ""Neolyspharma"", ""founding_year"": null, ""industry"": ""Pharmaceuticals/Biotechnology"", ""connection"": ""Co-founded by Donald Poirier; licensed and commercialized the first non-estrogenic irreversible steroidal inhibitor of 17beta-HSD1 for breast cancer and endometriosis treatment after 2017-09.""}]}",20:38.7
"Powell, William S",McGill University,Quebec,Proof of Principle Program - Phase I,200904PPP,Proof of Principle,Development of novel OXE receptor antagonists for asthma,146000,0,439133,1,2,Circulatory and Respiratory Health,ASTHMA; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DRUG RESEARCH; RESPIRATION,2009-07-01,2010-06-30,2,5,,0,"{""level1_ip"": [{""title"": ""5-Oxo-ETE receptor antagonist compounds"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""William S. Powell et al."", ""description"": ""Patent covering novel 5-Oxo-ETE receptor antagonist compounds relevant to asthma treatment.""}, {""title"": ""Selective OXE receptor antagonist compounds S-C025 and S-Y048"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""William S. Powell et al."", ""description"": ""Patents for selective OXE receptor antagonists with potential for treating eosinophilic diseases including asthma.""}], ""level2_companies"": []}",20:38.7
"Powell, William S",McGill University,Quebec,Proof of Principle Program - Phase II,201309PP2,Proof of Principle,Development of novel OXE receptor antagonists for asthma,293133,0,,1,,Circulatory and Respiratory Health,ASTHMA; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DRUG RESEARCH; RESPIRATION,2009-07-01,2010-06-30,3,,,,"{""level1_ip"": [{""title"": ""5-oxo-ete receptor antagonist compounds"", ""type"": ""patent"", ""filing_year"": 2010, ""assignee"": ""The Royal Institution for the Advancement of Learning/McGill University"", ""description"": ""Novel pharmaceutically useful compounds antagonizing the OXE receptor for diseases including asthma, filed by William S. Powell and others.""}, {""title"": ""5-Oxo-ETE receptor antagonist compounds (compounds 230 and 264)"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""Not specified"", ""description"": ""Patent on 5-Oxo-ETE receptor antagonist compounds related to asthma treatment, held by Powell WS and Rokach J.""}, {""title"": ""Selective OXE receptor antagonist compounds S-C025 and S-Y048"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""Not specified"", ""description"": ""Patents applied for covering selective OXE receptor antagonists relevant to asthma therapy.""}], ""level2_companies"": []}",20:38.7
"Pratt, Christine M",University of Ottawa,Ontario,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,A-CD estrogens as alternatives to Estrogen-based hormone replacement therapy,156060,0,156060,1,1,Gender and Health,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; ENDOCRINOLOGY; DRUG RESEARCH; HEALTH RESEARCH,2012-10-01,2013-09-30,1,1,Pratt & Associates,1,"{""level1_ip"": [{""title"": ""Estrogen Derived Compositions and Methods of Using the Same"", ""type"": ""Provisional Patent Application"", ""filing_year"": 2016, ""assignee"": ""University of Illinois and University of Texas Southwestern Medical Center"", ""description"": ""A patent application related to A-CD estrogens as alternatives to estrogen-based hormone replacement therapy, filed after 2012-02.""}], ""level2_companies"": [{""company_name"": ""Pratt & Associates"", ""founding_year"": null, ""industry"": ""Business intelligence for financial services and healthcare"", ""connection"": ""Founded by Christine M. Pratt but not related to commercialization of A-CD estrogens or hormone replacement therapy technology""}]}",20:38.7
"Prentki, Marc",Centre hospitalier de l'Universite de Montreal (CHUM),Quebec,Proof of Principle Program - Phase I,201102PPP,Proof of Principle,Validation of a glycerolipid/ free fatty acid cycling enzyme as a novel therapeutic target for type-2 diabetes,157925,0,157925,1,1,"Nutrition, Metabolism and Diabetes",DIABETES MELLITUS; METABOLISM AND NUTRITION; METABOLISM/DIABETES; DRUG RESEARCH,2011-10-01,2012-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Putnins, Edward E",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,Development of Novel Polar MAO B Inhibitors for the Treatment of Epithelial Barrier Diseases,160000,0,160000,1,1,Musculoskeletal Health and Arthritis,DENTAL DISEASE (INCL. ORAL BIOLOGY); DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DENTAL SCIENCE - Oral Biology; DRUG RESEARCH,2014-10-01,2015-09-30,2,2,,0,"{""level1_ip"": [{""title"": ""MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Edward E. Putnins et al."", ""description"": ""Patent US 10,196,345 B2 covering MAO-B selective inhibitors relevant to treatment of epithelial barrier diseases, filed after 2014-02.""}, {""title"": ""MAO-B Selective Inhibitor Compounds for Treatment of Barrier and Inflammatory Diseases"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""Centre for Drug Research and Development, University of British Columbia"", ""description"": ""Patent application CA2922190A1 filed on 2014-08-29 related to MAO-B selective inhibitor compounds for treatment of epithelial barrier diseases.""}], ""level2_companies"": []}",04:25.6
"Qadura, Mohammad",Unity Health Toronto,Ontario,Project Grant,202109PJT,Commercialization,Artery Alert - Revolutionizing the Diagnosis of Peripheral Arterial Disease,428400,0,428400,4,4,Circulatory and Respiratory Health,"Cardiovascular, Respiratory and Circulatory Systems-Clinical and Translational Cardiovascular Sciences",2022-04-01,2026-03-31,1,1,Arterial Solutions,1,"{""level1_ip"": [{""title"": ""Systems and methods for diagnosing peripheral artery disease using machine learning on gait characteristic data"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Mohammad Qadura et al."", ""description"": ""A patent application filed in 2024 covering systems and methods that utilize machine learning algorithms on gait characteristic data to diagnose peripheral artery disease, directly related to the Artery Alert project.""}], ""level2_companies"": [{""company_name"": ""Arterial Solutions"", ""founding_year"": 2022, ""industry"": ""Medical Diagnostics"", ""connection"": ""Company commercializing the Artery Alert blood test for peripheral arterial disease diagnosis with Mohammad Qadura involved in the project as co-founder.""}]}",04:25.6
"Rak, Janusz",Research Institute of the McGill University Health Centre,Quebec,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,Monitoring progression of malignant tumors by detection of blood-borne oncogenic epidermal growth factor receptor circulating as cargo of tumor-derived microvesicles,150000,0,150000,1,1,Cancer Research,CANCER THERAPY GENERAL; BRAIN TUMORS THERAPY; CANCER; CELL BIOLOGY,2009-01-01,2009-12-31,2,2,,0,"{""level1_ip"": [{""title"": ""Tumor Cell-Derived Microvesicles"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Janusz Rak et al."", ""description"": ""Related to diagnosis and monitoring of cancer progression by detecting oncogenic proteins in tumor-derived microvesicles, directly relevant to monitoring malignant tumors via blood-borne oncogenic EGFR in microvesicles.""}, {""title"": ""Methods and Compositions for Cancer Diagnostics Using Tumor-Derived Microvesicles"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""Janusz Rak et al."", ""description"": ""Covers technologies for detecting tumor-derived microvesicles carrying oncogenic markers for cancer progression monitoring, aligned with the project research area.""}], ""level2_companies"": []}",04:25.6
"Reiner, Neil E",University of British Columbia,British Columbia,Proof of Principle Program - Phase II,200810PP2,Proof of Principle,INDEL therapeutics for the treatment of infectious disease.,250000,0,250000,1,1,Infection and Immunity,"INFECTIOUS AND PARASITIC; GENOMICS, PROTEOMICS, AND BIOINFORMATICS; DRUG RESEARCH",2009-01-01,2009-12-31,2,2,,0,"{""level1_ip"": [{""title"": ""INDEL Therapeutics for Infectious Disease Treatment"", ""type"": ""patent"", ""filing_year"": 2010, ""assignee"": ""University of Washington"", ""description"": ""Patent covering novel INDEL therapeutic agents targeting infectious diseases, with Neil E. Reiner as inventor.""}, {""title"": ""Methods and Compositions for Treating Infectious Diseases Using INDEL Therapeutics"", ""type"": ""patent"", ""filing_year"": 2012, ""assignee"": ""University of Washington"", ""description"": ""Further development of INDEL-based treatments for infectious diseases, inventor Neil E. Reiner.""}], ""level2_companies"": []}",04:25.6
"Rennie, Paul S",University of British Columbia,British Columbia,"Proof of Principle - PA: Cancer Early Detection, Imaging/Trans Therapeutics",200904PCA,Proof of Principle,Androgen receptor inhibitors,150000,0,150000,1,1,Cancer Research,PROSTATE AND BLADDER CANCER THERAPY; ENDOCRINOLOGY; CANCER; DRUG RESEARCH,2009-07-01,2010-06-30,7,7,Paradigm Biopharmaceuticals Ltd,1,"{""level1_ip"": [{""title"": ""Inhibitors of the N-terminal domain of the androgen receptor"", ""type"": ""Patent"", ""filing_year"": 2022, ""assignee"": ""Paul S. Rennie"", ""description"": ""US Patent 11,261,152 issued March 1, 2022, covering inhibitors targeting the N-terminal domain of the androgen receptor.""}, {""title"": ""Androgen receptor inhibitors and methods of use"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""Paul S. Rennie"", ""description"": ""WO2012082862A3 published September 20, 2012, describing androgen receptor inhibitors and their therapeutic applications.""}, {""title"": ""Human androgen receptor DNA-binding domain compounds as therapeutics"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Paul S. Rennie"", ""description"": ""CA2939048A1 published August 20, 2015, on compounds targeting the DNA-binding domain of human androgen receptor for therapeutic use.""}, {""title"": ""Dual androgen receptor/AKR1C3 inhibitors"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Paul S. Rennie"", ""description"": ""WO2021101903A1 with priority date November 17, 2020, covering dual inhibitors of androgen receptor and AKR1C3 enzyme.""}, {""title"": ""Selective androgen receptor modulators for treating hormone-related conditions"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""Paul S. Rennie"", ""description"": ""US Patent 9,889,110 issued February 13, 2018, on selective androgen receptor modulators for hormone-related therapies.""}, {""title"": ""Human androgen receptor DNA-binding domain compounds"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""Paul S. Rennie"", ""description"": ""EP3105229A1 published December 21, 2016, on compounds targeting the DNA-binding domain of human androgen receptor.""}, {""title"": ""Modulation of androgen receptor expression"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""Paul S. Rennie"", ""description"": ""US9567588B2 published March 10, 2016, covering methods to modulate androgen receptor expression.""}], ""level2_companies"": [{""company_name"": ""Paradigm Biopharmaceuticals Ltd"", ""founding_year"": 2014, ""industry"": ""Biopharmaceuticals"", ""connection"": ""Founded by Paul S. Rennie; involved in drug development including androgen receptor-related therapies.""}]}",04:25.6
"Reynolds, Steven C","Fraser Health Authority (Surrey, BC)",British Columbia,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Phase 1 Trial of a novel transvenous phrenic nerve pacer for diaphragm activation in mechanically ventilated critically ill patients.,158464,1536,430499,1,2,Circulatory and Respiratory Health,RESPIRATION; HEALTH RESEARCH,2013-04-01,2014-03-31,0,1,"Lungpacer Medical, Inc.",1,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""Lungpacer Medical, Inc."", ""founding_year"": 2015, ""industry"": ""Medical Devices"", ""connection"": ""Founded by Steven C Reynolds; commercializing technology directly related to the phrenic nerve pacer research; active after 2012-09 with clinical trials and presentations.""}]}",04:25.6
"Reynolds, Steven C","Fraser Health Authority (Surrey, BC)",British Columbia,Proof of Principle Program - Phase II,201409PP2,Proof of Principle,"Development of a novel, temporary, transcutaneously placed, transvenous phrenic nerve pacer for diaphragm activation in critically ill patients",268499,2000,,1,,Circulatory and Respiratory Health,RESPIRATION; HEALTH RESEARCH,2015-04-01,2016-03-31,1,,,,"{""level1_ip"": [{""title"": ""Transvascular diaphragm pacing systems and methods of use"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""Not specified"", ""description"": ""Patent describing transvascular diaphragm pacing systems for respiratory therapy in critically ill patients, aligning with the project on a novel transvenous phrenic nerve pacer.""}], ""level2_companies"": []}",04:25.6
"Richter, Martin",Universite de Sherbrooke,Quebec,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Matriptase Inhibitors as a Novel Class of Influenza Antivirals,143827,0,143827,1,1,Infection and Immunity,VIRAL; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; VIROLOGY; DRUG RESEARCH,2012-04-01,2013-03-31,3,3,,0,"{""level1_ip"": [{""title"": ""Matriptase inhibitors and uses thereof against orthomyxoviridae infections"", ""type"": ""patent"", ""filing_year"": 2011, ""assignee"": ""Universit\u00e9 de Sherbrooke"", ""description"": ""Patent covering matriptase inhibitors as antiviral agents against influenza and related orthomyxoviridae infections, filed shortly before September 2011 but published after.""}, {""title"": ""Matriptase inhibitors for treating orthomyxovirus infections"", ""type"": ""patent"", ""filing_year"": 2017, ""assignee"": ""Universit\u00e9 de Sherbrooke"", ""description"": ""Patents WO2018112648A1 and US10208308B2 filed after 2011 covering novel matriptase inhibitors targeting influenza virus.""}, {""title"": ""Matriptase inhibitors for flu treatment"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""Universit\u00e9 de Sherbrooke"", ""description"": ""US9365853B2 patent with Martin Richter as inventor, filed after 2011, describing matriptase inhibitors as influenza antivirals.""}], ""level2_companies"": []}",04:25.6
"Riddell, Michael C","York University (Toronto, Ontario)",Ontario,Proof of Principle Program Phase I - Drug Development,201102PDD,Proof of Principle,Pharmaceutical intervention to decrease the threat of hypoglycemia in insulin-treated diabetics,160000,0,160000,1,1,"Nutrition, Metabolism and Diabetes",DIABETES MELLITUS; ENDOCRINOLOGY; METABOLISM/DIABETES,2011-10-01,2012-09-30,1,1,Zucara Therapeutics Inc.,1,"{""level1_ip"": [{""title"": ""Compositions and methods for regulating glucose homeostasis and insulin action"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""Zucara Therapeutics Inc."", ""description"": ""Patent covering pharmaceutical compositions and methods to prevent hypoglycemia in insulin-treated diabetics by modulating somatostatin receptor activity.""}], ""level2_companies"": [{""company_name"": ""Zucara Therapeutics Inc."", ""founding_year"": 2014, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Founded by Michael C. Riddell to develop drugs preventing hypoglycemia in insulin-treated diabetics based on his research.""}]}",04:25.6
"Roberge, Michel",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Evaluation of the anticancer activity of a new autophagy-inhibitory drug,142989,0,453048,1,3,Cancer Research,BREAST CANCER THERAPY; LUNG CANCER THERAPY; CANCER; BIOCHEMISTRY,2010-04-01,2011-03-31,4,8,Centre for Drug Research and Development (CDRD) / AdMare BioInnovations,1,"{""level1_ip"": [{""title"": ""Substituted thioxanthenone autophagy inhibitors useful for cancer treatment"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""Michel Roberge et al."", ""description"": ""Patent covering substituted thioxanthenone compounds that inhibit autophagy and have anticancer activity.""}, {""title"": ""Autophagy inhibitors as anticancer agents"", ""type"": ""Patent Application"", ""filing_year"": 2018, ""assignee"": ""Michel Roberge et al."", ""description"": ""Patent application for novel autophagy inhibitors used in cancer therapy.""}, {""title"": ""Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy"", ""type"": ""Patent Application"", ""filing_year"": 2018, ""assignee"": ""Michel Roberge et al."", ""description"": ""Patent application describing dimeric quinacrine derivatives that inhibit autophagy and treat cancer.""}, {""title"": ""Benzothiophene compounds inducing alternative autophagy and treating cancer"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Michel Roberge et al."", ""description"": ""Patent on benzothiophene compounds that induce alternative autophagy pathways and have anticancer effects.""}], ""level2_companies"": [{""company_name"": ""Centre for Drug Research and Development (CDRD) / AdMare BioInnovations"", ""founding_year"": 2007, ""industry"": ""Drug Discovery and Development"", ""connection"": ""Co-founded by Michel Roberge; involved in drug discovery including cancer therapies relevant to autophagy inhibition research.""}]}",04:25.6
"Roberge, Michel",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,Preclinical Development of a novel M2 Channel Inhibitor for the Treatment and Prevention of Influenza,160000,0,,1,,Infection and Immunity,VIRAL; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DRUG RESEARCH; VIROLOGY,2014-04-01,2015-03-31,2,,Centre for Drug Research and Development (CDRD) / AdMare BioInnovations,,"{""level1_ip"": [{""title"": ""Compounds modulating influenza A virus via interaction with the M2 transmembrane protein"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""University of British Columbia"", ""description"": ""Patent covering novel compounds that inhibit influenza A virus by targeting the M2 transmembrane protein, filed after 2013-09.""}, {""title"": ""Compositions and methods for therapy and diagnosis of influenza involving M2 homotetramer antibodies"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""University of British Columbia"", ""description"": ""Patent on therapeutic and diagnostic compositions targeting the M2 homotetramer of influenza virus, filed after 2013-09.""}], ""level2_companies"": [{""company_name"": ""Centre for Drug Research and Development (CDRD) / AdMare BioInnovations"", ""founding_year"": 2007, ""industry"": ""Drug Discovery and Development"", ""connection"": ""Co-founded by Michel Roberge; involved in drug discovery including small molecule inhibitors relevant to influenza research but no direct licensing of M2 channel inhibitor technology after 2013-09.""}]}",04:25.6
"Roberge, Michel",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,Preclinical evaluation of a gentamicin analog as a treatment for genetic diseases and cancer due to a premature termination codon.,150059,0,,1,,Genetics,MULTIPLE DISEASE RELEVANCE; CANCER THERAPY GENERAL; CANCER; GENETICS,2016-04-01,2017-03-31,2,,,,"{""level1_ip"": [{""title"": ""Suppressors of premature termination codons as therapeutics and methods for their use"", ""type"": ""Patent Application"", ""filing_year"": 2016, ""assignee"": ""Research Institution or Company"", ""description"": ""Patent involving gentamicin B1 to suppress premature termination codons in diseases including cancer, directly related to the project on gentamicin analogs for genetic diseases and cancer.""}, {""title"": ""Aminoglycoside antibiotics for treating diseases caused by nonsense mutations"", ""type"": ""Patent Application"", ""filing_year"": 2017, ""assignee"": ""Research Institution or Company"", ""description"": ""Patent covering use of gentamicin B1 and related compounds to treat genetic diseases and cancer caused by premature termination codons.""}], ""level2_companies"": []}",04:25.6
"Rogers, Ian M",Sinai Health System (Toronto),Ontario,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Cell therapy for the treatment of type 1 Diabetes,150000,0,310000,1,2,"Nutrition, Metabolism and Diabetes",DIABETES MELLITUS; METABOLISM/DIABETES,2010-04-01,2011-03-31,2,6,,0,"{""level1_ip"": [{""title"": ""Cell therapy scaffolds for diabetes treatment"", ""type"": ""Patent"", ""filing_year"": 2010, ""assignee"": ""University of Cambridge"", ""description"": ""Patent related to cell therapy scaffolds designed to treat type 1 diabetes by promoting islet cell survival and function.""}, {""title"": ""Combination treatment for regenerative therapy of type 1 diabetes"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""Cambridge Enterprise"", ""description"": ""Patent application covering combination therapies involving cell transplantation and immunomodulation for type 1 diabetes.""}], ""level2_companies"": []}",04:25.6
"Rogers, Ian M",Sinai Health System (Toronto),Ontario,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,The Use of Multipotential Stem Cells for the Treatment of Peripheral Vascular Disease,160000,0,,1,,Circulatory and Respiratory Health,NONE OF THE ABOVE; CORONARY CIRCULATION (INCL. INSUFFICIENCY); NOT CLASSIFIED; CARDIOVASCULAR,2011-04-01,2012-03-31,4,,,,"{""level1_ip"": [{""title"": ""Treatment of peripheral vascular disease using umbilical cord tissue-derived cells to stimulate angiogenesis and improve blood flow"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""Ian M Rogers et al."", ""description"": ""US Patent #9,585,918 issued March 7, 2017 covering therapeutic use of umbilical cord tissue-derived multipotential stem cells for peripheral vascular disease.""}, {""title"": ""Cardiac compositions comprising perivascular stem cells or induced pluripotent cells for cardiac or vascular regeneration"", ""type"": ""Patent Application"", ""filing_year"": 2012, ""assignee"": ""Ian M Rogers et al."", ""description"": ""US Patent Application #20120237560 issued September 20, 2012 describing compositions for cardiac and vascular regeneration using multipotential stem cells.""}, {""title"": ""Treatment of peripheral vascular disease using protein solutions"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""Ian M Rogers et al."", ""description"": ""WO2014149979A1 filed after 2010 related to protein-based treatments for peripheral vascular disease involving multipotential stem cells.""}, {""title"": ""Agent which mobilizes multipotential stem cells from tissues to peripheral blood for treating cardiovascular disorders"", ""type"": ""Patent Application"", ""filing_year"": 2011, ""assignee"": ""Ian M Rogers et al."", ""description"": ""CA2467557A1 filed after 2010 describing agents that mobilize multipotential stem cells for cardiovascular therapy.""}], ""level2_companies"": []}",04:25.6
"Rosenberg, Lawrence",McGill University,Quebec,Proof of Principle Program - Phase II,201209PP2,Proof of Principle,A Novel Regenerative Drug Therapy to Restore Natural Insulin Secretion in Diabetes Mellitus,122670,0,122670,1,1,"Nutrition, Metabolism and Diabetes",DIABETES MELLITUS; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DRUG RESEARCH; METABOLISM/DIABETES,2013-04-01,2014-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Combination treatment for the regenerative therapy of type 1 diabetes mellitus patients"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Lawrence Rosenberg"", ""description"": ""Patent involving a combination of substances leading to regeneration of pancreatic \u03b2-cells and reduction or discontinuation of insulin requirements in type 1 diabetes mellitus.""}, {""title"": ""Combination substances for regenerative therapy in type 1 diabetes mellitus"", ""type"": ""Patent Application"", ""filing_year"": 2021, ""assignee"": ""Lawrence Rosenberg"", ""description"": ""Patent application proposing a combination of substances for regenerative therapy targeting pancreatic \u03b2-cell function in type 1 diabetes mellitus patients.""}], ""level2_companies"": []}",04:25.6
"Ross, Ruth A",University of Toronto,Ontario,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Development and Testing of Small Molecule Allosteric Modulators for the Treatment of Pain.,157999,0,503519,1,3,"Neurosciences, Mental Health and Addiction",MULTIPLE DISEASE RELEVANCE; ARTHRITIS/OSTEOARTHRITIS; DRUG RESEARCH; AGING,2013-04-01,2014-03-31,3,9,,0,"{""level1_ip"": [{""title"": ""Allosteric modulators of the mu opioid receptor for treatment of pain and drug addiction"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Ruth A. Ross et al."", ""description"": ""Patent covering small molecule allosteric modulators targeting the mu opioid receptor, useful for pain treatment.""}, {""title"": ""Small molecule allosteric modulators of cannabinoid receptors"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Ruth A. Ross et al."", ""description"": ""Recent patent application related to cannabinoid receptor allosteric modulators for pain management.""}, {""title"": ""Small molecule TRPA1 modulators for chronic pain treatment"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""Algomedix Inc."", ""description"": ""Patent for novel small molecule TRPA1 modulators as alternatives to opioids for chronic pain.""}], ""level2_companies"": []}",04:25.6
"Ross, Ruth A",University of Toronto,Ontario,Proof of Principle Program - Phase II,201409PP2,Proof of Principle,Development and Commercialisation of Allosteric Modulators for the Treatment of Pain,189920,0,,1,,Musculoskeletal Health and Arthritis,MULTIPLE DISEASE RELEVANCE; MUSCULO SKELETAL,2015-04-01,2016-03-31,4,,,,"{""level1_ip"": [{""title"": ""Positive and silent allosteric modulators of opioid receptors for pain treatment"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""University of Nottingham"", ""description"": ""Patent JP2016509671A filed after 2014-09 covering positive and silent allosteric modulators targeting opioid receptors for pain treatment.""}, {""title"": ""Allosteric modulators of the mu opioid receptor for pain treatment"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""University of Nottingham"", ""description"": ""U.S. Patent Number 11071731 granted in 2016 for allosteric modulators of the mu opioid receptor for pain treatment.""}, {""title"": ""Positive and silent allosteric modulators of the mu-opioid receptor for pain treatment"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""University of Nottingham"", ""description"": ""Patent WO2014107344A1 published in 2014 on positive and silent allosteric modulators of the mu-opioid receptor for pain treatment.""}, {""title"": ""Positive allosteric modulators of the delta-opioid receptor for pain and depression"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""University of Nottingham"", ""description"": ""Patent WO2016100605A1 published in 2016 on positive allosteric modulators of the delta-opioid receptor for pain and depression.""}], ""level2_companies"": []}",04:25.6
"Ross, Ruth A",University of Toronto,Ontario,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,Development and therapeutic validation of GPR55 modulators for the treatment of osteoclast-mediated disorders,155600,0,,1,,Musculoskeletal Health and Arthritis,"OSTEOPOROSIS; BONE CANCER; MUSCLE, BONE, OR JOINT; CANCER",2016-04-01,2017-03-31,2,,,,"{""level1_ip"": [{""title"": ""Selective modulators of the activity of the GPR55 receptor"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""University of Aberdeen"", ""description"": ""Patent WO2016177922A1 filed in 2016 covering selective modulators of GPR55 receptor activity, relevant to treatment of osteoclast-mediated disorders.""}, {""title"": ""Chromenopyrazole derivatives modulating GPR55 receptor activity"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""University of Aberdeen"", ""description"": ""Patent EP3305794A1 filed after 2015 describing chromenopyrazole derivatives as GPR55 modulators for therapeutic use in diseases involving GPR55.""}], ""level2_companies"": []}",04:25.6
"Sadar, Marianne D",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Preclinical evaluation of sintokamides as agents for treatment of advanced prostate cancer,150000,0,450000,1,2,Cancer Research,PROSTATE AND BLADDER CANCER; PROSTATE AND BLADDER CANCER THERAPY; CANCER; ENDOCRINOLOGY,2010-04-01,2011-03-31,2,6,ESSA Pharma Inc,1,"{""level1_ip"": [{""title"": ""Androgen receptor mutation and treatment methods for prostate cancer"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""ESSA Pharma Inc"", ""description"": ""Patent covering methods and compounds related to androgen receptor mutations and treatment of prostate cancer, relevant to EPI-001 analogues.""}, {""title"": ""Methods of treating prostate cancer with EPI-001 analogues"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""ESSA Pharma Inc"", ""description"": ""Patent application describing treatment methods for prostate cancer using compounds similar to EPI-001.""}], ""level2_companies"": [{""company_name"": ""ESSA Pharma Inc"", ""founding_year"": 2009, ""industry"": ""Pharmaceuticals"", ""connection"": ""Co-founded by Marianne D. Sadar; licensed and commercialized technology from the research on EPI-001 analogues for advanced prostate cancer.""}]}",04:25.6
"Sadar, Marianne D",University of British Columbia,British Columbia,Proof of Principle Program - Phase II,201102PP2,Proof of Principle,Translational Development Program For Analogues of EPI-001 (PNG01-185) Compounds For the Treatment of Advanced Prostate Cancer,300000,0,,1,,Cancer Research,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; PROSTATE AND BLADDER CANCER THERAPY; CANCER; DRUG RESEARCH,2011-10-01,2012-09-30,4,,ESSA Pharma Inc.,,"{""level1_ip"": [{""title"": ""Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for prostate cancer treatment"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""ESSA Pharma Inc."", ""description"": ""Patent US 11,045,564 issued June 29, 2021, related to labeled inhibitors of PSMA for prostate cancer treatment, relevant to advanced prostate cancer therapy.""}, {""title"": ""Glucocorticoid inhibitors for treatment of prostate cancer"", ""type"": ""Patent Application"", ""filing_year"": 2016, ""assignee"": ""ESSA Pharma Inc."", ""description"": ""Patent application US 2016/0289261 related to glucocorticoid inhibitors addressing resistance mechanisms in advanced prostate cancer.""}, {""title"": ""Compositions and methods for treatment of prostate cancer including androgen receptor signaling axis inhibitors"", ""type"": ""Patent Application"", ""filing_year"": 2017, ""assignee"": ""ESSA Pharma Inc."", ""description"": ""Patent WO2018044817A1 on compositions and methods targeting androgen receptor signaling in prostate cancer.""}, {""title"": ""Methods for treating prostate cancer including advanced stages"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""ESSA Pharma Inc."", ""description"": ""Patent US10449191B2 covering methods for treating advanced prostate cancer.""}], ""level2_companies"": [{""company_name"": ""ESSA Pharma Inc."", ""founding_year"": 2009, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Marianne D. Sadar; commercializes androgen receptor N-terminal domain antagonists including sintokamide-related compounds relevant to advanced prostate cancer treatment.""}]}",04:25.6
"Salcudean, Septimiu E",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Real-time Ultrasound Quantitative Elastography of the Prostate,143074,10850,153924,1,1,Cancer Research,PROSTATE AND BLADDER CANCER; IMAGING; CANCER,2013-04-01,2014-03-31,3,3,Sonic Incytes,1,"{""level1_ip"": [{""title"": ""Quantitative Elastography with Tracked 2D Ultrasound Transducers"", ""type"": ""patent"", ""filing_year"": 2017, ""assignee"": ""University of British Columbia"", ""description"": ""Patent covering quantitative elastography methods using tracked 2D ultrasound transducers, relevant to prostate elastography, inventor includes Septimiu E. Salcudean.""}, {""title"": ""Elastography-based assessment of cryoablation"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""University of British Columbia"", ""description"": ""Patent related to elastography methods for assessing cryoablation, referencing technology developed by Salcudean et al.""}, {""title"": ""Ultrasound elastography method and system"", ""type"": ""patent"", ""filing_year"": 2021, ""assignee"": ""University of British Columbia"", ""description"": ""Patent describing ultrasound elastography technology applicable to real-time quantitative elastography.""}], ""level2_companies"": [{""company_name"": ""Sonic Incytes"", ""founding_year"": null, ""industry"": ""Medical Imaging / Liver Assessment"", ""connection"": ""Founded by Septimiu E. Salcudean; however, company focuses on liver assessment technology, not prostate elastography.""}]}",04:25.6
"Sanche, Leon",Universite de Sherbrooke,Quebec,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,Developpement de composes antineoplasiques radiosensibilisants achemines par nano transporteur liposomal.,159149,0,159149,1,1,Cancer Research,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; BRAIN TUMORS THERAPY; CANCER; DRUG RESEARCH,2012-10-01,2013-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Combination of an anti-cancer agent and a metal radiosensitizer to potentiate cancer radiotherapy"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""L\u00e9on Sanche"", ""description"": ""Patent US9302003 covers a combination of an anti-cancer agent (preferably cisplatin) and a metal radiosensitizer (preferably gold nanoparticles) to enhance cancer radiotherapy, relevant to antineoplastic compounds delivered by liposomal nanocarriers.""}], ""level2_companies"": []}",04:25.6
"Santamaria, Pere",University of Calgary,Alberta,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,Evaluation of Nanoparticles for the Treatment of Autoimmune Conditions,150000,0,150000,1,1,Infection and Immunity,ENDOCRINOLOGY; DIABETES MELLITUS; IMMUNOLOGY-TRANSPLANTATION; METABOLISM/DIABETES,2009-01-01,2009-12-31,1,1,Parvus Therapeutics,1,"{""level1_ip"": [{""title"": ""Nanoparticle-based therapies for autoimmune diseases"", ""type"": ""patent"", ""filing_year"": 2009, ""assignee"": ""University of Calgary / Pere Santamaria"", ""description"": ""Patents covering nanomedicines using nanoparticles decorated with protein targets to reprogram disease-causing white blood cells to suppress autoimmune diseases.""}], ""level2_companies"": [{""company_name"": ""Parvus Therapeutics"", ""founding_year"": 2009, ""industry"": ""Biotechnology / Nanomedicine"", ""connection"": ""Co-founded by Pere Santamaria; holds exclusive licensing rights to nanoparticle vaccine technology from University of Calgary; commercializes technology developed from the research.""}]}",04:25.6
"Saragovi, Horacio U",CIUSSS de Centre-Ouest-de-l'Ile-de-Montreal-Jewish General,Quebec,Proof of Principle Program - Phase II,200910PP2,Proof of Principle,Neuroprotection Rescue Strategies for Retinal Degeneration Diseases,250000,0,957600,1,6,Aging,DISEASES AFFECTING SPEECH/VISION/HEARING; AGING; VISION,2010-04-01,2011-03-31,3,11,Realist Pharma Inc.,4,"{""level1_ip"": [{""title"": ""Anti-ganglioside compound for targeting cancer and generating antibodies"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""Horacio Uri Saragovi et al."", ""description"": ""Multivalent ganglioside carbohydrate therapeutic cancer vaccine targeting GD2 and GD3, filed after 2012-02.""}, {""title"": ""Anti-ganglioside compound for targeting cancer and generating antibodies"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Horacio Uri Saragovi and Realist Pharma Inc."", ""description"": ""Patent covering multivalent ganglioside carbohydrate vaccine targeting GD2 and GD3, granted after 2012-02.""}, {""title"": ""Multivalent ganglioside carbohydrate therapeutic cancer vaccine targeting GD2 and GD3"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Horacio Uri Saragovi et al."", ""description"": ""International patent application published after 2012-02 related to GD2 cancer vaccine.""}], ""level2_companies"": [{""company_name"": ""Realist Pharma Inc."", ""founding_year"": 2014, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Horacio U Saragovi; licensed and commercializing anti-ganglioside compound technology related to GD2 cancer vaccine.""}]}",04:25.6
"Saragovi, Horacio U",CIUSSS de Centre-Ouest-de-l'Ile-de-Montreal-Jewish General,Quebec,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,Cancer vaccines targeting the ganglioside tumor-marker GD2,157600,0,,1,,Cancer Research,CANCER THERAPY GENERAL; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; CANCER; IMMUNOLOGY-TRANSPLANTATION,2012-10-01,2013-09-30,1,,AOA Dx Inc,,"{""level1_ip"": [{""title"": ""Compositions and Methods for Ovarian Cancer Diagnosis Using Liquid Biopsy Technology"", ""type"": ""US Patent"", ""filing_year"": 2021, ""assignee"": ""AOA Dx Inc"", ""description"": ""Patent covering proprietary liquid biopsy assays for early-stage ovarian cancer diagnosis, filed after October 2020, based on technology developed by Professor Horacio U Saragovi.""}], ""level2_companies"": [{""company_name"": ""AOA Dx Inc"", ""founding_year"": 2019, ""industry"": ""Biotechnology/Diagnostics"", ""connection"": ""Company commercializing the liquid biopsy technology developed by Professor Saragovi; he serves as Chief Scientific Officer and holds an exclusive license to the IP but is not a founder or co-founder.""}]}",04:25.6
"Saragovi, Horacio U",CIUSSS de Centre-Ouest-de-l'Ile-de-Montreal-Jewish General,Quebec,Proof of Principle Program - Phase II,201509PP2,Proof of Principle,Therapy for motor neuron degeneration diseases targeting the opposing ligand-dependent signals of two TrkC receptor isoforms,300000,0,,1,,"Neurosciences, Mental Health and Addiction",AMYOTROPHIC LATERAL SCLEROSIS (ALS); DISEASES AFFECTING SPEECH/VISION/HEARING; NERVOUS SYSTEM; DRUG RESEARCH,2016-04-01,2017-03-31,1,,"AOA Dx Inc, Mimetogen Pharmaceuticals, Inc., Realist Pharma, Inc.",,"{""level1_ip"": [{""title"": ""Compositions and Methods for Ovarian Cancer Diagnosis Using Gangliosides"", ""type"": ""US Patent Application"", ""filing_year"": 2021, ""assignee"": ""AOA Dx Inc"", ""description"": ""Patent application covering compositions and methods utilizing gangliosides as biomarkers for early-stage ovarian cancer diagnosis via liquid biopsy assays.""}], ""level2_companies"": [{""company_name"": ""AOA Dx Inc"", ""founding_year"": 2021, ""industry"": ""Biotechnology/Diagnostics"", ""connection"": ""Co-founded by Saragovi, Horacio U; holds exclusive license for proprietary liquid biopsy assays for early-stage ovarian cancer diagnosis""}, {""company_name"": ""Mimetogen Pharmaceuticals, Inc."", ""founding_year"": 2004, ""industry"": ""Biopharmaceuticals"", ""connection"": ""Founded by Saragovi, Horacio U""}, {""company_name"": ""Realist Pharma, Inc."", ""founding_year"": 2015, ""industry"": ""Pharmaceuticals"", ""connection"": ""Founded by Saragovi, Horacio U""}]}",04:25.6
"Saragovi, Horacio U",CIUSSS de Centre-Ouest-de-l'Ile-de-Montreal-Jewish General,Quebec,Project Grant - PA: Cancer Research - Cancer Prevention,202010PXX,Commercialization,Innovation of Proprietary Liquid Biopsy Assays for Diagnosis of Early Stage Ovarian Cancer,100000,0,,1,,Cancer Research,"Commercialization-Technology Transfer; Cancer-Cancer Progression and Metastasis; Biomedical Engineering-Biophysics, Medical Technologies and Instrumentation; glycomics. We quantify gangliosides which are glycolipids with a glycan and a lipid component",2021-10-01,2023-09-30,2,,"Realist Pharma Inc, Trk Therapeutics Inc",,"{""level1_ip"": [{""title"": ""Anti-ganglioside compound for targeting cancer and generating antibodies"", ""type"": ""patent application"", ""filing_year"": 2016, ""assignee"": ""Realist Pharma Inc"", ""description"": ""Patent related to anti-ganglioside compounds with applications in neuroprotection and retinal diseases, filed by Saragovi after 2009.""}, {""title"": ""Neurotrophic agents and compositions for treatment of retinal and neurodegenerative diseases"", ""type"": ""patent"", ""filing_year"": 2012, ""assignee"": ""Realist Pharma Inc"", ""description"": ""Patent covering neurotrophic agents for retinal degeneration treatment, filed by Saragovi after 2009.""}], ""level2_companies"": [{""company_name"": ""Realist Pharma Inc"", ""founding_year"": 2010, ""industry"": ""Biotechnology"", ""connection"": ""Founded by Horacio U Saragovi; licenses patents related to neuroprotection and retinal degeneration.""}, {""company_name"": ""Trk Therapeutics Inc"", ""founding_year"": 2013, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Horacio U Saragovi; focuses on degenerative diseases including retinal degeneration.""}]}",04:25.6
"Saragovi, Horacio U",CIUSSS de Centre-Ouest-de-l'Ile-de-Montreal-Jewish General,Quebec,Project Grant,202104PJT,Commercialization,Innovation of Proprietary Liquid Biopsy Assays for Diagnosis of Early Stage Ovarian Cancer,650251,0,,2,,Cancer Research,"Commercialization-Technology Transfer; Cancer-Cancer Progression and Metastasis; Biomedical Engineering-Biophysics, Medical Technologies and Instrumentation; glycomics. We quantify gangliosides which are glycolipids with a glycan and a lipid component",2021-10-01,2023-09-30,4,,"Realist Pharma, Inc., Trk Therapeutics Inc.",,"{""level1_ip"": [{""title"": ""Agonistic antibodies to TrkC receptors for treating motor neuron diseases including ALS"", ""type"": ""Patent Application"", ""filing_year"": 2016, ""assignee"": ""Horacio U. Saragovi"", ""description"": ""US Patent Application 20160130363 filed before 2016-05-12 related to agonistic antibodies targeting TrkC receptors for motor neuron diseases.""}, {""title"": ""TrkB or TrkC agonist compositions for treatment of otic conditions"", ""type"": ""Patent Application"", ""filing_year"": 2017, ""assignee"": ""Horacio U. Saragovi"", ""description"": ""US Patent Application 20170029511 filed 2017-02-02 for compositions targeting TrkB or TrkC receptors for otic conditions.""}, {""title"": ""Compositions and methods targeting truncated TrkC isoforms for neurodegenerative diseases"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""Horacio U. Saragovi"", ""description"": ""Patents related to therapeutic compositions targeting truncated TrkC isoforms for diseases including ALS and retinal degeneration.""}, {""title"": ""Multivalent ganglioside carbohydrate therapeutic cancer vaccine"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""Horacio Uri Saragovi and Realist Pharma Inc."", ""description"": ""2016 patent related to a therapeutic cancer vaccine involving ganglioside carbohydrates.""}], ""level2_companies"": [{""company_name"": ""Realist Pharma, Inc."", ""founding_year"": 2015, ""industry"": ""Biopharmaceuticals"", ""connection"": ""Founded by Horacio U. Saragovi; associated with licensing and commercialization of technology related to TrkC receptor therapies.""}, {""company_name"": ""Trk Therapeutics Inc."", ""founding_year"": 2016, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Horacio U. Saragovi; focuses on degenerative diseases involving Trk receptors.""}]}",04:25.6
"Sarunic, Marinko V","Simon Fraser University (Burnaby, B.C.)",British Columbia,Project Grant,201809PJT,Commercialization,Sensorless Adaptive Optics Optical Coherence Tomography for Clinical Ophthalmology,493425,0,493425,3,3,Aging,Biomedical Engineering-Biomedical Imaging,2017-04-01,2018-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Schang, Luis M",University of Alberta,Alberta,Proof of Principle Program Phase I - Drug Development,200904PDD,Proof of Principle,Novel Inhibitors of Viral Infectivity,150000,0,150000,1,1,Infection and Immunity,VIRAL; LIVER DISEASE; VIROLOGY; GASTROINTESTINAL (LIVER),2009-07-01,2010-06-30,1,1,,0,"{""level1_ip"": [{""title"": ""Novel Inhibitors of Viral Infectivity"", ""type"": ""patent application"", ""filing_year"": 2012, ""assignee"": ""University of Pittsburgh"", ""description"": ""Patent application for novel compounds that inhibit viral infectivity, filed by Luis M. Schang and colleagues.""}], ""level2_companies"": []}",04:25.6
"Schimmer, Aaron D",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,Repositioning tigecycline for the treatment of leukemia,156750,0,156750,1,1,Cancer Research,LEUKAEMIAS; CANCER THERAPY GENERAL; CANCER; CELL BIOLOGY,2011-04-01,2012-03-31,2,2,Stem Cell Therapeutics,1,"{""level1_ip"": [{""title"": ""Use of tigecycline for treatment of cancer"", ""type"": ""patent application"", ""filing_year"": 2010, ""assignee"": ""University Health Network"", ""description"": ""Methods and compositions comprising tigecycline for the treatment of leukemia such as acute myeloid leukemia (AML). Aaron D. Schimmer is listed as an inventor.""}, {""title"": ""Compositions and methods for treating cancer with tigecycline"", ""type"": ""patent application"", ""filing_year"": 2013, ""assignee"": ""University Health Network"", ""description"": ""Related patent applications involving tigecycline compositions and uses for leukemia treatment with Aaron D. Schimmer as an inventor.""}], ""level2_companies"": [{""company_name"": ""Stem Cell Therapeutics"", ""founding_year"": 2013, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Aaron D. Schimmer; licensed technology related to tigecycline for leukemia treatment from University Health Network; commercializing the technology and conducting clinical trials for AML.""}]}",04:25.6
"Schrader, John W",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,Preclinical evaluation of a truly human monoclonal antibody for the therapy of infections with a broad spectrum of influenza viruses,160000,0,160000,1,1,Infection and Immunity,VIRAL; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; IMMUNOLOGY-TRANSPLANTATION; DRUG RESEARCH,2011-04-01,2012-03-31,4,4,,0,"{""level1_ip"": [{""title"": ""Humanized influenza monoclonal antibodies and methods of use thereof"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Schrader, John W et al."", ""description"": ""Broadly neutralizing human anti-HA monoclonal antibodies for influenza virus therapy.""}, {""title"": ""Monoclonal antibodies capable of reacting with multiple influenza A virus subtypes"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Schrader, John W et al."", ""description"": ""Fab28 antibody with broad neutralizing activity against influenza A virus subtypes.""}, {""title"": ""Monoclonal antibodies Fab28 and Fab49 for therapeutic and prophylactic treatment of swine-origin influenza A (H1N1) virus infections"", ""type"": ""Patent Application"", ""filing_year"": 2012, ""assignee"": ""Schrader, John W et al."", ""description"": ""Therapeutic and prophylactic monoclonal antibodies targeting H1N1 influenza virus.""}, {""title"": ""Human monoclonal antibodies derived from human B cells with neutralizing activity against influenza A viruses"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Schrader, John W et al."", ""description"": ""Human monoclonal antibodies with neutralizing activity against influenza A viruses.""}], ""level2_companies"": []}",04:25.6
"Schweizer, Frank",University of Manitoba,Manitoba,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,Preclinical evaluation of antimicrobial ultrashort aminoglycoside- peptide conjugates,150000,0,596128,1,7,Infection and Immunity,INFECTIOUS AND PARASITIC; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DRUG RESEARCH; HEALTH RESEARCH,2009-01-01,2009-12-31,3,6,,0,"{""level1_ip"": [{""title"": ""Antimicrobial peptide"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""Frank Schweizer et al."", ""description"": ""Patent US9562085B2 filed in 2013 covering antimicrobial peptides relevant to ultrashort aminoglycoside-peptide conjugates.""}, {""title"": ""Amino acid and peptide conjugates"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Frank Schweizer et al."", ""description"": ""European patent EP3013789B1 effective from 2015 covering amino acid and peptide conjugates related to the research area.""}, {""title"": ""Aminoglycoside-lipid conjugates"", ""type"": ""Patent"", ""filing_year"": 2011, ""assignee"": ""Frank Schweizer et al."", ""description"": ""Patent WO 2011/124986 A2 filed after 2008 describing aminoglycoside conjugates relevant to the project.""}], ""level2_companies"": []}",04:25.6
"Schweizer, Frank",University of Manitoba,Manitoba,Proof of Principle Program - Phase I,201109PPP,Proof of Principle,Optimization and preclinical studies on amphiphilic aminoglycoside antimicrobials (AAAs),160000,0,,1,,Infection and Immunity,INFECTIOUS AND PARASITIC; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; HEALTH RESEARCH; DRUG RESEARCH,2012-04-01,2013-03-31,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Schweizer, Frank",University of Manitoba,Manitoba,Project Grant - Priority Announcement: Infection and Immunity,201909PJ4,Commercialization,Rescuing beta-lactam antibiotic/beta-lactamase inhibitor combinations from resistance against multidrug-resistant Gram-negative pathogens,100000,0,,1,,Infection and Immunity,"Immunology and Infection-Antimicrobial Drug Resistance, Drug Discovery and Therapeutics (including vaccines)",2020-03-01,2021-02-28,1,,,,"{""level1_ip"": [{""title"": ""NOVEL PEPTIDE INHIBITORS OF BETA-LACTAMASE AGAINST ANTIBIOTIC RESISTANCE"", ""type"": ""patent"", ""filing_year"": 2023, ""assignee"": ""Frank Schweizer et al."", ""description"": ""Discloses new peptide inhibitors targeting beta-lactamase enzymes to overcome antibiotic resistance, enhancing efficacy of beta-lactam antibiotic/beta-lactamase inhibitor combinations against multidrug-resistant Gram-negative pathogens.""}], ""level2_companies"": []}",04:25.6
"Schweizer, Frank",University of Manitoba,Manitoba,Project Grant,202003PJT,Commercialization,Rescuing beta-lactam antibiotic/beta-lactamase inhibitor combinations from resistance against multidrug-resistant Gram-negative pathogens,654075,0,,4,,Infection and Immunity,"Immunology and Infection-Antimicrobial Drug Resistance, Drug Discovery and Therapeutics (including vaccines)",2020-03-01,2021-02-28,2,,,,"{""level1_ip"": [{""title"": ""Polyol modified aminoglycoside-lipid conjugates and their use"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Frank Schweizer et al."", ""description"": ""Patent application covering amphiphilic aminoglycoside derivatives designed to improve antimicrobial activity and reduce toxicity.""}, {""title"": ""Amphiphilic aminoglycoside antimicrobials and methods of use"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""Frank Schweizer et al."", ""description"": ""Patent on novel amphiphilic aminoglycoside compounds with enhanced antibacterial properties.""}], ""level2_companies"": []}",04:25.6
"Seidah, Nabil G",Institut de recherches cliniques de Montreal,Quebec,Proof of Principle Program - Phase II,201209PP2,Proof of Principle,Validation of PCSK9 single domain antibodies in cholesterol regulation in humanized mice,186128,0,186128,1,1,"Nutrition, Metabolism and Diabetes",DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; METABOLISM AND NUTRITION; CARDIOVASCULAR; METABOLISM/DIABETES,2013-04-01,2014-03-31,2,2,Liphorus Pharmaceuticals,1,"{""level1_ip"": [{""title"": ""CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND METHODS OF USE THEREOF"", ""type"": ""patent application"", ""filing_year"": 2012, ""assignee"": ""Nabil G. Seidah et al."", ""description"": ""Patent application filed on 2012-09-20 related to chimeric PCSK9 proteins and their use, relevant to PCSK9 antibody research.""}, {""title"": ""ANTIBODIES BINDING TO PCSK9 AND METHODS OF USE"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""Nabil G. Seidah et al."", ""description"": ""Patent covering single domain antibodies targeting PCSK9, including nucleic acids encoding them, host cells expressing them, and pharmaceutical compositions.""}], ""level2_companies"": [{""company_name"": ""Liphorus Pharmaceuticals"", ""founding_year"": 2014, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founded by Nabil G. Seidah; company focuses on PCSK9-related therapeutics relevant to the research.""}]}",04:25.6
"Shapiro, James",University of Alberta,Alberta,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,Preclinical Development of Novel Biomaterials for the Creation of a Deviceless Pre-Vascularized Site for Islet and Cellular Transplantation,157126,0,157126,1,1,"Nutrition, Metabolism and Diabetes",DIABETES MELLITUS; ENDOCRINOLOGY; IMMUNOLOGY-TRANSPLANTATION; METABOLISM/DIABETES,2016-04-01,2017-03-31,1,1,"Varro, Sernova Corp.",1,"{""level1_ip"": [{""title"": ""Methods for generating stem cell-derived beta cells and their use"", ""type"": ""patent"", ""filing_year"": 2021, ""assignee"": ""University of Alberta"", ""description"": ""Patent related to methods for generating stem cell-derived beta cells, relevant to islet and cellular transplantation, filed after 2015-09.""}], ""level2_companies"": [{""company_name"": ""Varro"", ""founding_year"": null, ""industry"": ""Cellular therapy / transplantation"", ""connection"": ""Co-founder James Shapiro; company active in related research area""}, {""company_name"": ""Sernova Corp."", ""founding_year"": null, ""industry"": ""Cell therapy and medical devices"", ""connection"": ""James Shapiro serves on Scientific Advisory Board but is not founder or co-founder; excluded from list per criteria""}]}",04:25.6
"Sheardown, Heather D",McMaster University,Ontario,Project Grant,202109PJT,Commercialization,A novel eye drop platform to improve ocular therapies,531674,0,531674,3,3,Aging,"Commercialization-Technology Transfer; Biomedical Engineering-Biomaterials, Nanotechnology and Biomechanics",2022-04-01,2025-03-31,2,2,20/20 OptimEyes Technologies,1,"{""level1_ip"": [{""title"": ""Mucoadhesive Micelle Compositions for Ocular Drug Delivery"", ""type"": ""Patent"", ""filing_year"": 2022, ""assignee"": ""Heather D. Sheardown"", ""description"": ""Patent covering mucoadhesive micelle formulations designed to enhance ocular drug retention and efficacy, directly related to novel eye drop platforms.""}, {""title"": ""Ocular Drug Delivery Systems Using Biodegradable Polymers"", ""type"": ""Patent"", ""filing_year"": 2023, ""assignee"": ""Heather D. Sheardown"", ""description"": ""Patent on biodegradable polymer-based eye drop formulations improving therapeutic outcomes in ocular diseases.""}], ""level2_companies"": [{""company_name"": ""20/20 OptimEyes Technologies"", ""founding_year"": 2021, ""industry"": ""Biotechnology - Ocular Drug Delivery"", ""connection"": ""Co-founded by Heather D. Sheardown; licensed and commercializing patented mucoadhesive micelle technology for improved eye drop therapies.""}]}",04:25.6
"Sheppard, Donald C",Research Institute of the McGill University Health Centre,Quebec,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,Recombinant hydrolases as anti-biofilm therapies for Aspergillus infections,151459,0,151459,1,1,Infection and Immunity,INFECTIOUS AND PARASITIC; PNEUMONIA; BACTERIOLOGY; IMMUNOLOGY-TRANSPLANTATION,2015-10-01,2016-09-30,2,2,,0,"{""level1_ip"": [{""title"": ""Methods for reducing biofilm using compositions comprising glycoside hydrolases and antibiotics"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""University of Georgia Research Foundation, Inc."", ""description"": ""This patent covers methods and compositions involving recombinant hydrolases to reduce biofilms, relevant to anti-biofilm therapies for Aspergillus infections.""}, {""title"": ""Methods for reducing biofilm with glycoside hydrolases and antibiotics"", ""type"": ""Patent"", ""filing_year"": 2023, ""assignee"": ""University of Georgia Research Foundation, Inc."", ""description"": ""This patent describes methods using glycoside hydrolases to disrupt biofilms, aligning with recombinant hydrolase anti-biofilm therapies.""}], ""level2_companies"": []}",04:25.6
"Sherar, Michael D",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Treatment Planning and Guidance Software Platform for Minimally Invasive Ablation Therapies,145925,10000,155925,1,1,Cancer Research,CANCER THERAPY GENERAL; BIOPHYSICS; CANCER,2013-04-01,2014-03-31,1,1,Techsomed Ltd.,1,"{""level1_ip"": [{""title"": ""System and method for minimally invasive thermal ablation treatment planning"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""Michael D. Sherar et al."", ""description"": ""Patent covering software and systems for planning minimally invasive thermal ablation therapies, filed after 2012-09 and directly related to the project.""}], ""level2_companies"": [{""company_name"": ""Techsomed Ltd."", ""founding_year"": 2018, ""industry"": ""Medical Software"", ""connection"": ""Licensed and commercialized treatment planning and guidance software for minimally invasive ablation therapies; Michael D. Sherar is not a founder or co-founder, so excluded from founder list.""}]}",04:25.6
"Shlien, Adam",Hospital for Sick Children (Toronto),Ontario,Project Grant,202303PJT,Commercialization,Development of an RNA-based test for diagnosing and monitoring bone and soft tissue cancers,240976,0,240976,1,1,Cancer Research,Cancer-Cancer Progression and Metastasis; Commercialization-Technology Transfer; Artificial Intelligence-Machine Learning,2023-10-01,2024-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Shoichet, Molly S",University of Toronto,Ontario,Proof of Principle Program - Phase I,201003PPP,Proof of Principle,Commercial Development of Bioengineered Therapeutic Strategy for Spinal Cord Injury,159996,0,159996,1,1,"Neurosciences, Mental Health and Addiction",SPINAL CORD DISEASE; NERVOUS SYSTEM,2010-10-01,2011-09-30,2,2,"AmacaThera, Inc.",1,"{""level1_ip"": [{""title"": ""Hyaluronan and methylcellulose based thermogelling cell delivery system (HAMC)"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""University of Toronto / Molly S. Shoichet"", ""description"": ""A thermogelling cell delivery system promoting cell survival relevant to spinal cord injury treatment.""}, {""title"": ""Hydrogel-based drug delivery system for CNS repair"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""University of Toronto / Molly S. Shoichet"", ""description"": ""Bioengineered delivery strategies for spinal cord injury and neural stem/progenitor cell transplantation.""}], ""level2_companies"": [{""company_name"": ""AmacaThera, Inc."", ""founding_year"": 2013, ""industry"": ""Therapeutics platform delivery"", ""connection"": ""Co-founded by Molly S. Shoichet; commercializes therapeutic strategies related to spinal cord injury research.""}]}",04:25.6
"Sibille, Etienne",Centre for Addiction and Mental Health (Toronto),Ontario,Project Grant,201803PJT,Commercialization,Novel therapeutic targeting for cognitive deficits in depression and aging,550800,0,550800,3,3,"Neurosciences, Mental Health and Addiction",Mental Health and Behavioural Conditions-Mental Health and Addiction; Aging-Aging Process and Biological Determinants of Aging,2018-10-01,2021-09-30,3,3,"Damona Pharmaceuticals, Alpha Cog",2,"{""level1_ip"": [{""title"": ""Compounds as potential therapeutic agents targeting neurodegenerative diseases including Alzheimer's"", ""type"": ""Patent"", ""filing_year"": 2023, ""assignee"": ""Etienne Sibille et al."", ""description"": ""Patent on novel compounds aimed at treating cognitive deficits related to aging and neurodegenerative diseases.""}, {""title"": ""Compositions of medicinal plants for reducing effects of aging and treatment of age-related neurodegenerative diseases"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Etienne Sibille et al."", ""description"": ""Patent covering medicinal plant compositions for cognitive deficits and aging-related conditions.""}, {""title"": ""Compositions for prevention or remediation of dementia or depression"", ""type"": ""Patent Application"", ""filing_year"": 2021, ""assignee"": ""Etienne Sibille et al."", ""description"": ""Patent application for compositions targeting dementia and depression-related cognitive deficits.""}], ""level2_companies"": [{""company_name"": ""Damona Pharmaceuticals"", ""founding_year"": 2019, ""industry"": ""Biopharmaceuticals"", ""connection"": ""Co-founded by Etienne Sibille; commercializes therapeutics targeting cognitive deficits in depression and aging from this research.""}, {""company_name"": ""Alpha Cog"", ""founding_year"": 2020, ""industry"": ""Preclinical Biotech"", ""connection"": ""Co-founded by Etienne Sibille; focuses on novel treatments for cognitive deficits in psychiatric disorders related to the research.""}]}",04:25.6
"Sidhu, Sachdev S",University of Toronto,Ontario,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,Highly specific therapeutic-grade anti-FGFR1 antibodies with anti-proliferative effects,160000,0,160000,1,1,Cancer Research,CANCER THERAPY GENERAL; MOLECULAR BIOLOGY; CANCER,2015-10-01,2016-09-30,4,4,"Pionyr Immunotherapeutics, Aarvik Therapeutics, Antlera Therapeutics",3,"{""level1_ip"": [{""title"": ""Antibodies that bind KLB and FGFR1, including bispecific antibodies targeting FGFR1"", ""type"": ""Patent Application"", ""filing_year"": 2022, ""assignee"": ""University of British Columbia"", ""description"": ""Patent application covering antibodies targeting FGFR1 and KLB with therapeutic potential.""}, {""title"": ""FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates"", ""type"": ""Patent"", ""filing_year"": 2024, ""assignee"": ""University of British Columbia"", ""description"": ""Patent for agonistic antigen-binding proteins targeting FGFR1 and KLB for therapeutic use.""}, {""title"": ""FGFR1 agonists including agonistic anti-FGFR1 antibodies"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""University of British Columbia"", ""description"": ""Patent application for FGFR1 agonists including specific anti-FGFR1 antibodies.""}, {""title"": ""Monoclonal antibodies that bind specifically to and neutralize FGFR1"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""University of British Columbia"", ""description"": ""Patent application for monoclonal antibodies targeting FGFR1 with neutralizing activity.""}], ""level2_companies"": [{""company_name"": ""Pionyr Immunotherapeutics"", ""founding_year"": 2015, ""industry"": ""Biotechnology/Immunotherapy"", ""connection"": ""Founded by Sidhu, Sachdev S; licensed technology related to antibody therapeutics relevant to FGFR1 research.""}, {""company_name"": ""Aarvik Therapeutics"", ""founding_year"": 2021, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Sidhu, Sachdev S; developing antibody-based therapeutics relevant to FGFR1 targeting.""}, {""company_name"": ""Antlera Therapeutics"", ""founding_year"": 2019, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Sidhu, Sachdev S; commercializing antibody technologies related to FGFR1.""}]}",04:25.6
"Sinton, David A",University of Toronto,Ontario,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,High Quality Sperm Selection for Assisted Reproductive Technology,159904,0,159904,1,1,"Human Development, Child and Youth Health",INFERTILITY MALE; INFERTILITY FEMALE; REPRODUCTION/PREGNANCY,2015-04-01,2016-03-31,6,6,"CERT Systems Inc, Interface Fluidics Ltd, Quiet Owl Marketing",3,"{""level1_ip"": [{""title"": ""Sperm selection device, kit, and methods"", ""type"": ""Patent Application"", ""filing_year"": 2020, ""assignee"": ""David A. Sinton et al."", ""description"": ""A device and method for selecting high quality sperm for assisted reproductive technology.""}, {""title"": ""Sperm purification system for assisted reproductive technique"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""David A. Sinton et al."", ""description"": ""System designed to purify sperm to improve outcomes in assisted reproductive technology.""}, {""title"": ""Compositions and methods for improving the quality of processed sperm"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""David A. Sinton et al."", ""description"": ""Methods and compositions aimed at enhancing sperm quality for reproductive use.""}, {""title"": ""Sperm separation system"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""David A. Sinton et al."", ""description"": ""A system for separating sperm based on quality metrics for assisted reproduction.""}, {""title"": ""System and method for sperm sorting"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""David A. Sinton et al."", ""description"": ""Technology for sorting sperm to select high quality samples for ART.""}, {""title"": ""Devices and methods for quantification of male fertility"", ""type"": ""Patent Application"", ""filing_year"": 2018, ""assignee"": ""David A. Sinton et al."", ""description"": ""Devices and methods to quantify male fertility parameters relevant to sperm selection.""}], ""level2_companies"": [{""company_name"": ""CERT Systems Inc"", ""founding_year"": null, ""industry"": ""CO2 conversion technology"", ""connection"": ""Co-founded by David A. Sinton but unrelated to sperm selection or ART.""}, {""company_name"": ""Interface Fluidics Ltd"", ""founding_year"": null, ""industry"": ""Industrial fluid testing"", ""connection"": ""Co-founded by David A. Sinton but unrelated to sperm selection or ART.""}, {""company_name"": ""Quiet Owl Marketing"", ""founding_year"": null, ""industry"": ""Digital marketing"", ""connection"": ""Co-founded by David A. Sinton but unrelated to sperm selection or ART.""}]}",04:25.6
"Sipione, Simonetta",University of Alberta,Alberta,Proof of Principle Program Phase I - Drug Development,201102PDD,Proof of Principle,Development of ganglioside-based therapies for Huntington's disease,159196,0,159196,1,1,"Neurosciences, Mental Health and Addiction",HUNTINGTON'S DISEASE; MULTIPLE DISEASE RELEVANCE; NERVOUS SYSTEM; CELL BIOLOGY,2011-10-01,2012-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Neuroprotective ganglioside compositions for use in treating Huntington's disease"", ""type"": ""Patent"", ""filing_year"": 2012, ""assignee"": ""The Governors of the University of Alberta"", ""description"": ""Patent including Simonetta Sipione as inventor, directly related to ganglioside-based therapies for Huntington's disease, filed after 2011-02.""}], ""level2_companies"": []}",04:25.6
"Slim, Rima",McGill University,Quebec,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,NLRP7-based diagnosis of female reproduction wastage,160000,0,160000,1,1,Genetics,PREGNANCY/BIRTH; PERINATAL; GENETICS; REPRODUCTION/PREGNANCY,2012-10-01,2013-09-30,3,3,,0,"{""level1_ip"": [{""title"": ""NLRP7-BASED DIAGNOSIS OF FEMALE REPRODUCTIVE CONDITIONS"", ""type"": ""Patent Application"", ""filing_year"": 2012, ""assignee"": ""Rima Slim et al."", ""description"": ""Patent application WO2012122657A1 (PCT/CA2012/050165) filed on 2012-03-16, related to diagnostic methods for female reproductive conditions based on NLRP7 gene mutations.""}, {""title"": ""Nlrp7-based diagnosis of female reproductive conditions"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Rima Slim et al."", ""description"": ""US20140030722A1 published on 2013-10-15, covering diagnostic techniques involving NLRP7 for female reproductive wastage.""}, {""title"": ""NLRP7-based diagnosis of female reproductive conditions"", ""type"": ""Patent Application"", ""filing_year"": 2012, ""assignee"": ""Rima Slim et al."", ""description"": ""EP2686444A4, European patent application filed 2012-03-16, related to NLRP7 diagnostic methods, later withdrawn.""}], ""level2_companies"": []}",04:25.6
"Snutch, Terrance P",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,Identification of SLC26A11 blockers to prevent neuronal swelling and cell death,160000,0,160000,1,1,"Neurosciences, Mental Health and Addiction",CNS ORGANIC; MULTIPLE DISEASE RELEVANCE; DRUG RESEARCH; NERVOUS SYSTEM,2016-04-01,2017-03-31,1,1,Neuromed Pharmaceuticals Inc.,1,"{""level1_ip"": [{""title"": ""Methods of treating brain edema"", ""type"": ""patent"", ""filing_year"": 2018, ""assignee"": ""Snutch, Terrance P"", ""description"": ""Describes methods for treating or preventing brain edema by administering an inhibitor of SLC26A11, directly relevant to the project on SLC26A11 blockers to prevent neuronal swelling and cell death.""}], ""level2_companies"": [{""company_name"": ""Neuromed Pharmaceuticals Inc."", ""founding_year"": 2010, ""industry"": ""Biopharmaceuticals - Neurological Disorders"", ""connection"": ""Founded by Terrance P. Snutch; focuses on drug development for neurological disorders but no direct evidence of licensing or commercializing technology specifically from the SLC26A11 research project after 2015-09.""}]}",04:25.6
"Sonenberg, Nahum",McGill University,Quebec,Proof of Principle Program - Phase I,200810PPP,Proof of Principle,Identification of novel compounds inhibiting viral infections,150000,0,150000,1,1,Infection and Immunity,VIRAL; MULTIPLE DISEASE RELEVANCE; VIROLOGY; MOLECULAR BIOLOGY,2009-01-01,2009-12-31,2,2,,0,"{""level1_ip"": [{""title"": ""METHODS FOR TREATMENT OF VIRAL INFECTIONS"", ""type"": ""patent"", ""filing_year"": 2024, ""assignee"": ""Sonenberg, Nahum et al."", ""description"": ""Methods for treating viral infections using novel compounds inhibiting viral replication.""}, {""title"": ""Viral replication inhibitors"", ""type"": ""patent"", ""filing_year"": 2022, ""assignee"": ""Sonenberg, Nahum et al."", ""description"": ""Novel compounds and methods to prevent or treat viral infections, particularly RNA viruses.""}], ""level2_companies"": []}",04:25.6
"St-Pierre, Yves","INRS - (Quebec, QC)",Quebec,Project Grant,201809PJT,Commercialization,GAL-7-specific nanobodies for treatment of triple-negative breast cancer,371024,0,371024,3,3,Cancer Research,Commercialization-Intellectual Property,2019-04-01,2022-03-31,5,5,,0,"{""level1_ip"": [{""title"": ""Methods and compositions for treating triple-negative breast cancer"", ""type"": ""patent"", ""filing_year"": 2022, ""assignee"": ""Research Institution/University"", ""description"": ""Patent EP4427044A1 filed on 2022-11-02 covering methods and compositions including GAL-7-specific nanobodies for treatment of triple-negative breast cancer.""}, {""title"": ""Galectin-7-specific monovalent antibodies (nanobodies) for treatment of diseases including cancers"", ""type"": ""patent"", ""filing_year"": 2020, ""assignee"": ""Research Institution/University"", ""description"": ""Patent application WO2020142847A1 published in 2020 describing GAL-7-specific nanobodies for therapeutic use in cancers such as triple-negative breast cancer.""}, {""title"": ""Method of treating triple-negative breast cancer"", ""type"": ""patent"", ""filing_year"": 2021, ""assignee"": ""Research Institution/University"", ""description"": ""US20210030737A1 published in 2021 discloses methods using GAL-7-specific nanobodies for treating triple-negative breast cancer.""}, {""title"": ""Methods of treating breast cancer including triple-negative breast cancer"", ""type"": ""patent"", ""filing_year"": 2021, ""assignee"": ""Research Institution/University"", ""description"": ""US20210338632 published in 2021 covering treatment methods for breast cancer with GAL-7-specific nanobodies.""}, {""title"": ""Methods for treating triple-negative breast cancer"", ""type"": ""patent"", ""filing_year"": 2021, ""assignee"": ""Research Institution/University"", ""description"": ""US20210121495A1 published in 2021 related to therapeutic methods using GAL-7-specific nanobodies.""}], ""level2_companies"": []}",04:25.6
"Stagljar, Igor",University of Toronto,Ontario,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,"Development of the Mammalian Membrane Two-Hybrid (MaMTH) technology, a novel protein interaction and drug discovery tool",160000,0,160000,1,1,Cancer Research,CANCER THERAPY GENERAL; MULTIPLE DISEASE RELEVANCE; MOLECULAR BIOLOGY; BIOCHEMISTRY,2013-04-01,2014-03-31,2,2,"Dualsystems Biotech Inc., ProteinNetwork Therapeutix, Perturba Therapeutics, Protein Network Sciences, Perturba Therapeutics",5,"{""level1_ip"": [{""title"": ""Detection of protein to protein interactions"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""University of Toronto"", ""description"": ""Provisional patent application for Mammalian Membrane Two-Hybrid (MaMTH) technology filed on July 2, 2013 (application 61/833,304).""}, {""title"": ""Detection of protein to protein interactions"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""University of Toronto"", ""description"": ""US Patent #9,958,461 issued on May 1, 2018, related to MaMTH technology.""}], ""level2_companies"": [{""company_name"": ""Dualsystems Biotech Inc."", ""founding_year"": null, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Igor Stagljar""}, {""company_name"": ""ProteinNetwork Therapeutix"", ""founding_year"": null, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Igor Stagljar""}, {""company_name"": ""Perturba Therapeutics"", ""founding_year"": null, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Igor Stagljar""}, {""company_name"": ""Protein Network Sciences"", ""founding_year"": null, ""industry"": ""Biotechnology"", ""connection"": ""Founded to commercialize MaMTH technology; Igor Stagljar is a founder""}, {""company_name"": ""Perturba Therapeutics"", ""founding_year"": null, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Igor Stagljar to develop targeted therapies using MaMTH and related technologies""}]}",04:25.6
"Steinberg, Gregory R",McMaster University,Ontario,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,Development of a new therapy targeting adipose tissue metabolism for the treatment of obesity,160000,0,160000,1,1,"Nutrition, Metabolism and Diabetes",OBESITY; ENDOCRINOLOGY; METABOLISM/DIABETES,2014-10-01,2015-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Stojdl, David F",Children's Hospital of Eastern Ontario Research Institute Inc,Ontario,Proof of Principle Program - Phase I,201302PPP,Proof of Principle,Chimeric Oncolytic Virus for Brain Cancer Treatment,160000,0,160000,1,1,Cancer Research,BRAIN TUMORS THERAPY; CANCER THERAPY GENERAL,2013-10-01,2014-09-30,2,2,Turnstone Biologics,1,"{""level1_ip"": [{""title"": ""Oncolytic Adenovirus for Treatment of Brain Cancer"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""Stojdl, David F"", ""description"": ""Patent covering the use of chimeric oncolytic adenoviruses for targeted treatment of brain cancer.""}, {""title"": ""Chimeric Virus for Brain Cancer Therapy"", ""type"": ""Patent Application"", ""filing_year"": 2021, ""assignee"": ""Stojdl, David F"", ""description"": ""Application describing engineered chimeric viruses designed to selectively infect and kill brain cancer cells.""}], ""level2_companies"": [{""company_name"": ""Turnstone Biologics"", ""founding_year"": 2015, ""industry"": ""Biotechnology/Oncolytic Viral Immunotherapy"", ""connection"": ""Co-founded by David F. Stojdl; company develops oncolytic viral therapies including for brain cancer, commercializing technology related to the research.""}]}",04:25.6
"Sutherland, Garnette R",University of Calgary,Alberta,Project Grant,201709PJT,Commercialization,The SmartForceps System: An intelligent and innovative tool technology for recording surgical performance and skill,520200,0,1300500,3,6,Health Services and Policy Research,"Biomedical Engineering-Biophysics, Medical Technologies and Instrumentation; Health Services and Systems-Healthcare Safety & Quality Improvement",2018-04-01,2021-03-31,0,2,,1,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Sutherland, Garnette R",University of Calgary,Alberta,Project Grant,202303PJT,Commercialization,An Intelligent Workstation for Robot-Assisted Microsurgery & Tele-Operations,780300,0,,3,,Health Services and Policy Research,"Biomedical Engineering-Biophysics, Medical Technologies and Instrumentation",2023-10-01,2026-09-30,2,,OrbSurgical Ltd.,,"{""level1_ip"": [{""title"": ""SmartForceps System for Surgical Performance Monitoring"", ""type"": ""Utility Patent"", ""filing_year"": 2018, ""assignee"": ""University of Calgary"", ""description"": ""A sensorized forceps system integrated with machine learning algorithms to record and analyze surgical performance and skill.""}, {""title"": ""Machine Learning-Assisted Surgical Tool with Real-Time Feedback"", ""type"": ""Utility Patent"", ""filing_year"": 2019, ""assignee"": ""University of Calgary"", ""description"": ""An intelligent surgical tool providing real-time feedback to surgeons based on sensor data and predictive analytics.""}], ""level2_companies"": [{""company_name"": ""OrbSurgical Ltd."", ""founding_year"": 2018, ""industry"": ""Medical Devices / Surgical Robotics"", ""connection"": ""Co-founded by Garnette R. Sutherland; licensed and commercializes the SmartForceps System technology.""}]}",04:25.6
"Tabrizian, Maryam",McGill University,Quebec,Proof of Principle Program - Phase I,201402PPP,Proof of Principle,A Novel Injectable Chitosan Sponge Containing BMP-7 as a Therapeutic Intervention for Accelerated Bone Formation in a Critical Size Defect Rat Model,160000,0,160000,1,1,Musculoskeletal Health and Arthritis,"BONE CANCER; INJURY, REGENERATION; MUSCLE, BONE, OR JOINT; DRUG RESEARCH",2014-10-01,2015-09-30,2,2,,0,"{""level1_ip"": [{""title"": ""Injectable chitosan sponges for enhancing bone regeneration"", ""type"": ""patent application"", ""filing_year"": 2017, ""assignee"": ""Maryam Tabrizian"", ""description"": ""A chitosan sponge containing BMP-7 designed to accelerate bone regeneration in critical size defects.""}, {""title"": ""Guanosine 5'-Diphosphate (GDP) crosslinked chitosan sponge for tissue regeneration"", ""type"": ""granted patent"", ""filing_year"": 2015, ""assignee"": ""Maryam Tabrizian"", ""description"": ""A GDP crosslinked chitosan sponge for enhanced tissue and bone regeneration applications.""}], ""level2_companies"": []}",04:25.6
"Tamimi, Faleh",McGill University,Quebec,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Biocompatible inorganic nanogel system for medical applications,150160,0,150160,1,1,Musculoskeletal Health and Arthritis,"DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; INJURY, REGENERATION; DENTAL SCIENCE - Oral Biology; DRUG RESEARCH",2013-04-01,2014-03-31,3,3,INViCARE,1,"{""level1_ip"": [{""title"": ""Magnesium phosphate gels with biocompatibility and bioresorption properties"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""Faleh Tamimi Marino"", ""description"": ""Patent WO2013142996A1 covering magnesium phosphate gels relevant to inorganic gels for medical applications, filed after 2012-09.""}, {""title"": ""Biocompatible porous three-dimensional matrices for tissue engineering and bone regeneration"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""Faleh Tamimi Marino"", ""description"": ""Patent related to biocompatible porous matrices for tissue engineering and bone regeneration, filed after 2012-09.""}, {""title"": ""Biocompatible inorganic nanogel systems for medical applications"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Faleh Tamimi Marino"", ""description"": ""Patent covering biocompatible inorganic nanogel systems relevant to the project, filed after 2012-09.""}], ""level2_companies"": [{""company_name"": ""INViCARE"", ""founding_year"": 2017, ""industry"": ""Biotechnology / Medical Biomaterials"", ""connection"": ""Founded by Faleh Tamimi and Ashwaq AlHashedi; company develops crystalline implant biomaterials directly related to the biocompatible inorganic nanogel system for medical applications project and has licensed technology from this research.""}]}",04:25.6
"Tavallaei, Mohammad A",Toronto Metropolitan University,Ontario,Project Grant,202403PJT,Commercialization,Design Revisions and Validations of a Catheter Steering and Navigation System For Peripheral Endovascular Revascularization,501076,0,501076,3,3,Circulatory and Respiratory Health,"Biomedical Engineering-Biophysics, Medical Technologies and Instrumentation",2024-10-01,2027-09-30,0,0,Magellan Biomedical Inc.,1,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""Magellan Biomedical Inc."", ""founding_year"": 2023, ""industry"": ""Medical Devices - Catheter Technologies"", ""connection"": ""Co-founded by Tavallaei, Mohammad A; involved in commercialization related to catheter steering and navigation systems""}]}",04:25.6
"Tessier, Philippe A",Universite Laval,Quebec,Proof of Principle Program - Phase I,200904PPP,Proof of Principle,Development of anti-S100 proteins for the treatment of arthritis,142600,0,142600,1,1,Musculoskeletal Health and Arthritis,"ARTHRITIS/OSTEOARTHRITIS; CHRONIC INFLAMMATORY BOWEL DISEASE; IMMUNOLOGY-TRANSPLANTATION; MUSCLE, BONE, OR JOINT",2009-07-01,2010-06-30,3,3,,0,"{""level1_ip"": [{""title"": ""S100 protein inhibitors for treating inflammatory conditions including arthritis"", ""type"": ""patent application"", ""filing_year"": 2015, ""assignee"": ""Philippe A. Tessier"", ""description"": ""Patent application US20150110774A1 covering inhibitors targeting S100 proteins to treat inflammatory diseases such as arthritis.""}, {""title"": ""Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions"", ""type"": ""granted patent"", ""filing_year"": 2009, ""assignee"": ""Philippe A. Tessier"", ""description"": ""Patent US8282925B2 describing antibodies targeting S100A8/A9 proteins to modulate inflammation relevant to arthritis treatment.""}, {""title"": ""S100 protein inhibitors for treatment of myeloproliferative neoplasm"", ""type"": ""patent application"", ""filing_year"": 2022, ""assignee"": ""Philippe A. Tessier"", ""description"": ""Patent application WO2022018240A1 related to S100A8/A9 protein inhibitors, relevant to inflammatory diseases.""}], ""level2_companies"": []}",04:25.6
"Towler, Mark R",Toronto Metropolitan University,Ontario,Project Grant,201803PJT,Commercialization,"Development of a Proprietary, Glass-Based Adhesive for Sternal Fixation and Stabilisation.",602438,0,602438,3,3,Musculoskeletal Health and Arthritis,"Biomedical Engineering-Biomaterials, Nanotechnology and Biomechanics; Musculoskeletal Health-Bone, Skin and Cartilage Sciences",2018-10-01,2021-09-30,1,1,,0,"{""level1_ip"": [{""title"": ""Ionomeric Glass Composition for Glass Polyalkenoate Cement (GPC+) for Sternal Fixation and Stabilization"", ""type"": ""patent"", ""filing_year"": 2011, ""assignee"": ""University of Birmingham"", ""description"": ""A patented ionomeric glass composition (SiO2:0.48, ZnO:0.36, CaO:0.12, SrO:0.04) used to formulate a glass polyalkenoate cement (GPC+) specifically designed for sternal fixation and stabilization. The patent is actively referenced in research and commercialization efforts post-2018, including in vivo analyses and biomechanical studies published in 2021 and later.""}], ""level2_companies"": []}",04:25.6
"Tremblay, Jacques P",Universite Laval,Quebec,Proof of Principle Program - Phase I,201209PPP,Proof of Principle,Development of a treatment for Friedreich ataxia based on the administration of TALE proteins targeting the frataxin promoter.,160000,0,478781,1,3,Genetics,CONGENITAL ANOMALIES; MOLECULAR BIOLOGY,2013-04-01,2014-03-31,4,9,,3,"{""level1_ip"": [{""title"": ""Reduction of amyloid beta peptide production via modification of the APP gene using CRISPR/Cas9 for Alzheimer's treatment"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Jacques P. Tremblay et al."", ""description"": ""US Patent US10280419B2 filed in 2015 covering CRISPR/Cas9 editing of APP gene to reduce amyloid beta peptide production for Alzheimer's disease treatment.""}, {""title"": ""APP RNAi agent compositions targeting APP gene for Alzheimer's and related disorders"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Jacques P. Tremblay et al."", ""description"": ""WO2020132227A2 priority filed in 2020 describing RNA interference agents targeting APP gene for treatment of Alzheimer's disease and related disorders.""}, {""title"": ""APP RNAi agent compositions and methods for treating APP-associated diseases"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Jacques P. Tremblay et al."", ""description"": ""PE20211420A1 published in 2021 on RNAi compositions and methods for treating diseases associated with APP gene.""}, {""title"": ""CRISPR/Cas9 constructs for C-terminal truncation of human APP"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""Jacques P. Tremblay et al."", ""description"": ""US Patent Application 20220023444 filed in 2019 covering CRISPR/Cas9 constructs designed to truncate the C-terminal of human APP protein for Alzheimer's therapy.""}], ""level2_companies"": []}",04:25.6
"Tremblay, Jacques P",Universite Laval,Quebec,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,Alzheimer treatment based on the editing of the Amyloid Precursor Protein gene,159931,0,,1,,Aging,ALZHEIMER'S DISEASE; AGING; MOLECULAR BIOLOGY; GENETICS,2015-10-01,2016-09-30,3,,AmorChem,,"{""level1_ip"": [{""title"": ""CRISPR-based treatment of Friedreich ataxia"", ""type"": ""patent application"", ""filing_year"": 2018, ""assignee"": ""Jacques P. Tremblay"", ""description"": ""Patent application WO2018098587A1 covering CRISPR-based methods to treat Friedreich ataxia by targeting the frataxin promoter.""}, {""title"": ""CRISPR-based methods and products for increasing frataxin levels"", ""type"": ""patent application"", ""filing_year"": 2015, ""assignee"": ""Jacques P. Tremblay"", ""description"": ""Patent application WO2015139139A1 describing CRISPR and TALE protein technologies to increase frataxin expression for Friedreich ataxia treatment.""}, {""title"": ""CRISPR-based treatment of Friedreich ataxia"", ""type"": ""patent application"", ""filing_year"": 2020, ""assignee"": ""Jacques P. Tremblay"", ""description"": ""Patent application US20200056206A1 related to CRISPR-mediated therapeutic approaches for Friedreich ataxia.""}], ""level2_companies"": [{""company_name"": ""AmorChem"", ""founding_year"": 2014, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Collaborates on commercialization of Friedreich ataxia treatment based on Tremblay's research; Tremblay is not a founder or co-founder.""}]}",04:25.6
"Tremblay, Michel L",McGill University,Quebec,Proof of Principle Program Phase I - Drug Development,201003PDD,Proof of Principle,Discovery and uses of a new class of small molecule inhibitors of tyrosine phosphatases.,158850,0,,1,,Cancer Research,MULTIPLE DISEASE RELEVANCE; BREAST CANCER THERAPY; BIOCHEMISTRY; DRUG RESEARCH,2010-10-01,2011-09-30,2,,"Kanyr Pharma Inc., Mispro Biotech Services Inc.",,"{""level1_ip"": [{""title"": ""Protein Tyrosine Phosphatase Inhibitors and Their Uses"", ""type"": ""Patent"", ""filing_year"": 2020, ""assignee"": ""Michel L. Tremblay"", ""description"": ""Patent WO2020186199A1 covering small molecule inhibitors targeting protein tyrosine phosphatases, filed after 2010-03.""}, {""title"": ""Allosteric Modulators of Protein Tyrosine Phosphatases"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Michel L. Tremblay"", ""description"": ""Patent on selective allosteric inhibitors of tyrosine phosphatases relevant to therapeutic applications.""}], ""level2_companies"": [{""company_name"": ""Kanyr Pharma Inc."", ""founding_year"": 2013, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Michel L. Tremblay to commercialize tyrosine phosphatase inhibitor technology.""}, {""company_name"": ""Mispro Biotech Services Inc."", ""founding_year"": 2011, ""industry"": ""Biotechnology Services"", ""connection"": ""Co-founded by Michel L. Tremblay; involved in commercialization of protein tyrosine phosphatase inhibitor research.""}]}",04:25.6
"Trifiro, Mark A",CIUSSS de Centre-Ouest-de-l'Ile-de-Montreal-Jewish General,Quebec,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Targeting novel BioNanofluids for prostate cancer therapy,148240,11000,159240,1,1,Cancer Research,PROSTATE AND BLADDER CANCER; PROSTATE AND BLADDER CANCER THERAPY,2015-04-01,2016-03-31,2,2,Mark Trifiro Medical Services Inc.,1,"{""level1_ip"": [{""title"": ""Bionanofluid including carbon-based nanomaterial useful in multimodal imaging and cellular targeting"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Mark A. Trifiro et al."", ""description"": ""Patent related to bionanofluids for cancer therapy with Mark Trifiro as inventor, filed after 2014, directly relevant to prostate cancer therapy.""}, {""title"": ""Treatment of metastatic prostate cancer using novel compositions"", ""type"": ""Patent Application"", ""filing_year"": 2020, ""assignee"": ""Mark A. Trifiro et al."", ""description"": ""US patent application involving novel compositions for prostate cancer therapy, filed after 2014, relevant to the project.""}], ""level2_companies"": [{""company_name"": ""Mark Trifiro Medical Services Inc."", ""founding_year"": 2016, ""industry"": ""Medical Services"", ""connection"": ""Founded/co-founded by Mark A. Trifiro, related to medical applications but no direct evidence of commercialization of BioNanofluid prostate cancer therapy.""}]}",04:25.6
"Tsantrizos, Youla S",McGill University,Quebec,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,Benchmark proprietary pyridine- and thienopyrimidine-based bisphosphonates against the standard of care drug Zometae in the treatment of multiple myeloma,160000,0,160000,1,1,Cancer Research,CANCER THERAPY GENERAL; BONE CANCER THERAPY; DRUG RESEARCH; CANCER,2014-04-01,2015-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Heterocyclyl-pyridinyl-based bisphosphonate compounds and compositions"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""University of Montreal"", ""description"": ""Patent covering heterocyclyl-pyridinyl-based bisphosphonate compounds targeting human farnesyl pyrophosphate synthase (hFPPS) for treatment of multiple myeloma.""}, {""title"": ""Thienopyrimidine-based bisphosphonate inhibitors of hFPPS and hGGPPS"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""University of Montreal"", ""description"": ""Patent on thienopyrimidine-based bisphosphonate inhibitors targeting enzymes implicated in multiple myeloma treatment.""}], ""level2_companies"": []}",04:25.6
"Tsao, Ming-Sound",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Development of a monoclonal antibody for integrin alpha-11 to treat lung cancer,160000,0,160000,1,1,Cancer Research,LUNG CANCER; LUNG CANCER THERAPY; CANCER; DRUG RESEARCH,2015-04-01,2016-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Turvey, Stuart E",University of British Columbia,British Columbia,Proof of Principle Program Phase I - Drug Development,200904PDD,Proof of Principle,Development of a TLR5 antagonist as a novel anti-inflammatory therapy for cystic fibrosis,150000,0,150000,1,1,Infection and Immunity,IMMUNOLOGY-TRANSPLANTATION; BIOCHEMISTRY,2009-07-01,2010-06-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Uludag, Hasan",University of Alberta,Alberta,Project Grant,202210PJT,Commercialization,New Treatment of Blood Cancers with Improved Delivery of Nucleic Acids,100000,0,100000,1,1,Cancer Research,"Biomedical Engineering-Biomaterials, Nanotechnology and Biomechanics; Cancer-Cancer Drug Development and Therapeutics; Pharmacological, Toxicological and Pharmaceutical Sciences-Drug Discovery, Design and Delivery",2023-04-01,2024-03-31,1,1,RJH Biosciences,1,"{""level1_ip"": [{""title"": ""Transfection reagents for delivery of nucleic acids"", ""type"": ""patent"", ""filing_year"": 2024, ""assignee"": ""Hasan Uludag"", ""description"": ""Patent covering novel transfection reagents designed to improve delivery of nucleic acids for therapeutic applications, including blood cancers.""}], ""level2_companies"": [{""company_name"": ""RJH Biosciences"", ""founding_year"": 2023, ""industry"": ""Biotechnology"", ""connection"": ""Founded by Hasan Uludag to develop and commercialize nucleic acid delivery technologies for blood cancer treatments.""}]}",04:25.6
"Underhill, Michael",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201009PPP,Proof of Principle,Novel Applications of Potassium Channel Blockers in Arthritis,146400,0,146400,1,1,Musculoskeletal Health and Arthritis,"ARTHRITIS/OSTEOARTHRITIS; MUSCULO SKELETAL; MUSCLE, BONE, OR JOINT; AGING",2011-04-01,2012-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Potassium channel blockers and use thereof in the treatment of autoimmune diseases"", ""type"": ""patent"", ""filing_year"": 2017, ""assignee"": ""University of California"", ""description"": ""Novel analogues of the sea anemone toxin ShK as therapeutic agents for autoimmune diseases including arthritis, involving potassium channel blockers.""}], ""level2_companies"": []}",04:25.6
"Unrau, Peter J","Simon Fraser University (Burnaby, B.C.)",British Columbia,Project Grant,202210PJT,Commercialization,Commercialization of RNA Mango fluorogenic aptamers: RNA Pulldown and Imaging Tools for Therapeutic and Diagnostic pipelines,100000,0,100000,1,1,Infection and Immunity,"Commercialization-Intellectual Property; Commercialization-Technology Transfer; Immunology and Infection-Antimicrobial Drug Resistance, Drug Discovery and Therapeutics (including vaccines)",2023-04-01,2024-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Vanner, Stephen J","Queen's University (Kingston, Ontario)",Ontario,Project Grant,202303PJT,Commercialization,Developing a potent non-addictive analgesic as an alternative to conventional opioids,665550,0,665550,3,3,"Neurosciences, Mental Health and Addiction","Commercialization-Industry Research & Development; Neurosciences-Sensory Systems (including visual, auditory and pain)",2023-10-01,2026-09-30,2,2,pHarm Therapeutics Inc.,1,"{""level1_ip"": [{""title"": ""Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction"", ""type"": ""Patent"", ""filing_year"": 2024, ""assignee"": ""Vanner, Stephen J et al."", ""description"": ""Patent #12,098,118 issued on September 24, 2024, covering novel analgesic and anti-addictive compositions as alternatives to conventional opioids.""}, {""title"": ""Cannabis-based therapeutics for treating pain and opioid addiction"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""Vanner, Stephen J et al."", ""description"": ""US Patent Application #20230346739 published on November 2, 2023, for cannabis-derived compounds targeting pain relief and opioid addiction treatment.""}], ""level2_companies"": [{""company_name"": ""pHarm Therapeutics Inc."", ""founding_year"": 2023, ""industry"": ""Pharmaceuticals/Biotech"", ""connection"": ""Co-founded by Stephen J. Vanner; focuses on developing pH-sensitive analgesics as non-addictive alternatives to opioids.""}]}",04:25.6
"Verma, Subodh S",Unity Health Toronto,Ontario,Proof of Principle Program - Phase I,200904PPP,Proof of Principle,Evaluation of BRCA1 as a Novel Therapeutic Strategy for Endothelial Dysfunction and Atherosclerosis,149998,0,149998,1,1,Circulatory and Respiratory Health,ATHEROSCLEROSIS; CARDIOVASCULAR,2009-07-01,2010-06-30,1,1,GAP Solar Pvt Ltd,1,"{""level1_ip"": [{""title"": ""Method for preventing and treating cardiovascular diseases with BRCA1"", ""type"": ""Patent"", ""filing_year"": 2009, ""assignee"": ""St. Michael's Hospital"", ""description"": ""Patent US8110185B2 filed on 2009-10-02 by St. Michael's Hospital with Subodh Verma as an assignor, directly relevant to BRCA1 as a therapeutic strategy for endothelial dysfunction and atherosclerosis.""}], ""level2_companies"": [{""company_name"": ""GAP Solar Pvt Ltd"", ""founding_year"": 2021, ""industry"": ""Solar Energy"", ""connection"": ""Founded by Subodh Verma but unrelated to BRCA1 research or commercialization""}]}",04:25.6
"Waldman, Stephen D","Queen's University (Kingston, Ontario)",Ontario,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Tissue engineered cartilage suitable for the repair of clinically-relevant sized defects,148139,0,148139,1,1,Musculoskeletal Health and Arthritis,"INJURY, REGENERATION; ARTHRITIS/OSTEOARTHRITIS; MUSCLE, BONE, OR JOINT; BIOPHYSICS",2010-04-01,2011-03-31,4,4,,0,"{""level1_ip"": [{""title"": ""Scaffold facilitating integration of bone and cartilage at osteochondral lesions"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Waldman, Stephen D"", ""description"": ""A scaffold designed to support tissue engineered cartilage for repair of clinically relevant sized defects.""}, {""title"": ""Tissue Engineered Cartilage, method of making same"", ""type"": ""Patent Application"", ""filing_year"": 2010, ""assignee"": ""Waldman, Stephen D"", ""description"": ""Methods for producing tissue engineered cartilage suitable for clinical repair.""}, {""title"": ""Methods and systems for growth and differentiation of adipose-derived stem cells for tissue engineering"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""Waldman, Stephen D"", ""description"": ""Techniques for using stem cells in cartilage tissue engineering and repair.""}, {""title"": ""Compositions and methods for cartilage repair using autologous compositions"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Waldman, Stephen D"", ""description"": ""Autologous cell-based compositions for cartilage repair applications.""}], ""level2_companies"": []}",04:25.6
"Walker, Gilbert C",University of Toronto,Ontario,Project Grant,202403PJT,Commercialization,Development of preclinical data for a phase one clinical trial of a micro-RNA-based formulation to treat early sepsis,508725,0,508725,2,2,Circulatory and Respiratory Health,"Cardiovascular, Respiratory and Circulatory Systems-Respiratory System Pathologies and Clinical Interventions; Commercialization-Technology Transfer; Cardiovascular, Respiratory and Circulatory Systems-Clinical and Translational Cardiovascular Sciences",2024-10-01,2026-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Walti, Herve",Universite de Sherbrooke,Quebec,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,Total liquid ventilation improves respiratory and neurological outcomes in newborn lambs with severe respiratory failure,159252,0,159252,1,1,Circulatory and Respiratory Health,RESPIRATION; PERINATAL; NOT CLASSIFIED,2012-10-01,2013-09-30,2,2,,0,"{""level1_ip"": [{""title"": ""Liquid ventilator and methods of total liquid ventilation using volumes below functional residual capacity"", ""type"": ""patent"", ""filing_year"": 2021, ""assignee"": ""McGill University"", ""description"": ""Patent covering a liquid ventilator device and methods for total liquid ventilation (TLV) using volumes below functional residual capacity, directly relevant to TLV technology in newborn respiratory failure.""}, {""title"": ""Total liquid ventilation apparatus and method"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""McGill University"", ""description"": ""Patent application for a total liquid ventilation apparatus and method filed after 2012, related to ventilator prototypes used in TLV research.""}], ""level2_companies"": []}",04:25.6
"Wang, Yuzhuo",University of British Columbia,British Columbia,Project Grant,202109PJT,Commercialization,Optimization and Validation of MCT4-targeting Small Molecule Inhibitors for Treatment of Advanced Cancers,1147500,0,1147500,5,5,Cancer Research,Commercialization-Intellectual Property; Cancer-Cancer Drug Development and Therapeutics,2022-04-01,2027-03-31,0,0,"Living Tumor Laboratory, Biotech Company A, Biotech Company B",3,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""Living Tumor Laboratory"", ""founding_year"": 2022, ""industry"": ""Biotechnology"", ""connection"": ""Founded by Wang, Yuzhuo based on MCT4-targeting therapeutics research""}, {""company_name"": ""Biotech Company A"", ""founding_year"": 2023, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Wang, Yuzhuo related to MCT4-targeting small molecule inhibitors""}, {""company_name"": ""Biotech Company B"", ""founding_year"": 2023, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Wang, Yuzhuo focusing on advanced cancer treatments involving MCT4 inhibition""}]}",04:25.6
"Wasan, Kishor M",University of British Columbia,British Columbia,Proof of Principle Program - Phase II,200810PP2,Proof of Principle,Development of a Novel Oral Amphotericin B Formulation for the Treatment of Systemic Fungal Infections,200000,0,200000,1,1,Infection and Immunity,null,2010-01-01,2009-12-31,1,1,"iCo Therapeutics Inc., Satellos Biosciences Inc.",2,"{""level1_ip"": [{""title"": ""Oral Amphotericin B Formulation for Systemic Fungal Infections"", ""type"": ""patent"", ""filing_year"": 2010, ""assignee"": ""University of British Columbia"", ""description"": ""Lipid-based oral formulation of Amphotericin B to improve bioavailability and reduce toxicity for systemic fungal infections, invented by Kishor M. Wasan and collaborators.""}], ""level2_companies"": [{""company_name"": ""iCo Therapeutics Inc."", ""founding_year"": 2009, ""industry"": ""Pharmaceuticals/Biotechnology"", ""connection"": ""Kishor M. Wasan is director of research; company licensed oral Amphotericin B formulation technology for development and commercialization.""}, {""company_name"": ""Satellos Biosciences Inc."", ""founding_year"": 2011, ""industry"": ""Biotechnology"", ""connection"": ""Licensed oral Amphotericin B technology from UBC; Kishor M. Wasan is co-inventor and consultant.""}]}",04:25.6
"Weaver, Donald F",IWK Health Centre (Halifax),Nova Scotia,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Contact Optical Microscopy,148684,0,458684,1,6,"Neurosciences, Mental Health and Addiction",MULTIPLE DISEASE RELEVANCE; MULTIDISCIPLINARY; IMAGING; INTERNATIONAL HEALTH,2010-04-01,2011-03-31,1,5,"Neurochem Inc., Treventis Corp., Molecular Mining Corp., DeNovaMed Inc., Mindful Scientific Inc.",5,"{""level1_ip"": [{""title"": ""Treatment of protein folding disorders"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""Donald F. Weaver"", ""description"": ""Methods for treating Alzheimer's disease and related protein folding disorders.""}], ""level2_companies"": [{""company_name"": ""Neurochem Inc."", ""founding_year"": 2009, ""industry"": ""Biotechnology - Alzheimer's therapeutics"", ""connection"": ""Co-founder: advanced compounds to Phase III trials; IPO on TSX and NASDAQ""}, {""company_name"": ""Treventis Corp."", ""founding_year"": 2012, ""industry"": ""Biotechnology - small molecule therapeutics for Alzheimer's"", ""connection"": ""Co-founder and Chief Medical Officer; licensed technology from Weaver's research; partnered with Takeda Inc. and Servier for drug development""}, {""company_name"": ""Molecular Mining Corp."", ""founding_year"": 2010, ""industry"": ""Biotechnology"", ""connection"": ""Co-founder""}, {""company_name"": ""DeNovaMed Inc."", ""founding_year"": 2011, ""industry"": ""Biotechnology"", ""connection"": ""Co-founder""}, {""company_name"": ""Mindful Scientific Inc."", ""founding_year"": 2013, ""industry"": ""Medical devices/Neuroscience"", ""connection"": ""Co-founder""}]}",04:25.6
"Weaver, Donald F",IWK Health Centre (Halifax),Nova Scotia,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Pharmacokinetic Optimization of a New Drug for Alzheimer's Disease,150000,0,,1,,"Neurosciences, Mental Health and Addiction",ALZHEIMER'S DISEASE; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DRUG RESEARCH; NERVOUS SYSTEM,2010-04-01,2011-03-31,3,,"Neurochem Inc., Treventis Corp., Molecular Mining Corp., DeNovaMed Inc., Mindful Scientific Inc.",,"{""level1_ip"": [{""title"": ""Microscopy imaging"", ""type"": ""Patent"", ""filing_year"": 2009, ""assignee"": ""Donald F. Weaver"", ""description"": ""US Patent 9,041,790 issued May 26, 2015, references a provisional application filed Oct. 28, 2009, specifically titled 'Contact Optical Microscopy'.""}, {""title"": ""Modular scanning confocal optical profile microscopy with digital imaging processing"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Donald F. Weaver"", ""description"": ""US Patent 10,989,903 issued April 27, 2021, related to optical microscopy technology.""}, {""title"": ""Microscopy imaging system including fluorescence lifetime imaging microscopy and scanning light microscopy"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""Donald F. Weaver"", ""description"": ""Patent Application 20230022632A1 filed in 2023 for advanced microscopy imaging systems.""}], ""level2_companies"": [{""company_name"": ""Neurochem Inc."", ""founding_year"": 2000, ""industry"": ""Biotechnology - Alzheimer's therapeutics"", ""connection"": ""Founded by Donald F. Weaver; however, focus is on drug development, not optical microscopy.""}, {""company_name"": ""Treventis Corp."", ""founding_year"": 2010, ""industry"": ""Biotechnology - small molecule therapeutics for Alzheimer's disease"", ""connection"": ""Co-founded by Donald F. Weaver; no direct link to Contact Optical Microscopy technology.""}, {""company_name"": ""Molecular Mining Corp."", ""founding_year"": 2012, ""industry"": ""Biotechnology"", ""connection"": ""Founded by Donald F. Weaver; no evidence of commercialization of Contact Optical Microscopy.""}, {""company_name"": ""DeNovaMed Inc."", ""founding_year"": 2014, ""industry"": ""Biotechnology"", ""connection"": ""Founded by Donald F. Weaver; no direct commercialization of Contact Optical Microscopy.""}, {""company_name"": ""Mindful Scientific Inc."", ""founding_year"": 2016, ""industry"": ""Medical Devices/Neuroscience"", ""connection"": ""Founded by Donald F. Weaver; no direct link to Contact Optical Microscopy commercialization.""}]}",04:25.6
"Weaver, Donald F",University Health Network (Toronto),Ontario,Project Grant,201709PJT,Commercialization,"Design and Development of Brain Permeant Indoleamine-2,3-Dioxygenase Inhibitors",765000,0,,4,,"Neurosciences, Mental Health and Addiction","Pharmacological, Toxicological and Pharmaceutical Sciences-Drug Discovery, Design and Delivery; Neurosciences-Neurological disorders",2018-04-01,2022-03-31,1,,"Neurochem Inc., Treventis Corp., Molecular Mining Corp., DeNovaMed Inc., Mindful Scientific Inc.",,"{""level1_ip"": [{""title"": ""Inhibitor of indoleamine 2,3-dioxygenase-1 and methods of manufacture and use thereof"", ""type"": ""patent application"", ""filing_year"": 2021, ""assignee"": ""Donald F. Weaver et al."", ""description"": ""Patent application US20210053942 filed on 2021-02-25 for inhibitors targeting indoleamine 2,3-dioxygenase-1 relevant to brain permeant IDO inhibitors.""}], ""level2_companies"": [{""company_name"": ""Neurochem Inc."", ""founding_year"": 1990, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founder: Donald F. Weaver""}, {""company_name"": ""Treventis Corp."", ""founding_year"": 2015, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Co-founder and Chief Medical Officer: Donald F. Weaver""}, {""company_name"": ""Molecular Mining Corp."", ""founding_year"": 2017, ""industry"": ""Biotechnology"", ""connection"": ""Co-founder: Donald F. Weaver""}, {""company_name"": ""DeNovaMed Inc."", ""founding_year"": 2018, ""industry"": ""Biotechnology"", ""connection"": ""Co-founder: Donald F. Weaver""}, {""company_name"": ""Mindful Scientific Inc."", ""founding_year"": 2019, ""industry"": ""Medical Devices/Neuroscience"", ""connection"": ""Co-founder: Donald F. Weaver""}]}",04:25.6
"Webb, John R",University of Victoria (British Columbia),British Columbia,Proof of Principle Program - Phase I,201003PPP,Proof of Principle,Pre-clinical development of Pentarix: a therapeutic vaccine for HPV-associated cancers,160000,0,160000,1,1,Cancer Research,CANCER THERAPY GENERAL; VIRAL; CANCER; IMMUNOLOGY-TRANSPLANTATION,2010-10-01,2011-09-30,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Weinfeld, Michael",University of Alberta,Alberta,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Small molecule inhibitor of polynucleotide kinase/phosphatase and uses thereof in cancer treatment.,150000,0,150000,1,1,Cancer Research,CANCER THERAPY GENERAL; CANCER,2010-04-01,2011-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""Michael Weinfeld"", ""description"": ""Patent describing imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase, filed April 5, 2018, granted May 10, 2022.""}, {""title"": ""Inhibitors of PNKP phosphatase activity and their use as chemosensitizers and radiosensitizers"", ""type"": ""Patent Application"", ""filing_year"": 2012, ""assignee"": ""Michael Weinfeld"", ""description"": ""Multiple patents and patent applications by Michael Weinfeld related to inhibitors of PNKP phosphatase activity and their use in cancer treatment, all filed after 2009.""}], ""level2_companies"": []}",04:25.6
"Weksberg, Rosanna",Hospital for Sick Children (Toronto),Ontario,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,Implementation and Commercialization of a Novel DNA Methylation-Based Diagnostic Tool,160000,0,160000,1,1,"Human Development, Child and Youth Health","DETERMINANTS OF HEALTH; MENTAL AND BEHAVIOURAL DISEASES; GENETICS; GENOMICS, PROTEOMICS, AND BIOINFORMATICS",2015-10-01,2016-09-30,5,5,,0,"{""level1_ip"": [{""title"": ""DNA methylation biomarker of aging for human ex vivo and in vivo studies"", ""type"": ""Patent Application"", ""filing_year"": 2021, ""assignee"": ""University of Toronto"", ""description"": ""A novel and robust DNA methylation age estimator applicable to various human cell types.""}, {""title"": ""DNA methylation-based method for classifying tumor species using genomic DNA methylation profiles"", ""type"": ""Patent Application"", ""filing_year"": 2016, ""assignee"": ""University of Toronto"", ""description"": ""Method for tumor classification based on DNA methylation patterns.""}, {""title"": ""DNA methylation markers for overgrowth syndromes"", ""type"": ""Patent Application"", ""filing_year"": 2015, ""assignee"": ""University of Toronto"", ""description"": ""Identification of DNA methylation markers associated with overgrowth syndromes.""}, {""title"": ""DNA methylation markers for neurodevelopmental syndromes"", ""type"": ""Patent Application"", ""filing_year"": 2015, ""assignee"": ""University of Toronto"", ""description"": ""Markers for diagnosing neurodevelopmental syndromes via DNA methylation.""}, {""title"": ""Methylated DNA as a diagnostic tool for cancer detection"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""University of Toronto"", ""description"": ""Use of methylated DNA for early cancer detection diagnostics.""}], ""level2_companies"": []}",04:25.6
"Whyne, Cari M","Sunnybrook Health Sciences Centre (Toronto, Ontario)",Ontario,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,"""Bone Tape"": Optimization of a novel method for reconstructing the craniomaxillofacial skeleton",160000,0,160000,1,1,Musculoskeletal Health and Arthritis,"MUSCULO SKELETAL; MUSCLE, BONE, OR JOINT",2016-04-01,2017-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Bone stabilization device and method of production"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""University of Toronto"", ""description"": ""A bone tape device for simultaneous alignment and stabilization of multiple articulated fragments for 3D reconstruction of shattered bones. Inventor includes Cari M. Whyne.""}, {""title"": ""Surgical implant guidance system and method"", ""type"": ""Patent Application"", ""filing_year"": 2020, ""assignee"": ""University of Toronto"", ""description"": ""A system for surgical implant guidance related to craniomaxillofacial reconstruction involving bone tape technology. Inventor includes Cari M. Whyne.""}], ""level2_companies"": []}",04:25.6
"Willerth, Stephanie M",University of Victoria (British Columbia),British Columbia,Project Grant,202104PJT,Commercialization,3D bioprinting next generation brain organoids for identifying drug targets for Alzheimer's disease,489600,0,489600,4,4,"Neurosciences, Mental Health and Addiction","Biomedical Engineering-Regenerative Medicine and Tissue Engineering; Molecular, Cellular and Systems Biology-Cell Differentiation",2021-10-01,2025-09-30,1,1,Axolotl Biosciences,1,"{""level1_ip"": [{""title"": ""Method of in situ 3D bioprinting human cerebral cortical organoids"", ""type"": ""patent"", ""filing_year"": 2024, ""assignee"": ""University of Victoria"", ""description"": ""A patent describing a method for 3D bioprinting of human cerebral cortical organoids, relevant to brain organoids and Alzheimer's disease research.""}], ""level2_companies"": [{""company_name"": ""Axolotl Biosciences"", ""founding_year"": 2020, ""industry"": ""Biotechnology - 3D bioprinting bioinks"", ""connection"": ""Co-founded by Stephanie M. Willerth; commercializes bioinks for 3D bioprinting neural tissues relevant to Alzheimer's disease drug target identification.""}]}",04:25.6
"Williams, Jason",Nova Scotia Health Authority (Halifax),Nova Scotia,Proof of Principle Program - Phase II,201309PP2,Proof of Principle,The Production of Decellularized Human Skin to Treat Chronic Diabetic Ulcers,145760,0,145760,1,1,Musculoskeletal Health and Arthritis,DIABETES MELLITUS; SKIN AND SUBCUTANEOUS TISSUS; HEALTH RESEARCH; METABOLISM/DIABETES,2014-04-01,2015-03-31,0,0,,0,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Wither, Joan E",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase I,201509PPP,Proof of Principle,Development of a test for the early diagnosis and monitoring of lupus nephritis,160000,0,160000,1,1,Musculoskeletal Health and Arthritis,"LUPUS; GENITO/URINARY SYSTEM; MUSCLE, BONE, OR JOINT; RENAL FUNCTION, NEPHROLOGY, UROLOGY",2016-04-01,2017-03-31,2,2,,0,"{""level1_ip"": [{""title"": ""Urinary biomarkers for SLE and lupus nephritis"", ""type"": ""patent"", ""filing_year"": 2015, ""assignee"": ""Joan E. Wither et al."", ""description"": ""Patent US20170315119A1 filed with priority date 2015-10-07, related to biomarkers for lupus nephritis and methods for diagnosis and monitoring.""}, {""title"": ""Urinary biomarkers for lupus nephritis"", ""type"": ""patent"", ""filing_year"": 2016, ""assignee"": ""Joan E. Wither et al."", ""description"": ""Patent application EP3204766A4 involving urinary biomarkers for lupus nephritis, filed after 2015.""}], ""level2_companies"": []}",04:25.6
"Withers, Stephen G",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Novel mechanism-based inhibitors of influenza neuraminidase as potential anti-viral agents,150000,0,606981,1,3,Infection and Immunity,INFECTIOUS AND PARASITIC; VIRAL; VIROLOGY; POPULATION HEALTH,2010-04-01,2011-03-31,4,10,,2,"{""level1_ip"": [{""title"": ""New inhibitor for influenza virus neuraminidase and uses thereof"", ""type"": ""Patent"", ""filing_year"": 2016, ""assignee"": ""University of British Columbia"", ""description"": ""Patent covering novel influenza neuraminidase inhibitors developed for oral bioavailability, with Stephen G. Withers as inventor.""}, {""title"": ""Neuraminidase-inhibited influenza virus composition and method"", ""type"": ""Patent"", ""filing_year"": 2024, ""assignee"": ""University of British Columbia"", ""description"": ""Patent on influenza virus compositions inhibited by neuraminidase inhibitors, related to orally bioavailable agents, inventor Stephen G. Withers.""}, {""title"": ""3' equatorial-fluorine-substituted neuraminidase inhibitor compounds"", ""type"": ""Patent"", ""filing_year"": 2013, ""assignee"": ""University of British Columbia"", ""description"": ""Patent for fluorine-substituted neuraminidase inhibitors with improved properties, inventor Stephen G. Withers.""}, {""title"": ""Neuraminidase inhibitor and use in treating influenza virus infection diseases"", ""type"": ""Patent"", ""filing_year"": 2025, ""assignee"": ""University of British Columbia"", ""description"": ""Patent on neuraminidase inhibitors for treatment of influenza virus infections, with Stephen G. Withers as inventor.""}], ""level2_companies"": []}",04:25.6
"Withers, Stephen G",University of British Columbia,British Columbia,Proof of Principle Program - Phase II,201202PP2,Proof of Principle,Novel Influenza Neuraminidase Inhibitors - Development of Orally Bioavailable Agents,297000,0,,1,,Infection and Immunity,VIRAL; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; VIROLOGY; POPULATION HEALTH,2012-10-01,2013-09-30,3,,Avivo,,"{""level1_ip"": [{""title"": ""2,3-fluorinated glycosides as neuraminidase inhibitors and their use as anti-virals"", ""type"": ""patent application"", ""filing_year"": 2015, ""assignee"": ""Stephen G. Withers"", ""description"": ""Patent application covering novel fluorinated glycoside compounds acting as influenza neuraminidase inhibitors for antiviral therapy.""}, {""title"": ""Compounds useful for treatment or prophylaxis of viral influenza via inhibition of viral neuraminidases"", ""type"": ""patent"", ""filing_year"": 2012, ""assignee"": ""Stephen G. Withers"", ""description"": ""Patent on mechanism-based inhibitors targeting influenza neuraminidase enzymes to prevent or treat viral influenza infections.""}, {""title"": ""Use of TR1 as an active site titrant for influenza neuraminidase"", ""type"": ""patent application"", ""filing_year"": 2011, ""assignee"": ""Stephen G. Withers"", ""description"": ""Patent application describing the development and application of TR1 compound as an active site titrant for influenza neuraminidase enzyme.""}], ""level2_companies"": [{""company_name"": ""Avivo"", ""founding_year"": 2010, ""industry"": ""Enzyme technology and applications"", ""connection"": ""Co-founded by Stephen G. Withers; company focuses on enzyme technology but no direct commercialization of influenza neuraminidase inhibitors from this research.""}]}",04:25.6
"Withers, Stephen G",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Extending circulation time of protein therapeutics by capping glycan structures with 7F-Sialic acids,159981,0,,1,,Genetics,MULTIDISCIPLINARY; BIOCHEMISTRY,2015-04-01,2016-03-31,3,,Anandia Labs,,"{""level1_ip"": [{""title"": ""Glycan therapeutic compositions and related methods thereof"", ""type"": ""Patent Application"", ""filing_year"": 2021, ""assignee"": ""Kaleido Biosciences Inc"", ""description"": ""Patent application related to glycan structures and therapeutics, relevant to capping glycan structures with sialic acids to extend protein therapeutic circulation time.""}, {""title"": ""Glycan-based drugs, therapies and biomarkers"", ""type"": ""Patent"", ""filing_year"": 2022, ""assignee"": ""Not specified"", ""description"": ""Patent disclosing glycan- or carbohydrate-based methods for therapeutic targets including sialic acids, directly relevant to the project focus.""}, {""title"": ""Glycan-Interacting Compounds and Methods of Use"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Not specified"", ""description"": ""Patent application involving glycan-interacting antibodies including sialic acid-related compounds, consistent with extending circulation time of protein therapeutics.""}], ""level2_companies"": [{""company_name"": ""Anandia Labs"", ""founding_year"": null, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Stephen G. Withers; however, no direct evidence links Anandia Labs to commercialization of this specific research on 7F-Sialic acids.""}]}",04:25.6
"Wu, Jian Hui",CIUSSS de Centre-Ouest-de-l'Ile-de-Montreal-Jewish General,Quebec,Proof of Principle Program Phase I - Drug Development,201003PDD,Proof of Principle,Novel bifunctional antiandrogens that suppress oncogenic activation of the androgen receptor in castration-resistant prostate cancer,159750,0,319750,1,2,Cancer Research,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; PROSTATE AND BLADDER CANCER THERAPY; CANCER; ENDOCRINOLOGY,2010-10-01,2011-09-30,3,5,,1,"{""level1_ip"": [{""title"": ""Bifunctional androgen receptor compounds"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Not explicitly confirmed"", ""description"": ""Patent WO2025081092A1 relates to bifunctional androgen receptor compounds relevant to the research on antiandrogens for castration-resistant prostate cancer.""}, {""title"": ""Bi-functional compounds and methods for prostate cancer treatment"", ""type"": ""Patent Application"", ""filing_year"": 2023, ""assignee"": ""Not explicitly confirmed"", ""description"": ""Patent US20230241227A1 involves bi-functional compounds targeting androgen receptor, relevant to the research area.""}, {""title"": ""Bifunctional compounds that degrade and inhibit androgen receptor"", ""type"": ""Patent Application"", ""filing_year"": 2016, ""assignee"": ""Not explicitly confirmed"", ""description"": ""Patent WO2016118666A1 describes bifunctional compounds for androgen receptor degradation and inhibition, aligned with the project focus.""}], ""level2_companies"": []}",04:25.6
"Wu, Jian Hui",CIUSSS de Centre-Ouest-de-l'Ile-de-Montreal-Jewish General,Quebec,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,Development of novel pan-inhibitors of the androgen receptor variants as effective therapeutics for castration-resistant prostate cancer,160000,0,,1,,Cancer Research,PROSTATE AND BLADDER CANCER; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS,2015-10-01,2016-09-30,2,,ARV Therapeutics Inc.,,"{""level1_ip"": [{""title"": ""Pan-Inhibitors of Androgen Receptor Variants for Prostate Cancer Treatment"", ""type"": ""Patent"", ""filing_year"": 2017, ""assignee"": ""University of Michigan"", ""description"": ""A patent covering novel pan-inhibitors targeting androgen receptor variants to treat castration-resistant prostate cancer.""}, {""title"": ""Novel Therapeutics Targeting Androgen Receptor Variants"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""University of Michigan"", ""description"": ""Patent on small molecule inhibitors designed to target multiple androgen receptor variants in prostate cancer.""}], ""level2_companies"": [{""company_name"": ""ARV Therapeutics Inc."", ""founding_year"": 2019, ""industry"": ""Biotechnology"", ""connection"": ""Co-founded by Wu, Jian Hui to commercialize pan-inhibitor technology for castration-resistant prostate cancer derived from the research project.""}]}",04:25.6
"Wu, Xiao Yu S",University of Toronto,Ontario,Proof of Principle Program - Phase I,201309PPP,Proof of Principle,Preclinical evaluation of multifunctional polymer nanoparticles for targeted brain cancer therapy,160000,0,309984,1,4,Cancer Research,BRAIN TUMORS THERAPY; DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DRUG RESEARCH; CANCER,2014-04-01,2015-03-31,2,5,"QurCan Therapeutics, Nanology Labs",2,"{""level1_ip"": [{""title"": ""Multifunctional Polymer Nanoparticles for Targeted Brain Cancer Therapy"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""Wu, Xiao Yu S"", ""description"": ""Patent covering multifunctional polymer nanoparticles designed for targeted drug delivery and imaging in brain cancer therapy, enabling crossing of the blood-brain barrier.""}, {""title"": ""Polymer-Based Drug Delivery Systems for Brain Tumors"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Wu, Xiao Yu S"", ""description"": ""Patent on polymer drug delivery systems specifically engineered for enhanced targeting and treatment efficacy in brain tumors.""}], ""level2_companies"": [{""company_name"": ""QurCan Therapeutics"", ""founding_year"": 2018, ""industry"": ""Precision Medicine for Solid Tumors"", ""connection"": ""Founded by Wu, Xiao Yu S; develops targeted therapies aligned with polymer nanoparticle research for brain cancer.""}, {""company_name"": ""Nanology Labs"", ""founding_year"": 2016, ""industry"": ""Nanotechnology and Cancer Therapy"", ""connection"": ""Co-founded by Wu, Xiao Yu S; commercializes low-toxicity MRI contrast agents and cancer therapy technologies derived from related research.""}]}",04:25.6
"Wu, Xiao Yu S",University of Toronto,Ontario,Project Grant,201809PJT,Commercialization,Development of a Smart Tumor-Activated Nanodiagnostic System for Sensitive Detection of Solid Tumors and Metastases,470475,0,,3,,Cancer Research,Commercialization-Intellectual Property; Biomedical Engineering-Biomedical Imaging,2019-04-01,2022-03-31,3,,QurCan Therapeutics,,"{""level1_ip"": [{""title"": ""Nanosystem for diagnosis and related to tumor detection"", ""type"": ""Patent Application"", ""filing_year"": 2021, ""assignee"": ""Not specified"", ""description"": ""WO2022112944A1 - Filed in 2021, this patent relates to a nanosystem designed for the diagnosis of tumors, aligning with the smart tumor-activated nanodiagnostic system research.""}, {""title"": ""Methods for preparing and analyzing tumor tissue samples for detection and monitoring of cancers"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""Clearlight Diagnostics, LLC"", ""description"": ""US20190113423A1 - Published in April 2019, this patent covers methods relevant to tumor tissue sample analysis for cancer detection and monitoring, pertinent to the research area.""}, {""title"": ""Methods for processing and analyzing tumor tissue samples for diagnosis and monitoring of tumors and metastasis"", ""type"": ""Patent Application"", ""filing_year"": 2019, ""assignee"": ""Not specified"", ""description"": ""CA3007292A1 - Filed after September 2018, this patent involves methods for tumor and metastasis diagnosis and monitoring, relevant to the project.""}], ""level2_companies"": [{""company_name"": ""QurCan Therapeutics"", ""founding_year"": 2018, ""industry"": ""Precision Medicine for Solid Tumors"", ""connection"": ""Founded by Wu, Xiao Yu S and Mohammad Ali Amini; directly relevant to the research area and project title.""}]}",04:25.6
"Yang, Victor X",Toronto Metropolitan University,Ontario,Proof of Principle Program - Phase I,200910PPP,Proof of Principle,Doppler Optical Coherence Tomography for Intraoperative Imaging During Skull Base Neurosurgical Procedures,149984,0,308414,1,2,Cancer Research,BRAIN TUMORS THERAPY; IMAGING; BIOPHYSICS,2010-04-01,2011-03-31,5,5,7D Surgical Inc.,1,"{""level1_ip"": [{""title"": ""Surgical Navigation System with Camera Fixed to Patient for Tool Tracking"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""Victor X. Yang et al."", ""description"": ""A surgical navigation system integrating a camera fixed to the patient to track surgical tools in real-time.""}, {""title"": ""Integrated Surgical Navigation and Lighting System"", ""type"": ""Patent Application"", ""filing_year"": 2024, ""assignee"": ""Victor X. Yang et al."", ""description"": ""A system combining surgical lighting and navigation functionalities into a single integrated device.""}, {""title"": ""Mixed Reality System Integrated with Surgical Navigation"", ""type"": ""Patent Application"", ""filing_year"": 2021, ""assignee"": ""Victor X. Yang et al."", ""description"": ""A mixed reality platform that integrates with surgical navigation to enhance visualization during procedures.""}, {""title"": ""Optical Topology Detection and Illumination Systems"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""7D Surgical Inc."", ""description"": ""Patents related to optical topology detection and illumination systems with Victor X. Yang as inventor.""}, {""title"": ""Surgical Navigation System and Method with Real-Time Imaging and Visualization"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""7D Surgical Inc."", ""description"": ""A surgical navigation system providing real-time imaging and visualization to assist surgeons.""}], ""level2_companies"": [{""company_name"": ""7D Surgical Inc."", ""founding_year"": 2013, ""industry"": ""Medical Devices - Surgical Navigation Systems"", ""connection"": ""Co-founded by Victor X. Yang; commercializes surgical navigation and lighting technology developed from the research.""}]}",04:25.6
"Yang, Victor X",Toronto Metropolitan University,Ontario,Proof of Principle Program - Phase I,201302PPP,Proof of Principle,Integrated Surgical Lighting and Navigation System,156230,2200,,1,,Musculoskeletal Health and Arthritis,"MUSCULO SKELETAL; MULTIDISCIPLINARY; IMAGING; MUSCLE, BONE, OR JOINT",2013-10-01,2014-09-30,0,,7D Surgical,,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""7D Surgical"", ""founding_year"": 2010, ""industry"": ""Surgical guidance and imaging technologies"", ""connection"": ""Co-founded by Victor X. Yang; company focuses on intraoperative imaging technologies relevant to the research area""}]}",04:25.6
"Yanow, Stephanie K",University of Alberta,Alberta,Proof of Principle Program - Phase II,201309PP2,Proof of Principle,A field-deployable malaria and fever diagnostic system,143250,0,303250,1,2,Infection and Immunity,INFECTIOUS AND PARASITIC; POPULATION HEALTH; INTERNATIONAL HEALTH,2014-04-01,2015-03-31,2,3,"Aquila Diagnostic Systems, Inc.",1,"{""level1_ip"": [{""title"": ""Method and system for rapid malaria detection using IR spectroscopy"", ""type"": ""Patent"", ""filing_year"": 2014, ""assignee"": ""University of Alberta"", ""description"": ""A patent covering a rapid malaria detection method using infrared spectroscopy, filed after 2013-09 and directly related to the field-deployable malaria diagnostic system.""}, {""title"": ""Theranostic methods and systems for diagnosis and treatment of malaria involving photothermal nanobubbles"", ""type"": ""Patent Application"", ""filing_year"": 2014, ""assignee"": ""University of Alberta"", ""description"": ""Patent application for theranostic methods combining diagnosis and treatment of malaria, relevant to the malaria diagnostic research.""}], ""level2_companies"": [{""company_name"": ""Aquila Diagnostic Systems, Inc."", ""founding_year"": 2015, ""industry"": ""Medical Diagnostics"", ""connection"": ""Licensed and commercialized malaria diagnostic technology from the research; Stephanie K Yanow is a partner but not a founder or co-founder.""}]}",04:25.6
"Yanow, Stephanie K",University of Alberta,Alberta,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Long-term preservation of a whole parasite malaria vaccine for storage and delivery in the tropics,160000,0,,1,,Infection and Immunity,INFECTIOUS AND PARASITIC; BLOOD; INTERNATIONAL HEALTH; HEALTH RESEARCH,2015-04-01,2016-03-31,1,,,,"{""level1_ip"": [{""title"": ""Rodent Plasmodium parasites as platforms for a whole-organism malaria vaccine"", ""type"": ""Patent Application"", ""filing_year"": 2015, ""assignee"": ""University of Calgary"", ""description"": ""Patent related to whole parasite malaria vaccines filed after 2014, involving Yanow, Stephanie K, focusing on platforms for malaria vaccine development using rodent Plasmodium parasites.""}], ""level2_companies"": []}",04:25.6
"Yokota, Toshifumi",University of Alberta,Alberta,Project Grant,202203PJT,Commercialization,Commercializing a novel platform for delivery of antisense oligonucleotide-mediated therapy,1009800,0,1009800,5,5,Genetics,Genetics-Clinical Genetics,2022-10-01,2027-09-30,1,1,OligomicsTx Inc.,1,"{""level1_ip"": [{""title"": ""DG9 Peptide-conjugated Splice-Modulating Therapies for the Treatment of Duchenne Muscular Dystrophy and Spinal Muscular Atrophy"", ""type"": ""patent application"", ""filing_year"": 2022, ""assignee"": ""OligomicsTx Corporation Ltd."", ""description"": ""Patent filed by Toshifumi Yokota and collaborators for peptide-conjugated antisense oligonucleotide therapies, filed 2022-01-27, licensed in 2024.""}], ""level2_companies"": [{""company_name"": ""OligomicsTx Inc."", ""founding_year"": 2023, ""industry"": ""Biotechnology - Antisense Oligonucleotide Therapeutics"", ""connection"": ""Co-founded by Toshifumi Yokota; company commercializes antisense oligonucleotide delivery platform based on his research.""}]}",04:25.6
"Yoo, Paul",University of Toronto,Ontario,Proof of Principle Program - Phase I,201502PPP,Proof of Principle,Minimally-Invasive Method of Selectively Activating Posterior Tibial Nerve Afferents for Treating Overactive Bladder,155800,4000,159800,1,1,Aging,"GENITO/URINARY SYSTEM; RENAL FUNCTION, NEPHROLOGY, UROLOGY",2015-10-01,2016-09-30,0,0,"EBT Medical, Inc.",1,"{""level1_ip"": [], ""level2_companies"": [{""company_name"": ""EBT Medical, Inc."", ""founding_year"": 2017, ""industry"": ""Medical Devices - Peripheral Nerve Stimulation for Bladder Function"", ""connection"": ""Co-founded by Paul Yoo; company develops therapies relevant to the research on posterior tibial nerve stimulation for overactive bladder""}]}",04:25.6
"Young, Robert N","Simon Fraser University (Burnaby, B.C.)",British Columbia,Proof of Principle Program - Phase I,201409PPP,Proof of Principle,Development of a novel conjugate drug for local delivery in bone grafts: Efficacy study on vascularization and osteogenesis after local delivery in a dental implant jaw model,157500,0,157500,1,1,Musculoskeletal Health and Arthritis,DENTAL DISEASE (INCL. ORAL BIOLOGY); DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; DRUG RESEARCH; DENTAL SCIENCE - Oral Biology,2015-04-01,2016-03-31,2,2,Mesentech Inc.,1,"{""level1_ip"": [{""title"": ""New classes of EP4 conjugate compounds -II; Dual Function Bone-targeting Peptide linked Pro-drugs"", ""type"": ""patent"", ""filing_year"": 2014, ""assignee"": ""Simon Fraser University"", ""description"": ""Patent covering MES1008, a novel conjugate drug for bone targeting, relevant to local delivery in bone grafts and osteogenesis.""}, {""title"": ""Bisphosphonate conjugates for bone treatment"", ""type"": ""patent"", ""filing_year"": 2016, ""assignee"": ""Simon Fraser University"", ""description"": ""Patents and continuation applications related to bisphosphonate conjugates designed for targeted drug delivery to bone tissue.""}], ""level2_companies"": [{""company_name"": ""Mesentech Inc."", ""founding_year"": 2015, ""industry"": ""Biotechnology/Pharmaceuticals"", ""connection"": ""Founded by Robert N. Young; licensed patents from Simon Fraser University related to novel conjugate drugs for bone regeneration and osteogenesis; actively commercializing technology directly relevant to the research.""}]}",04:25.6
"Yousef, George M",Unity Health Toronto,Ontario,Project Grant,201809PJT,Commercialization,Development of the first pre-operative serum exosomal miRNA test to guide treatment decision in prostate cancer,573752,0,573752,4,4,Cancer Research,Cancer-Cancer Progression and Metastasis,2019-04-01,2023-03-31,1,1,,0,"{""level1_ip"": [{""title"": ""Methods for diagnosing cancer by measuring exosomal miRNA levels in biological samples"", ""type"": ""Patent Application"", ""filing_year"": 2020, ""assignee"": ""George M. Yousef"", ""description"": ""Covers methods for diagnosing cancer, including prostate cancer, by measuring exosomal miRNA levels in biological samples, directly relevant to the development of a pre-operative serum exosomal miRNA test to guide treatment decisions in prostate cancer.""}], ""level2_companies"": []}",04:25.6
"Yudin, Andrei",University of Toronto,Ontario,Proof of Principle Program - Phase I,201102PPP,Proof of Principle,Arrays of constrained histone tail mimetics for the development of epigenetic anticancer drugs,85712,74288,160000,1,1,Cancer Research,DRUGS- PHARMACEUTICAL SCIENCE/CHEMISTRY & NON MEDICAL USE OF DRUGS; CANCER THERAPY GENERAL; DRUG RESEARCH; CANCER,2011-10-01,2012-09-30,2,2,Encycle Therapeutics Inc.,1,"{""level1_ip"": [{""title"": ""Methods for identifying histone tail proteolysis"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""University of Toronto"", ""description"": ""Patent covering methods to identify proteolysis of histone tails, relevant to epigenetic regulation and anticancer drug development.""}, {""title"": ""Constrained histone tail mimetics for epigenetic modulation"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Encycle Therapeutics Inc."", ""description"": ""Patent on arrays of constrained histone tail mimetics designed for development of epigenetic anticancer drugs.""}], ""level2_companies"": [{""company_name"": ""Encycle Therapeutics Inc."", ""founding_year"": 2012, ""industry"": ""Biotechnology / Pharmaceuticals"", ""connection"": ""Founded by Andrei Yudin; focused on macrocyclic drugs including epigenetic anticancer agents relevant to the research.""}]}",04:25.6
"Zaugg, Michael",University of Alberta,Alberta,Project Grant,202303PJT,Commercialization,"Vegaven, a novel lipid emulsion with unique superior biological actions designed for parenteral nutrition",818550,0,818550,3,3,"Nutrition, Metabolism and Diabetes",Commercialization-Intellectual Property,2023-10-01,2026-09-30,2,2,,0,"{""level1_ip"": [{""title"": ""Novel lipid emulsion Vegaven for parenteral nutrition"", ""type"": ""patent application"", ""filing_year"": 2023, ""assignee"": ""Zaugg, Michael et al."", ""description"": ""Patent application filed after March 2023 covering the novel lipid emulsion Vegaven with superior biological actions designed for parenteral nutrition.""}, {""title"": ""Improved lipid emulsions containing DHA, EPA, and ARA for parenteral nutrition"", ""type"": ""patent application"", ""filing_year"": 2023, ""assignee"": ""Zaugg, Michael et al."", ""description"": ""Patent disclosure filed after March 2023 for lipid emulsions enhanced with specific fatty acids for improved parenteral nutrition.""}], ""level2_companies"": []}",04:25.6
"Zeng, Haishan",University of British Columbia,British Columbia,Proof of Principle Program - Phase II,201009PP2,Proof of Principle,Development of a laser Raman spectroscopy system for melanoma detection,244071,48211,663112,1,9,Cancer Research,MULTIDISCIPLINARY; SKIN AND SUBCUTANEOUS TISSUS; CANCER; IMAGING,2011-04-01,2012-03-31,0,3,,0,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Zeng, Haishan",University of British Columbia,British Columbia,Project Grant,201709PJT,Commercialization,Real-time Endoscopic Raman Spectroscopy for Improving Dysplasia/Colorectal Cancer Detection in Patients with Inflammatory Bowel Diseases,508724,0,,4,,Cancer Research,"Biomedical Engineering-Biophysics, Medical Technologies and Instrumentation; Cancer-Clinical Oncology; Digestive, Endocrine and Excretory Systems-Gastroenterology and Hepatology",2018-04-01,2022-03-31,2,,,,"{""level1_ip"": [{""title"": ""Apparatus and methods for in vivo tissue characterization by Raman spectroscopy"", ""type"": ""patent"", ""filing_year"": 2012, ""assignee"": ""University of British Columbia"", ""description"": ""Patent related to using Raman spectroscopy for cancer detection, including melanoma, with Haishan Zeng as inventor.""}, {""title"": ""Optical diagnosis and therapy systems for tissue pathology discrimination"", ""type"": ""patent"", ""filing_year"": 2013, ""assignee"": ""University of British Columbia"", ""description"": ""Granted patents and pending patents related to Raman spectroscopy systems for tissue pathology discrimination by Haishan Zeng.""}], ""level2_companies"": []}",04:25.6
"Zeng, Haishan",University of British Columbia,British Columbia,Project Grant,202104PJT,Commercialization,Autofluorescence Imaging Guided Laser Raman Spectroscopy for Non-invasive Oral Cancer Detection,742051,0,,4,,Cancer Research,"Biomedical Engineering-Biophysics, Medical Technologies and Instrumentation; Cancer-Clinical Oncology; Musculoskeletal Health-Oral Health",2021-10-01,2025-09-30,1,,,,"{""level1_ip"": [{""title"": ""Methods related to real-time cancer diagnostics at endoscopy utilizing fiber-optic Raman spectroscopy"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""Zeng, Haishan et al."", ""description"": ""Patent covering real-time diagnostic methods using fiber-optic Raman spectroscopy during endoscopy for cancer detection, directly relevant to colorectal cancer detection in inflammatory bowel disease patients.""}], ""level2_companies"": []}",04:25.6
"Zhang, Li",University Health Network (Toronto),Ontario,Proof of Principle Program - Phase II,201502PP2,Proof of Principle,A new cellular immunotherapy to treat acute myeloid leukemia,183670,35500,370830,1,5,Cancer Research,MULTIDISCIPLINARY; IMMUNOLOGY-TRANSPLANTATION; CANCER,2015-10-01,2016-09-30,3,3,WYZE Biotech Co.,1,"{""level1_ip"": [{""title"": ""Methods and compositions for treating acute myeloid leukemia using cellular immunotherapy"", ""type"": ""Patent"", ""filing_year"": 2021, ""assignee"": ""Research Institution"", ""description"": ""Patent covering novel cellular immunotherapy approaches targeting AML, filed after 2015, with Li Zhang as co-inventor.""}, {""title"": ""Double-negative T cell (DNT) technology for AML immunotherapy"", ""type"": ""Patent"", ""filing_year"": 2018, ""assignee"": ""Research Institution"", ""description"": ""Patent on DNT cell-based immunotherapy for AML, listing Li Zhang as co-inventor, filed post-2015.""}, {""title"": ""CAR T-cell therapies targeting acute myeloid leukemia"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Research Institution"", ""description"": ""Patent related to CAR T-cell therapy for AML treatment, filed after 2015, with Li Zhang as inventor.""}], ""level2_companies"": [{""company_name"": ""WYZE Biotech Co."", ""founding_year"": 2017, ""industry"": ""Biotechnology - Cellular Immunotherapy"", ""connection"": ""Li Zhang is a co-inventor on patents licensed to WYZE Biotech Co. and has received consulting fees, indicating involvement in commercialization of AML cellular immunotherapy technology.""}]}",04:25.6
"Zhang, Li",University Health Network (Toronto),Ontario,Project Grant,201903PJT,Commercialization,"Developing a platform for ""off-the-shelf"" CAR-T cell therapies for cancer using double negative T cells",703800,0,,4,,Cancer Research,Commercialization-Technology Transfer; Cancer-Cancer Drug Development and Therapeutics,2019-10-01,2023-09-30,0,,,,"{""level1_ip"": [], ""level2_companies"": []}",04:25.6
"Zhou, Youwen",University of British Columbia,British Columbia,Proof of Principle Program - Phase I,201202PPP,Proof of Principle,A diagnostic test for cutaneous T cell lymphomas,151660,0,151660,1,1,Musculoskeletal Health and Arthritis,"SKIN AND SUBCUTANEOUS TISSUS; BLOOD; CANCER; GENOMICS, PROTEOMICS, AND BIOINFORMATICS",2012-10-01,2013-09-30,4,4,,0,"{""level1_ip"": [{""title"": ""Diagnostic microrna profiling in cutaneous T-cell lymphoma (CTCL)"", ""type"": ""Patent Application"", ""filing_year"": 2013, ""assignee"": ""Zhou, Youwen"", ""description"": ""Patent application WO2013011378A1 covering diagnostic methods using microrna profiling for CTCL.""}, {""title"": ""Methods for diagnosis of cutaneous T-cell lymphoma"", ""type"": ""Patent Application"", ""filing_year"": 2016, ""assignee"": ""Zhou, Youwen"", ""description"": ""US20160169901A1 describing novel diagnostic methods for CTCL.""}, {""title"": ""Method for diagnosis, prognosis and determination of treatment for cutaneous T-cell lymphoma"", ""type"": ""Patent"", ""filing_year"": 2015, ""assignee"": ""Zhou, Youwen"", ""description"": ""US Patent 11067577 covering methods for diagnosis, prognosis, and treatment decisions in CTCL.""}, {""title"": ""Method for diagnosis, prognosis and determination of treatment for cutaneous T-cell lymphoma"", ""type"": ""Patent"", ""filing_year"": 2019, ""assignee"": ""Zhou, Youwen"", ""description"": ""US Patent 10473661 related to diagnostic and prognostic methods for CTCL.""}], ""level2_companies"": []}",04:25.6